 EXHIBIT    \t \t 

































AGREEMENT AND PLAN OF MERGER

AND REORGANIZATION

among:

TRANSCEPT PHARMACEUTICALS, INC.,

a Delaware corporation;

TIGRIS MERGER SUB, INC.,

a Delaware corporation;

TIGRIS ACQUISITION SUB, LLC,

a Delaware limited liability company; and

PARATEK PHARMACEUTICALS, INC.,

a Delaware corporation

Dated as of June 30, 2014

________________________________________





 Table of Contents 

--- 
| | 

|

|

Page 

Section 1.

|

Description of the Transaction

|

3 

1.1

|

Structure of the Merger and Second Merger

|

3 

1.2

|

Effects of the Merger and Second Merger

|

3 

1.3

|

Closing; Effective Time

|

3 

1.4

|

Certificate of Incorporation and Bylaws; Directors and Officers

|

3 

1.5

|

Conversion of Shares and Issuance of Warrants

|

4 

1.6

|

Calculation of Net Cash

|

5 

1.7

|

Closing of Potomac's Transfer Books

|

7 

1.8

|

Surrender of Certificates

|

7 

1.9

|

Appraisal Rights

|

9 

1.10

|

Further Action

|

9 

1.11

|

Tax Consequences

|

9 

Section 2.

|

Representations and Warranties of Potomac

|

10 

2.1

|

Subsidiaries; Due Organization; Etc.

|

10 

2.2

|

Certificate of Incorporation; Bylaws; Charters and Codes of Conduct

|

10 

2.3

|

Capitalization, Etc.

|

11 

2.4

|

Financial Statements

|

13 

2.5

|

Absence of Changes

|

14 

2.6

|

Title to Assets

|

16 

2.7

|

Real Property; Leasehold

|

16 

2.8

|

Intellectual Property

|

16 

2.9

|

Agreements, Contracts and Commitments

|

19 

2.10

|

Liabilities

|

21 

2.11

|

Compliance; Permits; Restrictions

|

21 

2.12

|

Tax Matters

|

23 

2.13

|

Employee and Labor Matters; Benefit Plans

|

26 

2.14

|

Environmental Matters

|

29 

2.15

|

Insurance

|

30 

2.16

|

Legal Proceedings; Orders

|

30 

2.17

|

Authority; Binding Nature of Agreement

|

31 

2.18

|

Inapplicability of Anti-takeover Statutes

|

31 

2.19

|

Vote Required

|

31 

2.20

|

Non-Contravention; Consents

|

32 

2.21

|

Bank Accounts; Receivables

|

33 

2.22

|

No Financial Advisor

|

33 

2.23

|

Subscription Agreement

|

33 

2.24

|

Disclosure

|

34 

 

--- 
| | 

Section 3.

|

Representations and Warranties of Tigris and Merger Sub

|

34 

3.1

|

Subsidiaries; Due Organization; Etc

|

34 

3.2

|

Certificate of Incorporation; Bylaws; Charters and Codes of Conduct

|

35 

3.3

|

Capitalization, Etc.

|

35 

3.4

|

SEC Filings; Financial Statements

|

36 

3.5

|

Absence of Changes

|

38 

3.6

|

Intellectual Property

|

40 

3.7

|

Agreements, Contracts and Commitments

|

42 

3.8

|

Liabilities

|

44 

3.9

|

Compliance; Permits; Restrictions

|

44 

3.10

|

Tax Matters

|

46 

3.11

|

Employee and Labor Matters; Benefit Plans

|

48 

3.12

|

Environmental Matters

|

51 

3.13

|

Insurance

|

52 

3.14

|

Transactions with Affiliates

|

52 

3.15

|

Legal Proceedings; Orders

|

52 

3.16

|

Authority; Binding Nature of Agreement

|

53 

3.17

|

Inapplicability of Anti-takeover Statutes

|

54 

3.18

|

Vote Required

|

54 

3.19

|

Non-Contravention; Consents

|

54 

3.20

|

Bank Accounts; Receivables; Deposits

|

55 

3.21

|

No Financial Advisor

|

55 

3.22

|

Valid Issuance

|

56 

3.23

|

Code of Ethics

|

56 

3.24

|

Title to Assets

|

56 

3.24

|

Real Property; Leasehold

|

56 

Section 4.

|

Certain Covenants of the Parties

|

56 

4.1

|

Access and Investigation

|

56 

4.2

|

Operation of Tigris' Business

|

57 

4.3

|

Operation of Potomac's Business

|

58 

4.4

|

Negative Obligations

|

59 

4.5

|

No Solicitation

|

62 

4.6

|

Undisclosed Liabilities

|

64 

Section 5.

|

Additional Agreements of the Parties

|

64 

5.1

|

Registration Statement; Proxy Statement/Prospectus/Information Statement

|

64 

5.2

|

Potomac Stockholder Written Consent

|

65 

5.3

|

Tigris Stockholders' Meeting

|

66 

5.4

|

Regulatory Approvals

|

68 

5.5

|

Potomac Options and Warrants

|

68 

5.6

|

Employee Benefits

|

69 

5.7

|

Indemnification of Officers and Directors

|

70 

 

--- 
| | 

5.8

|

Additional Agreements

|

71 

5.9

|

Disclosure

|

71 

5.10

|

Listing

|

72 

5.11

|

Tax Matters

|

72 

5.12

|

Legends

|

73 

5.13

|

Interpretation of Certain Agreements

|

73 

5.14

|

Cooperation

|

73 

5.15

|

Potomac Stockholder Approval

|

74 

5.16

|

Pre-Closing Dividend

|

74 

5.17

|

Directors and Officers

|

74 

5.18

|

Termination of Certain Agreements and Rights

|

74 

5.19

|

Disclosure of Liabilities

|

74 

5.20

|

Tigris Options

|

75 

Section 6.

|

Conditions Precedent to Obligations of Each Party

|

75 

6.1

|

Effectiveness of Registration Statement

|

75 

6.2

|

No Restraints

|

76 

6.3

|

Stockholder Approval

|

76 

6.4

|

Listing

|

76 

6.5

|

Regulatory Matters

|

76 

6.6

|

No Governmental Proceedings Relating to Contemplated Transactions or Right to
Operate Business

|

76 

Section 7.

|

Additional Conditions Precedent to Obligations of Tigris and Merger Sub

|

76 

7.1

|

Accuracy of Representations

|

77 

7.2

|

Performance of Covenants

|

77 

7.3

|

Lock-up Agreements

|

77 

7.4

|

Agreements and Other Documents

|

77 

7.5

|

No Other Proceedings

|

77 

7.6

|

Potomac Pre-Closing Financing

|

78 

7.7

|

FIRPTA Certificate

|

78 

7.8

|

No Potomac Material Adverse Effect

|

78 

7.9

|

Termination of Investor Agreements

|

78 

7.10

|

Preferred Stock Conversion

|

78 

Section 8.

|

Additional Conditions Precedent to Obligation of Potomac

|

78 

8.1

|

Accuracy of Representations

|

78 

8.2

|

Performance of Covenants

|

79 

8.3

|

Lock-up Agreements

|

79 

8.4

|

Documents

|

79 

8.5

|

No Other Proceedings

|

79 

8.6

|

Sarbanes-Oxley Certifications

|

80 

8.7

|

Board of Directors

|

80 

8.8

|

No Tigris Material Adverse Effect

|

80 

8.9

|

Potomac Pre-Closing Financing

|

80 

 

--- 
| | 

Section 9.

|

Termination

|

80 

9.1

|

Termination

|

80 

9.2

|

Effect of Termination

|

82 

9.3

|

Expenses; Termination Fees

|

82 

Section 10.

|

Miscellaneous Provisions

|

85 

10.1

|

Non-Survival of Representations and Warranties

|

85 

10.2

|

Amendment

|

85 

10.3

|

Waiver

|

85 

10.4

|

Entire Agreement; Counterparts; Exchanges by Facsimile

|

85 

10.5

|

Applicable Law; Jurisdiction

|

86 

10.6

|

Attorneys' Fees

|

86 

10.7

|

Assignability

|

86 

10.8

|

Notices

|

86 

10.9

|

Cooperation

|

87 

10.10

|

Severability

|

87 

10.11

|

Other Remedies; Specific Performance

|

88 

10.12

|

No Third Party Beneficiaries

|

88 

10.13

|

Construction

|

88 

 

Schedules:



| 
---|--- 

Schedule A

|

Persons Executing Potomac Stockholder Support Agreements 

| 
---|--- 

Schedule B

|

Persons Executing Tigris Stockholder Support Agreements 

| 
---|--- 

Schedule C

|

Pre-Closing Dividend Rights 

| 
---|--- 

Schedule D

|

Specified Litigation Matter 

| 
---|--- 

Schedule E

|

Subscription Agreement 

| 
---|--- 

Schedule F

|

Investor Agreements 

| 
---|--- 

Schedule G

|

Tigris Options 

 

Exhibits:

| 
---|--- 

Exhibit A

|

Definitions 

| 
---|--- 

Exhibit B

|

Form of Potomac Stockholder Voting Agreement 

| 
---|--- 

Exhibit C

|

Form of Tigris Stockholder Voting Agreement 

| 
---|--- 

Exhibit D

|

Form of Potomac Stockholder Written Consent 

| 
---|--- 

Exhibit E

|

Form of Lock-up Agreement 

 



AGREEMENT AND PLAN OF MERGER AND REORGANIZATION

THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this "Agreement") is
made and entered into as of June 30, 2014, by and among TRANSCEPT
PHARMACEUTICALS, INC., a Delaware corporation ("Tigris"), TIGRIS MERGER SUB,
INC., a Delaware corporation ("Merger Sub"), TIGRIS ACQUISITION SUB, LLC, a
single member Delaware limited liability company ("Merger LLC"), and PARATEK
PHARMACEUTICALS, INC., a Delaware corporation ("Potomac"). Certain capitalized
terms used in this Agreement are defined in Exhibit A.

RECITALS

A. Tigris and Potomac intend to effect a merger of Merger Sub into Potomac
(the "Merger") in accordance with this Agreement and the DGCL. Upon
consummation of the Merger, Merger Sub will cease to exist, and Potomac will
become a wholly-owned subsidiary of Tigris.

B. The Parties intend that the Merger shall be immediately followed by a
merger of the Surviving Corporation (as defined below) with and into Merger
LLC with Merger LLC surviving (the "Second Merger"), on the terms and subject
to the conditions of this Agreement and in accordance with the Delaware
Limited Liability Company Act (the "DLLCA").

C. The Parties intend that the Merger be mutually interdependent with and a
condition precedent to the Second Merger and that the Second Merger shall,
through the binding commitment evidenced by Section 1.1(b), be effected
immediately following the Effective Time (as defined below), on the terms and
subject to the conditions of this Agreement and in accordance with the DLLCA,
without further approval, authorization or direction from or by any of the
parties hereto.

D. The Parties intend to adopt this Agreement as a plan of reorganization
within the meaning of Treasury Regulation Sections 1.368-2(g) and 1.368-3(a)
and for the Merger and the Second Merger, considered together as a single
integrated transaction for United States federal income Tax purposes, to
qualify as a reorganization within the meaning of Section 368(a) of the Code
and the Treasury Regulations promulgated thereunder.

E. The Board of Directors of Tigris (i) has determined that the Merger is fair
to, and in the best interests of, Tigris and its stockholders, (ii) has
approved this Agreement, the Merger, the issuance of shares of Tigris Common
Stock to the stockholders of Potomac pursuant to the terms of this Agreement,
the change of control of Tigris, and the other actions contemplated by this
Agreement and (iii) has determined to recommend that the stockholders of
Tigris vote to approve the issuance of shares of Tigris Common Stock to the
stockholders of Potomac pursuant to the terms of this Agreement, the change of
control of Tigris and such other actions as contemplated by this Agreement.

F. The Board of Directors of Merger Sub (i) has determined that the Merger is
fair to, and in the best interests of, Merger Sub and its sole stockholder,
(ii) has approved this

 Agreement, the Merger, and the other actions contemplated by this Agreement
and has deemed this Agreement advisable and (iii) has determined to recommend
that the stockholder of Merger Sub vote to adopt this Agreement and thereby
approve the Merger and such other actions as contemplated by this Agreement.

G. The Board of Directors of Potomac (i) has determined that the Merger is
advisable and fair to, and in the best interests of, Potomac and its
stockholders, (ii) has approved this Agreement, the Merger and the other
transactions contemplated by this Agreement and has deemed this Agreement
advisable and (iii) has determined to recommend that the stockholders of
Potomac vote to adopt this Agreement and thereby approve the Merger and such
other actions as contemplated by this Agreement.

H. In order to induce Tigris to enter into this Agreement and to cause the
Merger to be consummated, the officers and directors of Potomac and
stockholders affiliated therewith listed on Schedule A hereto, are executing
support agreements in favor of Tigris concurrently with the execution and
delivery of this Agreement in the form substantially attached hereto as
Exhibit B (the "Potomac Stockholder Support Agreements").

I. In order to induce Potomac to enter into this Agreement and to cause the
Merger to be consummated, the officers, directors and certain stockholders of
Tigris listed on Schedule B hereto are executing support agreements in favor
of Potomac concurrently with the execution and delivery of this Agreement in
the form substantially attached hereto as Exhibit C (the "Tigris Stockholder
Support Agreements").

J. It is expected that within four (4) Business Days after the Form S-4
Registration Statement is declared effective under the Securities Act, the
holders of shares of capital stock of Potomac sufficient to adopt and approve
this Agreement and the Merger as required under the DGCL and Potomac's
Certificate of Incorporation and Bylaws will execute and deliver an action by
written consent adopting this Agreement, in a form reasonably acceptable to
Tigris, in order to obtain the Required Potomac Stockholder Vote (each, a
"Potomac Stockholder Written Consent" and collectively, the "Potomac
Stockholder Written Consents").

K. Immediately prior to the execution and delivery of this Agreement, and as a
condition of the willingness of Tigris to enter into this Agreement, certain
investors have executed the Subscription Agreement with Potomac pursuant to
which such investors have agreed to purchase certain shares of capital stock
of Potomac prior to the Closing in connection with the Potomac Pre-Closing
Financing.

L. Concurrently with the execution and delivery of this Agreement, and as a
condition of the willingness of Potomac to enter into this Agreement, Tigris
has provided certain bridge financing to Potomac pursuant to a Note Purchase
Agreement between Tigris and Potomac (each Promissory Note issued thereunder,
a "Tigris Note" and collectively, the "Tigris Notes").

 AGREEMENT

The parties to this Agreement, intending to be legally bound, agree as
follows:

Section 1. DESCRIPTION OF TRANSACTION

1.1 Structure of the Merger and Second Merger.

(a) Merger of Merger Sub into Potomac. Upon the terms and subject to the
conditions set forth in this Agreement, at the Effective Time, Merger Sub
shall be merged with and into Potomac, and the separate existence of Merger
Sub shall cease. Potomac will continue as the surviving corporation in the
Merger (the "Surviving Corporation").

(b) Second Merger. Immediately after the Effective Time on the Closing Date,
the Surviving Corporation shall be merged with and into Merger LLC, and the
separate existence of the Surviving Corporation shall cease. Merger LLC shall
be the successor or surviving entity in the Second Merger (the "Surviving
Company"). There shall be no conditions to the completion of the Second Merger
other than the completion of the Merger.

1.2 Effects of the Merger and Second Merger. The Merger shall have the effects
set forth in this Agreement and in the applicable provisions of the DGCL. As a
result of the Merger, Potomac will become a wholly-owned subsidiary of Tigris.
The Second Merger shall have the effects set forth in this Agreement and in
the applicable provisions of the DGCL and the DLLCA.

1.3 Closing; Effective Time. Unless this Agreement is earlier terminated
pursuant to the provisions of Section 9.1 of this Agreement, and subject to
the satisfaction or waiver of the conditions set forth in Sections 6, 7 and 8
of this Agreement, the consummation of the Merger (the "Closing") shall take
place at the offices of Latham and Watkins LLP, 140 Scott Drive, Menlo Park,
California, as promptly as practicable (but in no event later than the third
Business Day following the satisfaction or waiver of the last to be satisfied
or waived of the conditions set forth in Sections 6, 7 and 8, other than those
conditions that by their nature are to be satisfied at the Closing, but
subject to the satisfaction or waiver of each of such conditions), or at such
other time, date and place as Tigris and Potomac may mutually agree in
writing. The date on which the Closing actually takes place is referred to as
the "Closing Date." At the Closing, the Parties hereto shall cause the Merger
to be consummated by executing and filing with the Secretary of State of the
State of Delaware a Certificate of Merger with respect to the Merger,
satisfying the applicable requirements of the DGCL and in a form reasonably
acceptable to Tigris and Potomac (the "Certificate of Merger"). The Merger
shall become effective at the time of the filing of such Certificate of Merger
with the Secretary of State of the State of Delaware or at such later time as
may be specified in such Certificate of Merger with the consent of Tigris and
Potomac (the time as of which the Merger becomes effective being referred to
as the "Effective Time").

1.4 Certificate of Incorporation and Bylaws; Directors and Officers. At the
Effective Time:

 (a) the Certificate of Incorporation of the Surviving Corporation shall be
amended and restated in its entirety to read identically to the Certificate of
Incorporation of Merger Sub as in effect immediately prior to the Effective
Time, until thereafter amended as provided by the DGCL and such Certificate of
Incorporation;

(b) the Certificate of Incorporation of Tigris shall be the Certificate of
Incorporation of Tigris immediately prior to the Effective Time, until
thereafter amended as provided by the DGCL and such Certificate of
Incorporation; provided, however, that at the Effective Time, Tigris shall
file an amendment to its certificate of incorporation to change the name of
Tigris to "Paratek Pharmaceuticals, Inc.;" and to make such other changes as
are mutually agreeable to Tigris and Potomac;

(c) the Bylaws of the Surviving Corporation shall be amended and restated in
their entirety to read identically to the Bylaws of Merger Sub as in effect
immediately prior to the Effective Time, until thereafter amended as provided
by the DGCL and such Bylaws;

(d) the directors and officers of Tigris shall be as set forth in Section
5.17; and

(e) the directors and officers of the Surviving Corporation, each to hold
office in accordance with the Certificate of Incorporation and Bylaws of the
Surviving Corporation, shall be the directors and officers of Tigris as set
forth in Section 5.17, after giving effect to the provisions of Section 5.17.

1.5 Conversion of Shares and Issuance of Warrants.

(a) At the Effective Time, by virtue of the Merger and without any further
action on the part of Tigris, Merger Sub, Potomac or any stockholder of
Potomac:

(i) any shares of Potomac Common Stock or Potomac Preferred Stock held as
treasury stock or held or owned by Potomac, Merger Sub or any Subsidiary of
Potomac immediately prior to the Effective Time shall be canceled and retired
and shall cease to exist, and no consideration shall be delivered in exchange
therefor; and

(ii) subject to Section 1.5(c), each share of Potomac Common Stock outstanding
immediately prior to the Effective Time (excluding shares to be canceled
pursuant to Section 1.5(a)(i) and excluding Dissenting Shares) shall be
converted solely into the right to receive a number of shares of Tigris Common
Stock equal to the Exchange Ratio.

(b) If any shares of Potomac Common Stock outstanding immediately prior to the
Effective Time are unvested or are subject to a repurchase option or the risk
of forfeiture under any applicable restricted stock purchase agreement or
other agreement with Potomac, then the shares of Tigris Common Stock issued in
exchange for such shares of Potomac Common Stock will to the same extent be
unvested and subject to the same repurchase option or risk of forfeiture, and
the certificates representing such shares of Tigris Common Stock shall
accordingly be marked with appropriate legends. Potomac shall take all actions
that may be necessary to ensure that, from and after the Effective Time,
Tigris is entitled to exercise any such

 repurchase option or other right set forth in any such restricted stock
purchase agreement or other agreement.

(c) No fractional shares of Tigris Common Stock shall be issued in connection
with the Merger, and no certificates or scrip for any such fractional shares
shall be issued. Any holder of Potomac Common Stock who would otherwise be
entitled to receive a fraction of a share of Tigris Common Stock (after
aggregating all fractional shares of Tigris Common Stock issuable to such
holder) shall, in lieu of such fraction of a share and upon surrender by such
holder of a letter of transmittal in accordance with Section 1.8 and
accompanying documents as required therein, be paid in cash the dollar amount
(rounded to the nearest whole cent), without interest, determined by
multiplying such fraction by the closing price of a share of Tigris Common
Stock on The NASDAQ Global Market (or such other NASDAQ market on which the
Tigris Common Stock then trades) on the date the Merger becomes effective.

(d) All Potomac Options outstanding immediately prior to the Effective Time
under the 2014 Plan and all Potomac Warrants outstanding immediately prior to
the Effective Time shall be exchanged for options to purchase Tigris Common
Stock or warrants to purchase Tigris Common Stock, as applicable, in
accordance with Section 5.5. All other Potomac Options shall be cancelled
immediately prior to the Effective Time.

(e) Each share of Common Stock, $0.001 par value per share, of Merger Sub
issued and outstanding immediately prior to the Effective Time shall be
converted into and exchanged for one validly issued, fully paid and
nonassessable share of Common Stock, $0.001 par value per share, of the
Surviving Corporation. Each stock certificate of Merger Sub evidencing
ownership of any such shares shall, as of the Effective Time, evidence
ownership of such shares of Common Stock of the Surviving Corporation.

(f) If, between the date of this Agreement and the Effective Time, the
outstanding shares of Potomac Capital Stock or Tigris Common Stock shall have
been changed into, or exchanged for, a different number of shares or a
different class, by reason of any stock dividend, subdivision,
reclassification, recapitalization, split, combination or exchange of shares,
the Exchange Ratio shall be correspondingly adjusted to provide the holders of
Potomac Common Stock, Potomac Preferred Stock, Potomac Options and Potomac
Warrants the same economic effect as contemplated by this Agreement prior to
such event.

(g) Immediately following the consummation of the Merger, Tigris shall file a
certificate of merger for the Second Merger (the "Second Step Certificate of
Merger") with the Secretary of State of the State of Delaware in a form
reasonably acceptable to each of Tigris and Potomac and in accordance with the
relevant provisions of the DGCL and the DLLCA. The Second Merger shall become
effective upon the filing of the Second Step Certificate of Merger. Each
issued and outstanding share of capital stock of the Surviving Corporation
shall be cancelled and exchanged for an equivalent percentage of the
membership interests of the Surviving Company, and all of the membership
interests of Merger LLC shall become all of the membership interests of the
Surviving Company.

1.6 Calculation of Net Cash.

 (a) For the purposes of this Agreement, the "Determination Date" shall be the
date that is ten (10) calendar days prior to the anticipated date for Closing,
as agreed upon by Tigris and Potomac at least ten (10) calendar days prior to
the Tigris Stockholders' Meeting (the "Anticipated Closing Date"). Within five
(5) calendar days following the Determination Date, Tigris shall deliver to
Potomac a schedule (the "Net Cash Schedule") setting forth, in reasonable
detail, Tigris' good faith, estimated calculation of Net Cash (using an
estimate of Tigris' accounts payable and accrued expenses, in each case as of
the Anticipated Closing Date and determined in a manner substantially
consistent with the manner in which such items were determined for Tigris'
most recent SEC filings) (the "Net Cash Calculation") as of the Anticipated
Closing Date prepared and certified by Tigris' Chief Financial Officer. Tigris
shall make the work papers and back-up materials used or useful in preparing
the Net Cash Schedule, as reasonably requested by Potomac, available to
Potomac and, if requested by Potomac, its accountants and counsel at
reasonable times and upon reasonable notice.

(b) Within three (3) calendar days after Tigris delivers the Net Cash Schedule
(the "Response Date"), Potomac shall have the right to dispute any part of
such Net Cash Schedule by delivering a written notice to that effect to Tigris
(a "Dispute Notice"). Any Dispute Notice shall identify in reasonable detail
the nature of any proposed revisions to the Net Cash Calculation.

(c) If on or prior to the Response Date, (i) Potomac notifies Tigris in
writing that it has no objections to the Net Cash Calculation or (ii) Potomac
fails to deliver a Dispute Notice as provided in Section 1.6(b), then the Net
Cash Calculation as set forth in the Net Cash Schedule shall be deemed to have
been finally determined for purposes of this Agreement and to represent the
Net Cash at the Determination Date for purposes of this Agreement.

(d) If Potomac delivers a Dispute Notice on or prior to the Response Date,
then Representatives of Tigris and Potomac shall promptly meet and attempt in
good faith to resolve the disputed item(s) and negotiate an agreed-upon
determination of Net Cash, which agreed upon Net Cash amount shall be deemed
to have been finally determined for purposes of this Agreement and to
represent the Net Cash at the Determination Date for purposes of this
Agreement.

(e) If Representatives of Tigris and Potomac are unable to negotiate an
agreed-upon determination of Net Cash at the Determination Date pursuant to
Section 1.6(d) within three (3) calendar days after delivery of the Dispute
Notice (or such other period as Tigris and Potomac may mutually agree upon),
then Tigris and Potomac shall jointly select an independent auditor of
recognized national standing (the "Accounting Firm") to resolve any remaining
disagreements as to the Net Cash Calculation. Tigris shall promptly deliver to
the Accounting Firm the work papers and back-up materials used in preparing
the Net Cash Schedule, and Tigris and Potomac shall use commercially
reasonable efforts to cause the Accounting Firm to make its determination
within ten (10) calendar days of accepting its selection. Potomac and Tigris
shall be afforded the opportunity to present to the Accounting Firm any
material related to the unresolved disputes and to discuss the issues with the
Accounting Firm; provided, however, that no such presentation or discussion
shall occur without

 the presence of a Representative of each of Potomac and Tigris. The
determination of the Accounting Firm shall be limited to the disagreements
submitted to the Accounting Firm. The determination of the amount of Net Cash
made by the Accounting Firm shall be deemed to have been finally determined
for purposes of this Agreement and to represent the Net Cash at the
Determination Date for purposes of this Agreement, and the Parties shall delay
the Closing until the resolution of the matters described in this Section
1.6(e). The fees and expenses of the Accounting Firm shall be allocated
between Tigris and Potomac in the same proportion that the disputed amount of
the Net Cash that was unsuccessfully disputed by such Party (as finally
determined by the Accounting Firm) bears to the total disputed amount of the
Net Cash amount. If this Section 1.6(e) applies as to the determination of the
Net Cash at the Determination Date described in Section 1.6(a), upon
resolution of the matter in accordance with this Section 1.6(e), the Parties
shall not be required to determine Net Cash again even though the Closing Date
may occur later than the Anticipated Closing Date, unless the Closing Date is
more than fifteen (15) calendar days after the Anticipated Closing Date.

1.7 Closing of Potomac's Transfer Books. At the Effective Time: (a) all shares
of Potomac Common Stock outstanding immediately prior to the Effective Time
shall be treated in accordance with Section 1.5(a), and all holders of
certificates representing shares of Potomac Common Stock and Potomac Preferred
Stock that were outstanding immediately prior to the Effective Time shall
cease to have any rights as stockholders of Potomac; and (b) the stock
transfer books of Potomac shall be closed with respect to all shares of
Potomac Common Stock and Potomac Preferred Stock outstanding immediately prior
to the Effective Time. No further transfer of any such shares of Potomac
Common Stock shall be made on such stock transfer books after the Effective
Time. If, after the Effective Time, a valid certificate previously
representing any shares of Potomac Common Stock, including any valid
certificate representing any shares of Potomac Preferred Stock previously
converted into shares of Potomac Common Stock in connection with the Preferred
Stock Conversion, outstanding immediately prior to the Effective Time (a
"Potomac Stock Certificate") is presented to the Exchange Agent or to the
Surviving Corporation, such Potomac Stock Certificate shall be canceled and
shall be exchanged as provided in Sections 1.5 and 1.8.

1.8 Surrender of Certificates.

(a) On or prior to the Closing Date, Tigris and Potomac shall agree upon and
select a reputable bank, transfer agent or trust company to act as exchange
agent in the Merger (the "Exchange Agent"). At the Effective Time, Tigris
shall deposit with the Exchange Agent: (i) certificates representing the
shares of Tigris Common Stock issuable pursuant to Section 1.5(a) and (ii)
cash sufficient to make payments in lieu of fractional shares in accordance
with Section 1.5(c). The shares of Tigris Common Stock and cash amounts so
deposited with the Exchange Agent, together with any dividends or
distributions received by the Exchange Agent with respect to such shares, are
referred to collectively as the "Exchange Fund."

(b) At or before the Effective Time, Potomac will deliver to Tigris a true,
complete and accurate listing of all record holders of Potomac Stock
Certificates at the Effective Time, including the number and class of shares
of Potomac's capital stock held by such record

 holder, and the number of shares of Tigris Common Stock such holder is
entitled to receive pursuant to Section 1.5. Promptly after the Effective
Time, the Parties shall cause the Exchange Agent to mail to the Persons who
were record holders of Potomac Stock Certificates immediately prior to the
Effective Time: (i) a letter of transmittal in customary form and containing
such provisions as Tigris may reasonably specify (including a provision
confirming that delivery of Potomac Stock Certificates shall be effected, and
risk of loss and title to Potomac Stock Certificates shall pass, only upon
delivery of such Potomac Stock Certificates to the Exchange Agent); and (ii)
instructions for effecting the surrender of Potomac Stock Certificates in
exchange for certificates representing Tigris Common Stock. Upon surrender of
a Potomac Stock Certificate to the Exchange Agent for exchange, together with
a duly executed letter of transmittal and such other documents as may be
reasonably required by the Exchange Agent or Tigris: (A) the holder of such
Potomac Stock Certificate shall be entitled to receive in exchange therefor a
certificate representing the number of whole shares of Tigris Common Stock
that such holder has the right to receive pursuant to the provisions of
Section 1.5(a) (and cash in lieu of any fractional share of Tigris Common
Stock pursuant to the provisions of Section 1.5(c)); and (B) the Potomac Stock
Certificate so surrendered shall be canceled. Until surrendered as
contemplated by this Section 1.8(b), each Potomac Stock Certificate shall be
deemed, from and after the Effective Time, to represent only the right to
receive shares of Tigris Common Stock (and cash in lieu of any fractional
share of Tigris Common Stock). If any Potomac Stock Certificate shall have
been lost, stolen or destroyed, Tigris may, in its discretion and as a
condition precedent to the delivery of any shares of Tigris Common Stock,
require the owner of such lost, stolen or destroyed Potomac Stock Certificate
to provide an applicable affidavit with respect to such Potomac Stock
Certificate and post a bond indemnifying Tigris against any claim suffered by
Tigris related to the lost, stolen or destroyed Potomac Stock Certificate or
any Tigris Common Stock issued in exchange therefor as Tigris may reasonably
request.

(c) No dividends or other distributions declared or made with respect to
Tigris Common Stock with a record date after the Effective Time shall be paid
to the holder of any unsurrendered Potomac Stock Certificate with respect to
the shares of Tigris Common Stock that such holder has the right to receive in
the Merger until such holder surrenders such Potomac Stock Certificate or an
affidavit of loss or destruction in lieu thereof in accordance with this
Section 1.8 (at which time such holder shall be entitled, subject to the
effect of applicable abandoned property, escheat or similar laws, to receive
all such dividends and distributions, without interest).

(d) Any portion of the Exchange Fund that remains undistributed to holders of
Potomac Stock Certificates as of the date 180 days after the Closing Date
shall be delivered to Tigris upon demand, and any holders of Potomac Stock
Certificates who have not theretofore surrendered their Potomac Stock
Certificates in accordance with this Section 1.8 shall thereafter look only to
Tigris for satisfaction of their claims for Tigris Common Stock, cash in lieu
of fractional shares of Tigris Common Stock and any dividends or distributions
with respect to shares of Tigris Common Stock.

(e) Each of the Exchange Agent, Tigris and the Surviving Corporation shall be
entitled to deduct and withhold from any consideration deliverable pursuant to
this Agreement to

 any holder of any Potomac Stock Certificate such amounts as are required to be
deducted or withheld from such consideration under the Code or under any other
applicable Legal Requirement and shall be entitled to request any reasonably
appropriate Tax forms, including Form W-9 (or the appropriate Form W-8, as
applicable) from any recipient of payments hereunder. To the extent such
amounts are so deducted or withheld, and remitted to the appropriate taxing
authority, such amounts shall be treated for all purposes under this Agreement
as having been paid to the Person to whom such amounts would otherwise have
been paid.

(f) No party to this Agreement shall be liable to any holder of any Potomac
Stock Certificate or to any other Person with respect to any shares of Tigris
Common Stock (or dividends or distributions with respect thereto) or for any
cash amounts, delivered to any public official pursuant to any applicable
abandoned property law, escheat law or similar Legal Requirement.

1.9 Appraisal Rights.

(a) Notwithstanding any provision of this Agreement to the contrary, shares of
Potomac Capital Stock that are outstanding immediately prior to the Effective
Time and which are held by stockholders who have exercised and perfected
appraisal rights for such shares of Potomac Capital Stock in accordance with
the DGCL (collectively, the "Dissenting Shares") shall not be converted into
or represent the right to receive the per share amount of the merger
consideration described in Section 1.5 attributable to such Dissenting Shares.
Such stockholders shall be entitled to receive payment of the appraised value
of such shares of Potomac Capital Stock held by them in accordance with the
DGCL, unless and until such stockholders fail to perfect or effectively
withdraw or otherwise lose their appraisal rights under the DGCL. All
Dissenting Shares held by stockholders who shall have failed to perfect or who
effectively shall have withdrawn or lost their right to appraisal of such
shares of Potomac Capital Stock under the DGCL shall thereupon be deemed to be
converted into and to have become exchangeable for, as of the Effective Time,
the right to receive the per share amount of the merger consideration
attributable to such Dissenting Shares upon their surrender in the manner
provided in Section 1.5.

(b) Potomac shall give Tigris prompt written notice of any demands by
dissenting stockholders received by Potomac, withdrawals of such demands and
any other instruments served on Potomac and any material correspondence
received by Potomac in connection with such demands.

1.10 Further Action. If, at any time after the Effective Time, any further
action is determined by the Surviving Corporation to be necessary or desirable
to carry out the purposes of this Agreement or to vest the Surviving
Corporation with full right, title and possession of and to all rights and
property of Potomac, then the officers and directors of the Surviving
Corporation shall be fully authorized, and shall use their commercially
reasonable efforts (in the name of Potomac, in the name of Merger Sub and
otherwise) to take such action.

1.11 Tax Consequences. For federal income tax purposes, the Merger and the
Second Merger, considered together as a single integrated transaction for
United States federal income

 Tax purposes, is intended to constitute a reorganization within the meaning of
Section 368(a) of the Code and the Treasury Regulations promulgated
thereunder. The parties to this Agreement adopt this Agreement as a "plan of
reorganization" within the meaning of Section 1.368-2(g) of the Treasury
Regulations.

Section 2. REPRESENTATIONS AND WARRANTIES OF POTOMAC

Potomac represents and warrants to Tigris and Merger Sub as follows, except as
set forth in the written disclosure schedule delivered by Potomac to Tigris
(the "Potomac Disclosure Schedule"). The Potomac Disclosure Schedule shall be
arranged in sections and subsections corresponding to the numbered and
lettered sections and subsections contained in this Section 2. The disclosures
in any section or subsection of the Potomac Disclosure Schedule shall qualify
other sections and subsections in this Section 2 to the extent it is
reasonably clear from a reading of the disclosure that such disclosure is
applicable to such other sections and subsections. The inclusion of any
information in the Potomac Disclosure Schedule (or any update thereto) shall
not be deemed to be an admission or acknowledgment, in and of itself, that
such information is required by the terms hereof to be disclosed, is material,
has resulted in or would result in a Potomac Material Adverse Effect, or is
outside the Ordinary Course of Business.

2.1 Subsidiaries; Due Organization; Etc.

(a) Potomac has no Subsidiaries, except for the Entities identified in Part
2.1(a) of the Potomac Disclosure Schedule; and neither Potomac nor any of the
other Entities identified in Part 2.1(a) of the Potomac Disclosure Schedule
owns any capital stock of, or any equity interest of any nature in, any other
Entity, other than the Entities identified in Part 2.1(a) of the Potomac
Disclosure Schedule. Potomac has not agreed nor is obligated to make, nor is
bound by any Contract under which it may become obligated to make, any future
investment in or capital contribution to any other Entity. Potomac has not, at
any time, been a general partner of, or has otherwise been liable for any of
the debts or other obligations of, any general partnership, limited
partnership or other Entity.

(b) Each of Potomac and the Potomac Subsidiaries is a corporation duly
organized, validly existing and in good standing under the laws of the
jurisdiction of its incorporation and has all necessary power and authority:
(i) to conduct its business in the manner in which its business is currently
being conducted; (ii) to own and use its assets in the manner in which its
assets are currently owned and used; and (iii) to perform its obligations
under all Contracts by which it is bound.

(c) Each of Potomac and the Potomac Subsidiaries is qualified to do business
as a foreign corporation, and is in good standing, under the laws of all
jurisdictions where the nature of its business requires such qualification
other than in jurisdictions where the failure to be so qualified individually
or in the aggregate would not be reasonably expected to have a Potomac
Material Adverse Effect.

2.2 Certificate of Incorporation; Bylaws; Charters and Codes of Conduct.
Potomac has delivered to Tigris accurate and complete copies of the
certificate of incorporation,

 bylaws and other charter and organizational documents, including all currently
effective amendments thereto for Potomac and each Potomac Subsidiary. Part 2.2
of the Potomac Disclosure Schedule lists, and Potomac has delivered to Tigris,
accurate and complete copies of: (a) the charters of all committees of
Potomac's board of directors; and (b) any code of conduct or similar policy
adopted by Potomac or by the board of directors, or any committee of the board
of directors, of Potomac. Neither Potomac nor any Potomac Subsidiary has taken
any action in breach or violation of any of the provisions of its certificate
of incorporation, bylaws and other charter and organizational documents nor is
in breach or violation of any of the material provisions of their respective
certificates of incorporation, bylaws and other charter and organizational
documents, except as would not reasonably be expected to have, individually or
in the aggregate, a Potomac Material Adverse Effect.

2.3 Capitalization, Etc.

(a) The authorized capital stock of Potomac as of the date of this Agreement
consists of (i) 150,000,000 shares of Potomac Common Stock, par value $0.001
per share, of which 2,000,000 shares have been issued and are outstanding as
of the date of this Agreement, and (ii) 100,000,000 shares of Series A
Preferred Stock, par value $0.001 per share, of which 36,932,213 shares have
been issued and are outstanding as of the date of this Agreement. The
authorized capital stock of Potomac as of immediately prior to the Closing
shall consist of (i) 250,000,000 shares of Potomac Common Stock, 189,461,175
shares of which will be issued and outstanding, and (ii) 120,000,000 shares of
preferred stock, par value $0.001 per share (the "Potomac Preferred Stock"),
of which 40,000,000 shares will have been designated Series A Preferred Stock,
40,000,000 of which shares will have been designated Series A-2 Preferred
Stock and 40,000,000 of which shares will have been designated Series A-3
Preferred Stock, none of which shares of Potomac Preferred Stock will be
issued and outstanding. Potomac does not hold any shares of its capital stock
in its treasury. All of the outstanding shares of Potomac Common Stock and
Potomac Preferred Stock have been duly authorized and validly issued, and are
fully paid and nonassessable. Except as set forth in Part 2.3(a) of the
Potomac Disclosure Schedule, none of the outstanding shares of Potomac Common
Stock or Potomac Preferred Stock is entitled or subject to any preemptive
right, right of participation, right of maintenance or any similar right and
none of the outstanding shares of Potomac Common Stock or Potomac Preferred
Stock is subject to any right of first refusal in favor of Potomac. Except as
contemplated herein or as set forth in Part 2.3(a) of the Potomac Disclosure
Schedule, there is no Potomac Contract relating to the voting or registration
of, or restricting any Person from purchasing, selling, pledging or otherwise
disposing of (or granting any option or similar right with respect to), any
shares of Potomac Common Stock or Potomac Preferred Stock. Potomac is not
under any obligation, nor is it bound by any Contract pursuant to which it may
become obligated, to repurchase, redeem or otherwise acquire any outstanding
shares of Potomac Common Stock or other securities. Part 2.3(a) of the Potomac
Disclosure Schedule accurately and completely lists all repurchase rights held
by Potomac with respect to shares of Potomac Common Stock (including shares
issued pursuant to the exercise of stock options) and Potomac Preferred Stock,
and specifies each holder of Potomac Common Stock or Potomac Preferred Stock,
the date of purchase of such Potomac Common Stock or Potomac Preferred Stock,
the number of shares of Potomac Common Stock or Potomac Preferred Stock
subject to such

 repurchase rights, the purchase price paid by such holder, the vesting
schedule under which such repurchase rights lapse, and whether the holder of
such Potomac Common Stock or Potomac Preferred Stock filed an election under
Section 83(b) of the Code with respect to such Potomac Common Stock or Potomac
Preferred Stock within thirty (30) days of purchase. Each share of Potomac
Preferred Stock is convertible into one share of Potomac Common Stock.

(b) Except for the Potomac 2014 Equity Incentive Plan, as amended (the "2014
Plan"), and except as set forth in Part 2.3(b) of the Potomac Disclosure
Schedule, Potomac does not have any stock option plan or any other plan,
program, agreement or arrangement providing for any equity-based compensation
for any Person. Potomac has reserved 12,970,844 shares of Potomac Common Stock
for issuance under the 2014 Plan, of which 1,000,000 shares have been issued
and are currently outstanding, 11,970,844 have been reserved for issuance upon
exercise of Potomac Options granted under the 2014 Plan, and no shares of
Potomac Common Stock remain available for future issuance pursuant to the 2014
Plan. 142,437 shares of Potomac Preferred Stock are reserved for future
issuance pursuant to warrants to purchase Potomac Preferred Stock
(collectively, the "Potomac Warrants"). Part 2.3(b) of the Potomac Disclosure
Schedule sets forth the following information with respect to each Potomac
Option outstanding as of the date of this Agreement: (A) the name of the
optionee; (B) the number of shares of Potomac Common Stock subject to such
Potomac Option at the time of grant; (C) the number of shares of Potomac
Common Stock subject to such Potomac Option as of the date of this Agreement;
(D) the exercise price of such Potomac Option; (E) the date on which such
Potomac Option was granted; (F) the applicable vesting schedule, including the
number of vested and unvested shares; (G) the date on which such Potomac
Option expires; and (H) whether such Potomac Option is an "incentive stock
option" (as defined in the Code) or a non-qualified stock option. Potomac has
made available to Tigris an accurate and complete copy of the 2014 Plan and
forms of all stock option agreements approved for use thereunder. No vesting
of Potomac Options will accelerate in connection with the closing of the
Contemplated Transactions.

(c) Except for the outstanding Potomac Options, Potomac Warrants or as set
forth on Part 2.3(c) of the Potomac Disclosure Schedule, there is no: (i)
outstanding subscription, option, call, warrant or right (whether or not
currently exercisable) to acquire any shares of the capital stock or other
securities of Potomac or any of its Subsidiaries; (ii) outstanding security,
instrument or obligation that is or may become convertible into or
exchangeable for any shares of the capital stock or other securities of
Potomac or any of its Subsidiaries; (iii) stockholder rights plan (or similar
plan commonly referred to as a "poison pill") or Contract under which Potomac
or any of its Subsidiaries is or may become obligated to sell or otherwise
issue any shares of its capital stock or any other securities; or (iv)
condition or circumstance that may give rise to or provide a basis for the
assertion of a claim by any Person to the effect that such Person is entitled
to acquire or receive any shares of capital stock or other securities of
Potomac or any of its Subsidiaries. There are no outstanding or authorized
stock appreciation, phantom stock, profit participation or other similar
rights with respect to Potomac or any of its Subsidiaries.

(d) All outstanding shares of Potomac Common Stock, Potomac Preferred Stock,
options, warrants and other securities of Potomac have been issued and granted
in

 material compliance with (i) all applicable securities laws and other
applicable Legal Requirements, and (ii) all requirements set forth in
applicable Contracts. Potomac has delivered to Tigris accurate and complete
copies of all Potomac Warrants.

2.4 Financial Statements.

(a) Part 2.4(a) of the Potomac Disclosure Schedule includes true and complete
copies of (i) Potomac's audited consolidated balance sheets at December 31,
2012 and December 31, 2013, (ii) the Potomac Unaudited Interim Balance Sheet,
(iii) Potomac's audited consolidated statements of income, cash flow and
shareholders' equity for the years ended December 31, 2012 and December 31,
2013, and (iv) Potomac's draft unaudited statements of income, cash flow and
shareholders' equity for the three (3) months ended March 31, 2014
(collectively, the "Potomac Financials"). The Potomac Financials (i) were
prepared in accordance with United States generally accepted accounting
principles ("GAAP") (except as may be indicated in the footnotes to such
Potomac Financials and that unaudited financial statements may not have notes
thereto and other presentation items that may be required by GAAP and are
subject to normal and recurring year-end adjustments that are not reasonably
expected to be material in amount) applied on a consistent basis unless
otherwise noted therein throughout the periods indicated and (ii) fairly
present the financial condition and operating results of Potomac and its
consolidated Subsidiaries as of the dates and for the periods indicated
therein.

(b) Each of Potomac and its Subsidiaries maintains a system of internal
accounting controls designed to provide reasonable assurance that: (i)
transactions are executed in accordance with management's general or specific
authorizations; (ii) transactions are recorded as necessary to permit
preparation of financial statements in conformity with GAAP and to maintain
asset accountability; (iii) access to assets is permitted only in accordance
with management's general or specific authorization; and (iv) the recorded
accountability for assets is compared with the existing assets at reasonable
intervals and appropriate action is taken with respect to any differences;
provided, however, that neither Potomac nor any of its Subsidiaries has
adopted or conducted an evaluation of compliance of Potomac's or such
Subsidiary's internal accounting controls with, the Internal Control Framework
developed by the Committee of Sponsoring Organizations of the Treadway
Commission. Potomac and each of its Subsidiaries maintains internal control
over financial reporting that provides reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with GAAP.

(c) Part 2.4(c) of the Potomac Disclosure Schedule lists, and Potomac has
delivered to Tigris accurate and complete copies of the documentation creating
or governing, all securitization transactions and "off-balance sheet
arrangements" (as defined in Item 303(c) of Regulation S-K under the Exchange
Act) effected by Potomac or any of its Subsidiaries since January 1, 2010.

(d) Since January 1, 2010, there have been no formal internal investigations
regarding financial reporting or accounting policies and practices discussed
with, reviewed by or initiated at the direction of the chief executive
officer, chief financial officer or general counsel of Potomac, Potomac's
Board of Directors or any committee thereof. Since January 1, 2010,

 neither Potomac nor its independent auditors have identified (i) any
significant deficiency or material weakness in the system of internal
accounting controls utilized by Potomac and the Potomac Subsidiaries, (ii) any
fraud, whether or not material, that involves Potomac's management or other
employees who have a role in the preparation of financial statements or the
internal accounting controls utilized by Potomac and the Potomac Subsidiaries
or (iii) any claim or allegation regarding any of the foregoing.

2.5 Absence of Changes. Except as set forth on Part 2.5 of the Potomac
Disclosure Schedule, between December 31, 2013 and the date of this Agreement:

(a) there has not been any Potomac Material Adverse Effect or an event or
development that would, individually or in the aggregate, reasonably be
expected to have a Potomac Material Adverse Effect;

(b) there has not been any material loss, damage or destruction to, or any
material interruption in the use of, any of the assets or business of Potomac
or any Potomac Subsidiary (whether or not covered by insurance);

(c) Potomac has not: (i) declared, accrued, set aside or paid any dividend or
made any other distribution in respect of any shares of capital stock; or (ii)
repurchased, redeemed or otherwise reacquired any shares of capital stock or
other securities except for the repurchase or reacquisition of shares pursuant
to Potomac rights arising upon an individual's termination as an employee,
director or consultant;

(d) Potomac has not sold, issued or granted, or authorized the issuance of:
(i) any capital stock or other security (except for Potomac Common Stock
issued upon the valid exercise of outstanding Potomac Options); (ii) any
option, warrant or right to acquire any capital stock or any other security
(except for Potomac Options identified in Part 2.3(b) of the Potomac
Disclosure Schedule); or (iii) any instrument convertible into or exchangeable
for any capital stock or other security except for Potomac Options identified
in Part 2.3(b) of the Potomac Disclosure Schedule;

(e) there has been no amendment to the certificate of incorporation, bylaws or
other charter or organizational documents of Potomac or any Potomac
Subsidiary, and neither Potomac nor any Potomac Subsidiary has effected or
been a party to any merger, consolidation, share exchange, business
combination, recapitalization, reclassification of shares, stock split,
reverse stock split or similar transaction;

(f) Potomac has not amended or waived any of its rights under, or exercised
its discretion to permit the acceleration of vesting under any provision of:
(i) the 2014 Plan; (ii) any Potomac Option or any Contract evidencing or
relating to any Potomac Option; (iii) any restricted stock purchase agreement;
or (iv) any other Contract evidencing or relating to any equity award (whether
payable in cash or stock);

(g) Neither Potomac nor any Potomac Subsidiary has formed any Subsidiary or
acquired any equity interest or other interest in any other Entity;

 (h) Neither Potomac nor any Potomac Subsidiary has: (i) lent money to any
Person; (ii) incurred or guaranteed any indebtedness; (iii) issued or sold any
debt securities or options, warrants, calls or other rights to acquire any
debt securities; (iv) guaranteed any debt securities of others; or (v) made
any capital expenditure or commitment in excess of $100,000;

(i) Neither Potomac nor any Potomac Subsidiary has changed any of its
accounting methods, principles or practices;

(j) Neither Potomac nor any Potomac Subsidiary has made, changed or revoked
any material Tax election, filed any material amendment to any Tax Return,
adopted or changed any accounting method in respect of Taxes, changed any
annual Tax accounting period, entered into any Tax allocation agreement, Tax
sharing agreement or Tax indemnity agreement, other than commercial contracts
entered into in the Ordinary Course of Business with vendors, customers or
landlords, entered into any closing agreement with respect to any Tax, settled
or compromised any claim, notice, audit report or assessment in respect of
material Taxes, applied for or entered into any ruling from any Tax authority
with respect to Taxes, surrendered any right to claim a material Tax refund,
or consented to any extension or waiver of the statute of limitations period
applicable to any material Tax claim or assessment;

(k) Neither Potomac nor any Potomac Subsidiary has commenced or settled any
Legal Proceeding;

(l) Neither Potomac nor any Potomac Subsidiary has entered into any material
transaction outside the Ordinary Course of Business;

(m) Neither Potomac nor any Potomac Subsidiary has acquired any material
assets nor sold, leased or otherwise irrevocably disposed of any of its
material assets or properties, nor has any Encumbrance been granted with
respect to such assets or properties, except for Encumbrances of immaterial
assets in the Ordinary Course of Business consistent with past practices;

(n) there has been no entry into, amendment or termination of any Potomac
Material Contract;

(o) there has been no (i) material change in pricing or royalties or other
payments set or charged by Potomac or any Potomac Subsidiary to its customers
or licensees, (ii) agreement by Potomac or any Potomac Subsidiary to change
pricing or royalties or other payments set or charged by persons who have
licensed Intellectual Property to Potomac or any Potomac Subsidiary, or (iii)
material change in pricing or royalties or other payments set or charged by
persons who have licensed Intellectual Property to Potomac or any Potomac
Subsidiary; and

(p) Neither Potomac nor any Potomac Subsidiary has negotiated, agreed or
committed to take any of the actions referred to in clauses "(c)" through
"(o)" above (other than negotiations between the Parties to enter into this
Agreement).

 2.6 Title to Assets. Each of Potomac and the Potomac Subsidiaries owns, and
has good and valid title to, or, in the case of leased properties and assets,
valid leasehold interests in, all tangible properties or assets and equipment
used or held for use in its business or operations or purported to be owned by
it, including: (a) all assets reflected on the Potomac Unaudited Interim
Balance Sheet; and (b) all other assets reflected in the books and records of
Potomac or any Potomac Subsidiary as being owned by Potomac or such Potomac
Subsidiary. All of said assets are owned by Potomac or a Potomac Subsidiary
free and clear of any Encumbrances, except for: (i) any lien for current Taxes
not yet due and payable or for Taxes that are being contested in good faith
and for which adequate reserves have been made on the Potomac Unaudited
Interim Balance Sheet; (ii) minor liens that have arisen in the Ordinary
Course of Business and that do not (in any case or in the aggregate)
materially detract from the value of the assets subject thereto or materially
impair the operations of Potomac or any Potomac Subsidiary; and (iii) liens
listed in Part 2.6 of the Potomac Disclosure Schedule.

2.7 Real Property; Leasehold. Neither Potomac nor any Potomac Subsidiary owns
any real property or any interest in real property, except for the leaseholds
created under the real property leases identified in Part 2.7 of the Potomac
Disclosure Schedule which are in full force and effect and with no existing
default thereunder.

2.8 Intellectual Property.

(a) Potomac, directly or through a Potomac Subsidiary, owns, or has the right
to use, and has the right to bring actions for the infringement of, all
Potomac IP Rights, except for any failure to own or have the right to use, or
have the right to bring actions that would not reasonably be expected to have
a Potomac Material Adverse Effect.

(b) Part 2.8(b) of the Potomac Disclosure Schedule is an accurate, true and
complete listing of all Potomac Registered IP.

(c) Part 2.8(c) of the Potomac Disclosure Schedule accurately identifies (i)
all Potomac IP Rights licensed to Potomac or any Potomac Subsidiary (other
than (I) any non-customized software that (A) is so licensed solely in
executable or object code form pursuant to a non-exclusive, internal use
software license and other Intellectual Property associated with such software
and (B) is not incorporated into, or material to the development,
manufacturing, or distribution of, any of Potomac's or any Potomac
Subsidiary's products or services and (II) any Intellectual Property licensed
ancillary to the purchase or use of equipment, reagents or other materials);
(ii) the corresponding Potomac Contracts pursuant to which such Potomac IP
Rights are licensed to Potomac or any Potomac Subsidiary; and (iii) whether
the license or licenses granted to Potomac or any Potomac Subsidiary are
exclusive or non-exclusive.

(d) Part 2.8(d)(i) of the Potomac Disclosure Schedule accurately identifies
each Potomac Contract pursuant to which any Person has been granted any
license under, or otherwise has received or acquired any right (whether or not
currently exercisable) or interest in, any Potomac IP Rights. Except as
identified in Part 2.8(d)(ii) of the Potomac Disclosure Schedule, Potomac is
not bound by, and no Potomac IP Rights are subject to, any Contract containing
any covenant or other provision that in any way limits or restricts the
ability of

 Potomac or any Potomac Subsidiary to use, exploit, assert, or enforce any
Potomac IP Rights anywhere in the world in each case as would materially limit
the business of Potomac as conducted or planned to be conducted.

(e) Except as identified in Part 2.8(e) of the Potomac Disclosure Schedule, to
the Knowledge of Potomac and its Subsidiaries, Potomac or one of its
Subsidiaries exclusively owns all right, title, and interest to and in Potomac
IP Rights (other than Potomac IP Rights (i) exclusively and non-exclusively
licensed to Potomac or one of its Subsidiaries, as identified in Part 2.8(c)
of the Potomac Disclosure Schedule and (ii) (I) any non-customized software
that (A) is so licensed solely in executable or object code form pursuant to a
non-exclusive, internal use software license and other Intellectual Property
associated with such software and (B) is not incorporated into, or material to
the development, manufacturing, or distribution of, any of Potomac's or any
Potomac Subsidiary's products or services and (II) any Intellectual Property
licensed ancillary to the purchase or use of equipment, reagents or other
materials) free and clear of any Encumbrances (other than those Encumbrances
which would not materially limit the business of Potomac as conducted or
planned to be conducted). Without limiting the generality of the foregoing:

(i) All documents and instruments necessary to register or apply for or renew
registration of Potomac Registered IP have been validly executed, delivered,
and filed in a timely manner with the appropriate Governmental Body except for
any such failure, individually or collectively, that would not reasonably be
expected to have a Potomac Material Adverse Effect.

(ii) Each Person who is or was an employee or contractor of Potomac or any
Potomac Subsidiary and who is or was involved in the creation or development
of any Potomac IP Rights has signed a valid, enforceable agreement containing
an assignment of such Intellectual Property to Potomac or such Subsidiary and
confidentiality provisions protecting trade secrets and confidential
information of Potomac and its Subsidiaries. To the Knowledge of Potomac and
its Subsidiaries, no current or former stockholder, officer, director, or
employee of Potomac or any of its Subsidiaries has any claim, right (whether
or not currently exercisable), or interest to or in any Potomac IP Rights. To
the Knowledge of Potomac and its Subsidiaries, no employee of Potomac or any
or any Potomac Subsidiary is (a) bound by or otherwise subject to any Contract
restricting him or her from performing his or her duties for Potomac or such
Subsidiary or (b) in breach of any Contract with any former employer or other
Person concerning Potomac IP Rights or confidentiality provisions protecting
trade secrets and confidential information comprising Potomac IP Rights.

(iii) No funding, facilities, or personnel of any Governmental Body were used,
directly or indirectly, to develop or create, in whole or in part, any Potomac
IP Rights in which Potomac or any of its Subsidiaries has an ownership
interest.

(iv) Potomac and each of its Subsidiaries has taken reasonable steps to
maintain the confidentiality of and otherwise protect and enforce its rights
in all proprietary information that Potomac or such Subsidiary holds, or
purports to hold, as a trade secret.

 (v) Neither Potomac nor any of its Subsidiaries has assigned or otherwise
transferred ownership of, or agreed to assign or otherwise transfer ownership
of, any Potomac IP Rights to any other Person.

(vi) To the Knowledge of Potomac and its Subsidiaries, the Potomac IP Rights
constitute all Intellectual Property necessary for Potomac and its
Subsidiaries to conduct its business as currently conducted and planned to be
conducted.

(f) Potomac has delivered, or made available to Tigris, a complete and
accurate copy of all Potomac IP Rights Agreements. Neither Potomac nor any
Potomac Subsidiary is a party to any Contract (A) pursuant to which the
execution, delivery and performance of this Agreement and the consummation of
the Contemplated Transactions will constitute a breach, or (B) as a result of
such execution, delivery and performance of this Agreement and the
consummation of the Contemplated Transactions will cause the forfeiture or
termination of or Encumbrance upon, or the grant of any license or other right
to, or give rise to a right of forfeiture or termination of or Encumbrance
upon, any Potomac IP Rights or impair the right of Potomac or the Surviving
Corporation and its Subsidiaries to use, sell or license any Potomac IP Rights
or portion thereof, except for the occurrence of any such breach, forfeiture,
termination, Encumbrance, grant or impairment that would not individually or
in the aggregate, reasonably be expected to result in a Potomac Material
Adverse Effect. With respect to each of the Potomac IP Rights Agreements: (i)
each such agreement is valid and binding on Potomac or its Subsidiaries, as
applicable, and in full force and effect; (ii) Potomac has not received any
written notice of termination or cancellation under such agreement, or
received any written notice of breach or default under such agreement, which
breach has not been cured or waived; and (iii) neither Potomac nor its
Subsidiaries, and to the Knowledge of Potomac, no other party to any such
agreement, is in breach or default thereof in any material respect.

(g) The manufacture, marketing, license, sale or intended use of any product
or technology currently licensed or sold or under development by Potomac or
any of its Subsidiaries does not violate any license or agreement between
Potomac or its Subsidiaries and any third party, and, to the Knowledge of
Potomac and its Subsidiaries, does not infringe or misappropriate any
Intellectual Property right of any other party, which infringement or
misappropriation would reasonably be expected to have a Potomac Material
Adverse Effect. Potomac has disclosed in correspondence to Tigris the third-
party patents and patent applications found during all freedom to operate
searches that were conducted by Potomac or its Subsidiaries related to any
product or technology currently licensed or sold or under development by
Potomac or its Subsidiaries. To the Knowledge of Potomac and its Subsidiaries,
no third party is infringing upon, or violating any license or agreement with
Potomac or its Subsidiaries relating to any Potomac IP Rights. There is no
current or pending challenge, claim or Legal Proceeding (including, but not
limited to, opposition, interference or other proceeding in any patent or
other government office) contesting the validity, ownership or right to use,
sell, license or dispose of any Potomac IP Rights, nor has Potomac or any of
its Subsidiaries received any written notice asserting that any Potomac IP
Rights or the proposed use, sale, license or disposition thereof conflicts
with or infringes or misappropriates or will conflict with or infringe or
misappropriate the rights of any other Person.

 (h) Each item of Potomac IP Rights that is Potomac Registered IP is and at all
times has been filed and maintained in compliance with all applicable Legal
Requirements and all filings, payments, and other actions required to be made
or taken to maintain such item of Potomac Registered IP in full force and
effect have been made by the applicable deadline, except for any failure to
perform any of the foregoing, individually or collectively, that would not
reasonably be expected to have a Potomac Material Adverse Effect.

(i) To the Knowledge of Potomac and its Subsidiaries, no trademark (whether
registered or unregistered) or trade name owned, used, or applied for by
Potomac or any of its Subsidiaries conflicts or interferes with any trademark
(whether registered or unregistered) or trade name owned, used, or applied for
by any other Person. None of the goodwill associated with or inherent in any
trademark (whether registered or unregistered) in which Potomac or any of its
Subsidiaries has or purports to have an ownership interest has been impaired
as determined by Potomac or any of its Subsidiaries in accordance with GAAP.

(j) Except as set forth in Parts 2.8(c) or 2.8(d) of the Potomac Disclosure
Schedule (i) neither Potomac nor any of its Subsidiaries is bound by any
Contract to indemnify, defend, hold harmless, or reimburse any other Person
with respect to any Intellectual Property infringement, misappropriation, or
similar claim, and (ii) neither Potomac nor any of its Subsidiaries has ever
assumed, or agreed to discharge or otherwise take responsibility for, any
existing or potential liability of another Person for infringement,
misappropriation, or violation of any Intellectual Property right, which
assumption, agreement or responsibility remains in force as of the date of
this Agreement.

2.9 Agreements, Contracts and Commitments. Part 2.9 of the Potomac Disclosure
Schedule identifies, except for Potomac Contracts set forth in Part 2.13 of
the Potomac Disclosure Schedule:

(a) each Potomac Contract relating to any bonus, deferred compensation,
severance, incentive compensation, pension, profit-sharing or retirement
plans, or any other employee benefit plans or arrangements;

(b) each Potomac Contract relating to the employment of, or the performance of
employment-related services by, any Person, including any employee, consultant
or independent contractor, not terminable by Potomac or its Subsidiaries on
ninety (90) days notice without liability, except to the extent general
principles of wrongful termination law may limit Potomac's, Potomac's
Subsidiaries' or such successor's ability to terminate employees at will;

(c) each Potomac Contract relating to any agreement or plan, including,
without limitation, any stock option plan, stock appreciation right plan or
stock purchase plan, any of the benefits of which will be increased, or the
vesting of benefits of which will be accelerated, by the occurrence of any of
the Contemplated Transactions (either alone or in conjunction with any other
event, such as termination of employment) or the value of any of the benefits
of which will be calculated on the basis of any of the Contemplated
Transactions;

 (d) each Potomac Contract relating to any agreement of indemnification or
guaranty not entered into in the Ordinary Course of Business other than
indemnification agreements between Potomac and any of its respective officers
or directors;

(e) each Potomac Contract relating to any agreement, contract or commitment
containing any covenant limiting the freedom of Potomac, its Subsidiaries or
the Surviving Corporation to engage in any line of business or compete with
any Person;

(f) each Potomac Contract relating to any agreement, contract or commitment
relating to capital expenditures and involving obligations after the date of
this Agreement in excess of $100,000 and not cancelable without penalty;

(g) each Potomac Contract relating to any agreement, contract or commitment
currently in force relating to the disposition or acquisition of material
assets or any ownership interest in any Entity;

(h) each Potomac Contract relating to any mortgages, indentures, loans, notes
or credit agreements, security agreements or other agreements or instruments
relating to the borrowing of money or extension of credit in excess of
$100,000 or creating any material Encumbrances with respect to any assets of
Potomac or any Potomac Subsidiary or any loans or debt obligations with
officers or directors of Potomac;

(i) each Potomac Contract relating to (i) any distribution agreement
(identifying any that contain exclusivity provisions); (ii) any agreement
involving provision of services or products with respect to any pre-clinical
or clinical development activities of Potomac (iii) any dealer, distributor,
joint marketing, alliance, joint venture, cooperation, development or other
agreement currently in force under which Potomac or its Subsidiaries has
continuing obligations to develop or market any product, technology or
service, or any agreement pursuant to which Potomac or its Subsidiaries has
continuing obligations to develop any Intellectual Property that will not be
owned, in whole or in part, by Potomac or such Potomac Subsidiary; or (iv) any
Contract currently in force to license any third party to manufacture or
produce any Potomac product, service or technology or any Contract currently
in force to sell, distribute or commercialize any Potomac products or service
except agreements with distributors or sales representatives in the Ordinary
Course of Business;

(j) each Potomac Contract with any Person, including without limitation any
financial advisor, broker, finder, investment banker or other Person,
providing advisory services to Potomac in connection with the Contemplated
Transactions; or

(k) any other agreement, contract or commitment (i) which involves payment or
receipt by Potomac or its Subsidiaries under any such agreement, contract or
commitment of $100,000 or more in the aggregate or obligations after the date
of this Agreement in excess of $100,000 in the aggregate, or (ii) that is
material to the business or operations of Potomac and its Subsidiaries.

 Potomac has delivered to Tigris accurate and complete (except for applicable
redactions thereto) copies of all Potomac Material Contracts, including all
amendments thereto. There are no Potomac Material Contracts that are not in
written form. Except as set forth on Part 2.9 of the Potomac Disclosure
Schedule, neither Potomac nor any of its Subsidiaries has, nor to Potomac's
Knowledge, as of the date of this Agreement has any other party to a Potomac
Material Contract, breached, violated or defaulted under, or received notice
that it has breached, violated or defaulted under, any of the terms or
conditions of any of the agreements, contracts or commitments to which Potomac
or its Subsidiaries is a party or by which it is bound of the type described
in clauses (a) through (k) above (any such agreement, contract or commitment,
a "Potomac Material Contract") in such manner as would permit any other party
to cancel or terminate any such Potomac Material Contract, or would permit any
other party to seek damages which would reasonably be expected to have a
Potomac Material Adverse Effect. As to Potomac and its Subsidiaries, as of the
date of this Agreement, each Potomac Material Contract is valid, binding,
enforceable and in full force and effect, subject to: (i) laws of general
application relating to bankruptcy, insolvency and the relief of debtors; and
(ii) rules of law governing specific performance, injunctive relief and other
equitable remedies. The consummation of the Contemplated Transactions shall
not result in any material payment or payments becoming due from Potomac, any
Potomac Subsidiary, the Surviving Corporation or Tigris to any Person under
any Potomac Contract or give any Person the right to terminate or alter the
provisions of any Potomac Contract. No Person is renegotiating, or has a right
pursuant to the terms of any Potomac Material Contract to change, any material
amount paid or payable to Potomac under any Potomac Material Contract or any
other material term or provision of any Potomac Material Contract.

2.10 Liabilities. As of the date hereof, neither Potomac nor any Potomac
Subsidiary has any liability, indebtedness, obligation, expense, claim,
deficiency, guaranty or endorsement of any kind, whether accrued, absolute,
contingent, matured, unmatured or other (whether or not required to be
reflected in the financial statements in accordance with GAAP) (each a
"Liability"), individually or in the aggregate, except for: (a) Liabilities
identified as such in the "liabilities" column of the Potomac Unaudited
Interim Balance Sheet; (b) normal and recurring current Liabilities that have
been incurred by Potomac or its Subsidiaries since the date of the Potomac
Unaudited Interim Balance Sheet in the Ordinary Course of Business and which
are not in excess of $100,000 in the aggregate; (c) Liabilities for
performance of obligations of Potomac or any Potomac Subsidiary under Potomac
Contracts; (d) Liabilities incurred in connection with this Agreement, the
Subscription Agreement, the Tigris Notes, and the Debt Conversion Agreement
entered into between Potomac and certain holders of its secured debt
instruments; and (e) Liabilities listed in Part 2.10 of the Potomac Disclosure
Schedule.

2.11 Compliance; Permits; Restrictions.

(a) Potomac and each Potomac Subsidiary are, and since January 1, 2010 have
been, in compliance in all material respects with all applicable Legal
Requirements. No investigation, claim, suit, proceeding, audit or other action
by any Governmental Body or authority is pending or, to the Knowledge of
Potomac, threatened against Potomac or any Potomac Subsidiary, nor has any
Governmental Body or authority indicated to Potomac an

 intention to conduct the same. There is no agreement, judgment, injunction,
order or decree binding upon Potomac or any Potomac Subsidiary which (i) has
or would reasonably be expected to have the effect of prohibiting or
materially impairing any business practice of Potomac or any Potomac
Subsidiary, any acquisition of material property by Potomac or any Potomac
Subsidiary or the conduct of business by Potomac or any Potomac Subsidiary as
currently conducted, (ii) may have an adverse effect on Potomac's ability to
comply with or perform any covenant or obligation under this Agreement, or
(iii) may have the effect of preventing, delaying, making illegal or otherwise
interfering with the Merger or any of the Contemplated Transactions.

(b) Potomac and the Potomac Subsidiaries hold all required Governmental
Authorizations which are material to the operation of the business of Potomac
(the "Potomac Permits") as currently conducted. Part 2.11(b) of the Potomac
Disclosure Schedule identifies each Potomac Permit. Each of Potomac and each
Potomac Subsidiary is in material compliance with the terms of the Potomac
Permits. No action, proceeding, revocation proceeding, amendment procedure,
writ, injunction or claim is pending or, to the Knowledge of Potomac,
threatened, which seeks to revoke, limit, suspend, or materially modify any
Potomac Permit. The rights and benefits of each material Potomac Permit will
be available to the Surviving Corporation immediately after the Effective Time
on terms substantially identical to those enjoyed by Potomac and its
Subsidiaries as of the date of this Agreement and immediately prior to the
Effective Time.

(c) There are no proceedings pending or threatened with respect to an alleged
violation by Potomac or any of its Subsidiaries of the Federal Food, Drug, and
Cosmetic Act ("FDCA"), Food and Drug Administration ("FDA") regulations
adopted thereunder, the Controlled Substance Act or any other similar Legal
Requirements promulgated by the FDA or other comparable Governmental Body
responsible for regulation of the development, clinical testing,
manufacturing, sale, marketing, distribution and importation or exportation of
drug products ("Drug Regulatory Agency").

(d) Potomac and each of its Subsidiaries holds all required Governmental
Authorizations issuable by any Drug Regulatory Agency necessary for the
conduct of the business of Potomac or such Subsidiary as currently conducted,
and development, clinical testing, manufacturing, marketing, distribution and
importation or exportation, as currently conducted, of any of its products or
product candidates (the "Potomac Product Candidates") (collectively, the
"Potomac Regulatory Permits") and no such Potomac Regulatory Permit has been
(i) revoked, withdrawn, suspended, cancelled or terminated or (ii) modified in
any adverse manner, other than immaterial adverse modifications. Potomac and
each Potomac Subsidiary is in compliance in all material respects with the
Potomac Regulatory Permits and has not received any written notice or other
written communication from any Drug Regulatory Agency regarding (A) any
material violation of or failure to comply materially with any term or
requirement of any Potomac Regulatory Permit or (B) any revocation,
withdrawal, suspension, cancellation, termination or material modification of
any Potomac Regulatory Permit. Except for the information and files identified
in Part 2.11(d) of the Potomac Disclosure Schedule, Potomac has made available
to Tigris all information requested by Tigris in Potomac's or its
Subsidiaries' possession or control relating to the Potomac Product Candidates
and the development, clinical

 testing, manufacturing, importation and exportation of the Potomac Product
Candidates, including without limitation, complete copies of the following (to
the extent there are any): (x) adverse event reports; clinical study reports
and material study data; and inspection reports, notices of adverse findings,
warning letters, filings and letters and other written correspondence to and
from any Drug Regulatory Agency; and meeting minutes with any Drug Regulatory
Agency; and (y) similar reports, material study data, notices, letters,
filings, correspondence and meeting minutes with any other Governmental
Authority.

(e) All clinical, pre-clinical and other studies and tests conducted by or on
behalf of, or sponsored by, Potomac or its Subsidiaries or in which Potomac or
its Subsidiaries or their respective current products or product candidates,
including the Potomac Product Candidates, have participated were and, if still
pending, are being conducted in all material respects in accordance with
standard medical and scientific research procedures and in compliance with the
applicable regulations of the Drug Regulatory Agencies and other applicable
Legal Requirements, including, without limitation, 21 C.F.R. Parts 50, 54, 56,
58 and 312. Since January 1, 2010, neither Potomac nor any of its Subsidiaries
has received any notices, correspondence, or other communications from any
Drug Regulatory Agency requiring, or to the Knowledge of Potomac, threatening
to initiate, the termination or suspension of any clinical studies conducted
by or on behalf of, or sponsored by, Potomac or any of its Subsidiaries or in
which Potomac or any of its Subsidiaries or their respective current products
or product candidates, including the Potomac Product Candidates, have
participated.

(f) Neither Potomac nor any of the Potomac Subsidiaries is the subject of any
pending, or to the Knowledge of Potomac or the Potomac Subsidiaries,
threatened investigation in respect of its business or products by the FDA
pursuant to its "Fraud, Untrue Statements of Material Facts, Bribery, and
Illegal Gratuities" Final Policy set forth in 56 Fed. Reg. 46191 (September
10, 1991) and any amendments thereto. To the Knowledge of Potomac or any of
the Potomac Subsidiaries, neither Potomac nor any of the Potomac Subsidiaries
has committed any acts, made any statement, or failed to make any statement,
in each case in respect of its business or products that would violate the
FDA's "Fraud, Untrue Statements of Material Facts, Bribery, and Illegal
Gratuities" Final Policy, and any amendments thereto. None of Potomac, any of
its Subsidiaries or any of their respective officers, employees or agents has
been convicted of any crime or engaged in any conduct that could result in a
debarment or exclusion (i) under 21 U.S.C. Section 335a or (ii) any similar
applicable Legal Requirement. To the Knowledge of Potomac, no debarment or
exclusionary claims, actions, proceedings or investigations in respect of
their business or products are pending or threatened against Potomac, any
Potomac Subsidiary or any of their respective officers, employees or agents.

2.12 Tax Matters.

(a) Potomac and each Potomac Subsidiary have timely filed all federal income
Tax Returns and other material Tax Returns that they were required to file
under applicable Legal Requirements. All such Tax Returns were correct and
complete in all material respects and have been prepared in material
compliance with all applicable Legal Requirements. Neither Potomac nor any
Potomac Subsidiary is currently the beneficiary of any extension of

 time within which to file any Tax Return. No claim has ever been made by an
authority in a jurisdiction where Potomac or any Potomac Subsidiary does not
file Tax Returns that it is subject to taxation by that jurisdiction.

(b) All material Taxes due and owing by Potomac or any Potomac Subsidiary on
or before the date hereof (whether or not shown on any Tax Return) have been
paid. The unpaid Taxes of Potomac and any Potomac Subsidiary have been
reserved for on the Potomac Unaudited Interim Balance Sheet in accordance with
GAAP. Since the date of the Potomac Unaudited Interim Balance Sheet, neither
Potomac nor any Potomac Subsidiary has incurred any Liability for Taxes
outside the Ordinary Course of Business or otherwise inconsistent with past
custom and practice.

(c) Potomac and each Potomac Subsidiary have withheld and paid all Taxes
required to have been withheld and paid in connection with any amounts paid or
owing to any employee, independent contractor, creditor, stockholder, or other
third party.

(d) There are no Encumbrances for Taxes (other than Taxes not yet due and
payable or Taxes that are being contested in good faith and for which adequate
reserves have been made on Potomac's Unaudited Interim Balance Sheet) upon any
of the assets of Potomac or any Potomac Subsidiary.

(e) No deficiencies for Taxes with respect to Potomac or any Potomac
Subsidiary have been claimed, proposed or assessed by any Governmental Body in
writing. There are no pending (or, based on written notice, threatened)
audits, assessments or other actions for or relating to any liability in
respect of Taxes of Potomac or any Potomac Subsidiary. No issues relating to
Taxes of Potomac or any Potomac Subsidiary were raised by the relevant Tax
authority in any completed audit or examination that would reasonably be
expected to result in a material amount of Taxes in a later taxable period.
Potomac has delivered or made available to Tigris complete and accurate copies
of all federal income Tax and all other material Tax Returns of Potomac and
each Potomac Subsidiary (and predecessors of each) for all taxable years
remaining open under the applicable statute of limitations, and complete and
accurate copies of all examination reports and statements of deficiencies
assessed against or agreed to by Potomac and each Potomac Subsidiary (and
predecessors of each), with respect to federal income Tax and all other
material Taxes. Neither Potomac nor any Potomac Subsidiary (or any of their
predecessors) has waived any statute of limitations in respect of Taxes or
agreed to any extension of time with respect to a Tax assessment or
deficiency, nor has any request been made in writing for any such extension or
waiver.

(f) All material elections with respect to Taxes affecting Potomac or any
Potomac Subsidiary as of the date hereof, to the extent such elections are not
shown on or in the Tax Returns that have been delivered or made available to
Tigris, are set forth on Schedule 2.12(f). Neither Potomac nor any Potomac
Subsidiary (i) has consented at any time under former Section 341(f)(1) of the
Code to have the provisions of former Section 341(f)(2) of the Code apply to
any disposition of the assets of Potomac or any Potomac Subsidiary; (ii) has
agreed, or is required, to make any adjustment under Section 481(a) of the
Code by reason of a change in accounting method or otherwise; (iii) has made
an election, or is required, to treat any of its

 assets as owned by another Person for Tax purposes or as a tax-exempt bond
financed property or tax-exempt use property within the meaning of Section 168
of the Code; (iv) has acquired or owns any assets that directly or indirectly
secure any debt the interest on which is tax exempt under Section 103(a) of
the Code; (v) has made or will make a consent dividend election under Section
565 of the Code; (vi) has elected at any time to be treated as an S
corporation within the meaning of Sections 1361 or 1362 of the Code; or (vii)
has made any of the foregoing elections or is required to apply any of the
foregoing rules under any comparable provision of state, local or foreign law.

(g) Neither Potomac nor any Potomac Subsidiary has been a United States real
property holding corporation within the meaning of Section 897(c)(2) of the
Code during the applicable period specified in Section 897(c)(1)(A)(ii) of the
Code.

(h) Neither Potomac nor any Potomac Subsidiary is a party to any Tax
allocation, Tax sharing or similar agreement (including indemnity
arrangements), other than commercial contracts entered into in the Ordinary
Course of Business with vendors, customers and landlords.

(i) Neither Potomac nor any Potomac Subsidiary has ever been a member of an
affiliated group filing a consolidated, combined or unitary Tax Return (other
than a group the common parent of which is Potomac) for federal, state, local
or foreign Tax purposes. Neither Potomac nor any Potomac Subsidiary has any
Liability for the Taxes of any Person (other than Potomac and any Potomac
Subsidiary) under Treasury Regulations Section 1.1502-6 (or any similar
provision of state, local, or foreign law), as a transferee or successor, by
Contract, or otherwise.

(j) Neither Potomac nor any Potomac Subsidiary has distributed stock of
another Person, or has had its stock distributed by another Person, in a
transaction that was purported or intended to be governed in whole or in part
by Section 355 of the Code or Section 361 of the Code.

(k) Neither Potomac nor any Potomac Subsidiary will be required to include any
item of income in, or exclude any item of deduction from, taxable income for
any period (or any portion thereof) ending after the Closing Date as a result
of any (i) installment sale or other open transaction disposition made on or
prior to the Closing Date, or (ii) agreement with any Tax authority (including
any closing agreement described in Section 7121 of the Code or any similar
provision of state, local or foreign law) made or entered into on or prior to
the Closing Date.

(l) Neither Potomac nor any Potomac Subsidiary is a partner for Tax purposes
with respect to any joint venture, partnership, or, to the Knowledge of
Potomac, other arrangement or contract which is treated as a partnership for
Tax purposes.

(m) Neither Potomac nor any Potomac Subsidiary has entered into any
transaction identified as a "listed transaction" for purposes of Treasury
Regulations Sections 1.6011-4(b)(2) or 301.6111-2(b)(2).

 (n) Neither Potomac nor any Potomac Subsidiary has taken any action, or has
any knowledge of any fact or circumstance, that could reasonably be expected
to prevent the transactions contemplated hereby, including the Merger and the
Second Merger, considered together as a single integrated transaction for
United States federal income Tax purposes, from qualifying as a reorganization
within the meaning of Section 368(a) of the Code.

2.13 Employee and Labor Matters; Benefit Plans.

(a) The employment of each of the Potomac and Potomac Subsidiary employees is
terminable by Potomac or the applicable Potomac Subsidiary at will (or
otherwise in accordance with general principles of wrongful termination law).
Potomac has made available to Tigris accurate and complete copies of all
employee manuals and handbooks, disclosure materials, policy statements and
other materials relating to the employment of Potomac Associates to the extent
currently effective and material.

(b) To the Knowledge of Potomac, no officer or Key Employee of Potomac or any
Potomac Subsidiary intends to terminate his or her employment with Potomac or
the applicable Potomac Subsidiary, nor has any such officer or Key Employee
threatened or expressed in writing any intention to do so.

(c) Neither Potomac nor any Potomac Subsidiary is a party to, bound by, nor
has a duty to bargain under, any collective bargaining agreement or other
Contract with a labor organization representing any of its employees, and
there are no labor organizations representing, purporting to represent or, to
the Knowledge of Potomac, seeking to represent any employees of Potomac or any
Potomac Subsidiary.

(d) There has never been, nor has there been any threat of, any strike,
slowdown, work stoppage, lockout, job action, union, organizing activity,
question concerning representation or any similar union activity or dispute,
affecting Potomac or any Potomac Subsidiary.

(e) Neither Potomac nor any Potomac Subsidiary is or has been engaged in any
unfair labor practice within the meaning of the National Labor Relations Act.
There is no Legal Proceeding, claim, labor dispute or grievance pending or, to
the Knowledge of Potomac, threatened or reasonably anticipated relating to any
employment contract, privacy right, labor dispute, wages and hours, leave of
absence, plant closing notification, workers' compensation policy, long-term
disability policy, harassment, retaliation, immigration, employment statute or
regulation, safety or discrimination matter involving any Potomac Associate,
including charges of unfair labor practices or discrimination complaints. Part
2.13(e) of the Potomac Disclosure Schedule lists all written and all non-
written employee benefit plans (as defined in Section 3(3) of ERISA) and all
bonus, equity-based, incentive, deferred compensation, retirement or
supplemental retirement, profit sharing, severance, golden parachute,
vacation, cafeteria, dependent care, medical care, employee assistance
program, education or tuition assistance programs and other similar fringe or
employee benefit plans, programs or arrangements, including any employment or
executive compensation or severance agreements, written or otherwise, which
are currently in effect relating to any present or former employee or director
of

 Potomac or any Potomac Subsidiary (or any trade or business (whether or not
incorporated) which is a Potomac Affiliate) or which is maintained by,
administered or contributed to by, or required to be contributed to by,
Potomac, any Potomac Subsidiary or any Potomac Affiliate, or under which
Potomac or any Potomac Subsidiary or any Potomac Affiliate has any current or
may incur liability after the date hereof (each, a "Potomac Employee Plan").

(f) With respect to Potomac Options granted pursuant to the 2014 Plan, (i)
each Potomac Option intended to qualify as an "incentive stock option" under
Section 422 of the Code so qualifies, (ii) each grant of a Potomac Option was
duly authorized no later than the date on which the grant of such Potomac
Option was by its terms to be effective (the "Grant Date") by all necessary
corporate action, including, as applicable, approval by the board of directors
of Potomac (or a duly constituted and authorized committee thereof) and any
required stockholder approval by the necessary number of votes or written
consents, and the award agreement governing such grant (if any) was duly
executed and delivered by each party thereto, (iii) each Potomac Option grant
was made in accordance with the terms of the 2014 Plan and all other
applicable laws and regulatory rules or requirements and (iv) the per share
exercise price of each Potomac Option was equal to the fair market value of a
share of Potomac Common Stock on the applicable Grant Date.

(g) Each Potomac Employee Plan that is intended to be qualified under Section
401(a) of the Code has received a favorable determination with respect to such
qualified status from the Internal Revenue Service. To the Knowledge of
Potomac, nothing has occurred that would reasonably be expected to adversely
affect the qualified status of any such Potomac Employee Plan or the exempt
status of any related trust.

(h) Each Potomac Employee Plan has been maintained in compliance, in all
material respects, with its terms and, both as to form and operation, with all
applicable Legal Requirements, including without limitation, the Code and
ERISA.

(i) Neither Potomac nor any Potomac Subsidiary has engaged in any transaction
in violation of Sections 404 or 406 of ERISA or any "prohibited transaction,"
as defined in Section 4975(c)(1) of the Code, for which no exemption exists
under Section 408 of ERISA or Section 4975(c)(2) or (d) of the Code, or has
otherwise violated the provisions of Part 4 of Title I, Subtitle B of ERISA.
Neither Potomac nor any Potomac Subsidiary has knowingly participated in a
violation of Part 4 of Title I, Subtitle B of ERISA by any plan fiduciary of
any Potomac Employee Plan subject to ERISA and neither Potomac nor any Potomac
Subsidiary has been assessed any civil penalty under Section 502(l) of ERISA.

(j) No Potomac Employee Plan is subject to Title IV or Section 302 of ERISA or
Section 412 of the Code, and neither Potomac nor any Potomac Subsidiary or
Potomac Affiliate has ever maintained, contributed to or partially or
completely withdrawn from, or incurred any obligation or liability with
respect to, any such plan. No Potomac Employee Plan is a Multiemployer Plan,
and neither Potomac nor any Potomac Subsidiary or Potomac Affiliate has ever
contributed to or had an obligation to contribute, or incurred any liability
in respect of a contribution, to any Multiemployer Plan. No Potomac Employee
Plan is a Multiple Employer Plan.

 (k) No Potomac Employee Plan provides for medical or death benefits beyond
termination of service or retirement, other than (i) pursuant to COBRA or an
analogous state law requirement or (ii) death or retirement benefits under a
Potomac Employee Plan qualified under Section 401(a) of the Code.

(l) Neither Potomac nor any Potomac Subsidiary is a party to any Contract that
has resulted or would reasonably be expected to result, separately or in the
aggregate, in the payment of (i) any "excess parachute payment" within the
meaning of section 280G of the Code and (ii) any amount the deduction for
which would be disallowed under Section 162(m) of the Code.

(m) To the Knowledge of Potomac, no payment pursuant to any Potomac Employee
Plan or other arrangement to any "service provider" (as such term is defined
in Section 409A of the Code and the United States Treasury Regulations and IRS
guidance thereunder) to Potomac or any Potomac Subsidiary, including the
grant, vesting or exercise of any stock option, would subject any Person to
tax pursuant to Section 409A(1) of the Code, whether pursuant to the
transactions contemplated by this Agreement or otherwise.

(n) Potomac and each of its Subsidiaries has complied with all state and
federal laws applicable to employees, including but not limited to COBRA,
FMLA, CFRA, HIPAA, the Women's Health and Cancer Rights Act of 1998, the
Newborn's and Mothers' Health Protection Act of 1996, and any similar
provisions of state law applicable to its employees. To the extent required
under HIPAA and the regulations issued thereunder, Potomac and each of its
Subsidiaries has, prior to the Closing Date, performed all obligations under
the medical privacy rules of HIPAA (45 C.F.R. Parts 160 and 164), the
electronic data interchange requirements of HIPAA (45 C.F.R. Parts 160 and
162), and the security requirements of HIPAA (45 C.F.R. Part 142). Neither
Potomac nor any of its Subsidiaries has any unsatisfied obligations to any
employees or qualified beneficiaries pursuant to COBRA, HIPAA or any state law
governing health care coverage or extension.

(o) Potomac and each of its Subsidiaries is in compliance with all applicable
foreign, federal, state and local laws, rules and regulations respecting
employment, employment practices, terms and conditions of employment, worker
classification, tax withholding, prohibited discrimination, equal employment,
fair employment practices, meal and rest periods, immigration status, employee
safety and health, wages (including overtime wages), compensation, and hours
of work, and in each case, with respect to employees: (i) has withheld and
reported all amounts required by law or by agreement to be withheld and
reported with respect to wages, salaries and other payments to employees, (ii)
is not liable for any arrears of wages, severance pay or any Taxes or any
penalty for failure to comply with any of the foregoing, and (iii) is not
liable for any payment to any trust or other fund governed by or maintained by
or on behalf of any governmental authority, with respect to unemployment
compensation benefits, social security or other benefits or obligations for
employees (other than routine payments to be made in the normal course of
business and consistent with past practice). There are no actions, suits,
claims or administrative matters pending, threatened or reasonably anticipated
against Potomac or any of its Subsidiaries relating to any employee,
employment

 agreement or Potomac Employee Plan. There are no pending or threatened or
reasonably anticipated claims or actions against Potomac, any of its
Subsidiaries, any Potomac trustee or any trustee of any Subsidiary under any
worker's compensation policy or long-term disability policy. Neither Potomac
nor any Subsidiary thereof is party to a conciliation agreement, consent
decree or other agreement or order with any federal, state, or local agency or
governmental authority with respect to employment practices.

(p) Part 2.13(p) of the Disclosure Schedule lists all liabilities of Potomac
or any of its Subsidiaries to any employee, that result from the termination
by Potomac or any of its Subsidiaries of such employee's employment or
provision of services, a change of control of Potomac, or a combination
thereof. Neither Potomac nor any of its Subsidiaries has any material
liability with respect to any misclassification of: (a) any Person as an
independent contractor rather than as an employee, (b) any employee leased
from another employer, or (c) any employee currently or formerly classified as
exempt from overtime wages. Neither Potomac nor any Subsidiary has taken any
action which would constitute a "plant closing" or "mass layoff" within the
meaning of the WARN Act or similar state or local law, issued any notification
of a plant closing or mass layoff required by the WARN Act or similar state or
local law, or incurred any liability or obligation under WARN or any similar
state or local law that remains unsatisfied. No terminations of employees of
Potomac or any of its Subsidiaries prior to the Closing would trigger any
notice or other obligations under the WARN Act or similar state or local law.

(q) With respect to each Potomac Employee Plan, Potomac has made available to
Tigris a true and complete copy of, to the extent applicable, (i) such Potomac
Employee Plan, (ii) the three (3) most recent annual reports (Form 5500) as
filed with the Internal Revenue Service, (iii) each currently effective trust
agreement related to such Potomac Employee Plan, (iv) the most recent summary
plan description for each Potomac Employee Plan for which such description is
required, along with all summaries of material modifications, amendments,
resolutions and all other material plan documentation related thereto in the
possession of Potomac, and (v) the most recent Internal Revenue Service
determination or opinion letter or analogous ruling under foreign law issued
with respect to any Potomac Employee Plan.

2.14 Environmental Matters. Potomac and each Potomac Subsidiary is in
compliance with all applicable Environmental Laws, which compliance includes
the possession by Potomac of all permits and other Governmental Authorizations
required under applicable Environmental Laws and compliance with the terms and
conditions thereof. Neither Potomac nor any Potomac Subsidiary has received
since January 1, 2010 any written notice or other communication (in writing or
otherwise), whether from a Governmental Body, citizens group, employee or
otherwise, that alleges that Potomac or any Potomac Subsidiary is not in
compliance with any Environmental Law, and, to the Knowledge of Potomac, there
are no circumstances that may prevent or interfere with Potomac's or any of
its Subsidiaries' compliance with any Environmental Law in the future. To the
Knowledge of Potomac: (i) no current or prior owner of any property leased or
controlled by Potomac or any of its Subsidiaries has received since January 1,
2010 any written notice or other communication relating to property owned or
leased at any time by Potomac or any of its Subsidiaries, whether from a

 Governmental Body, citizens group, employee or otherwise, that alleges that
such current or prior owner or Potomac or any of its Subsidiaries is not in
compliance with or violated any Environmental Law relating to such property
and (ii) it has no material liability under any Environmental Law.

2.15 Insurance.

(a) Potomac has delivered to Tigris accurate and complete copies of all
material insurance policies and all material self insurance programs and
arrangements relating to the business, assets, liabilities and operations of
Potomac and each Potomac Subsidiary. Each of such insurance policies is in
full force and effect and Potomac and each Potomac Subsidiary are in
compliance with the terms thereof. Other than customary end of policy
notifications from insurance carriers, since January 1, 2010, neither Potomac
nor any Potomac Subsidiary has received any notice or other communication
regarding any actual or possible: (i) cancellation or invalidation of any
insurance policy; (ii) refusal or denial of any coverage, reservation of
rights or rejection of any material claim under any insurance policy; or (iii)
material adjustment in the amount of the premiums payable with respect to any
insurance policy. There is no pending workers' compensation or other claim
under or based upon any insurance policy of Potomac or any Potomac Subsidiary.
All information provided to insurance carriers (in applications and otherwise)
on behalf of Potomac and each Potomac Subsidiary is accurate and complete.
Potomac and each Potomac Subsidiary have provided timely written notice to the
appropriate insurance carrier(s) of each Legal Proceeding pending or
threatened against Potomac or any Potomac Subsidiary, and no such carrier has
issued a denial of coverage or a reservation of rights with respect to any
such Legal Proceeding, or informed Potomac or any Potomac Subsidiary of its
intent to do so.

(b) Potomac has delivered to Tigris accurate and complete copies of the
existing policies (primary and excess) of directors' and officers' liability
insurance maintained by Potomac and each Potomac Subsidiary as of the date of
this Agreement (the "Existing Potomac DandO Policies"). Part 2.15(b) of the
Potomac Disclosure Schedule accurately sets forth the most recent annual
premiums paid by Potomac and each Potomac Subsidiary with respect to the
Existing Potomac DandO Policies.

2.16 Legal Proceedings; Orders.

(a) Except as set forth on Part 2.16 of the Potomac Disclosure Schedule, there
is no pending Legal Proceeding, and, to the Knowledge of Potomac, no Person
has threatened in writing to commence any Legal Proceeding: (i) that involves
Potomac or any of its Subsidiaries, any Potomac Associate (in his or her
capacity as such) or any of the material assets owned or used by Potomac or
its Subsidiaries; or (ii) that challenges, or that may have the effect of
preventing, delaying, making illegal or otherwise interfering with, the Merger
or any of the other Contemplated Transactions. To the Knowledge of Potomac, no
event has occurred, and no claim, dispute or other condition or circumstance
exists, that will, or that would reasonably be expected to, give rise to or
serve as a basis for the commencement of any such Legal Proceeding. With
regard to any Legal Proceeding set forth on Part 2.16 of the Potomac
Disclosure Schedule, Potomac has provided Tigris or its counsel all pleadings
and material written correspondence related to such Legal Proceeding, all
insurance policies and material written correspondence with brokers and
insurers related to such

 Legal Proceedings and other information material to an assessment of such
Legal Proceeding. Potomac has an insurance policy or policies that is expected
to cover such Legal Proceeding and has complied with the requirements of such
insurance policy or policies to obtain coverage with respect to such Legal
Proceeding under such insurance policy or policies.

(b) There is no order, writ, injunction, judgment or decree to which Potomac
or any Potomac Subsidiary, or any of the material assets owned or used by
Potomac or any Potomac Subsidiary, is subject. To the Knowledge of Potomac, no
officer or other Key Employee of Potomac or any Potomac Subsidiary is subject
to any order, writ, injunction, judgment or decree that prohibits such officer
or other employee from engaging in or continuing any conduct, activity or
practice relating to the business of Potomac or any Potomac Subsidiary or to
any material assets owned or used by Potomac or any Potomac Subsidiary.

2.17 Authority; Binding Nature of Agreement. Potomac and each Potomac
Subsidiary has all necessary corporate power and authority to enter into and
to perform its obligations under this Agreement. The Board of Directors of
Potomac (at one or more meetings duly called and held) has: (a) determined
that the Merger is advisable and fair to and in the best interests of Potomac
and its stockholders; (b) duly authorized and approved by all necessary
corporate action, the execution, delivery and performance of this Agreement
and the transactions contemplated hereby, including the Merger; and (c)
recommended the adoption and approval of this Agreement by the holders of
Potomac Common Stock and Potomac Preferred Stock and directed that this
Agreement and the Merger be submitted for consideration by Potomac's
stockholders in connection with the solicitation of the Required Potomac
Stockholder Vote. This Agreement has been duly executed and delivered by
Potomac and assuming the due authorization, execution and delivery by Tigris,
constitutes the legal, valid and binding obligation of Potomac, enforceable
against Potomac in accordance with its terms, subject to: (i) laws of general
application relating to bankruptcy, insolvency and the relief of debtors; and
(ii) rules of law governing specific performance, injunctive relief and other
equitable remedies. Prior to the execution of the Potomac Stockholder Support
Agreements, the Board of Directors of Potomac approved the Potomac Stockholder
Support Agreements and the transactions contemplated thereby.

2.18 Inapplicability of Anti-takeover Statutes. The Board of Directors of
Potomac has taken and will take all actions necessary to ensure that the
restrictions applicable to business combinations contained in Section 203 of
the DGCL are, and will be, inapplicable to the execution, delivery and
performance of this Agreement and the Potomac Stockholder Support Agreements
and to the consummation of the Merger and the other Contemplated Transactions.
No other state takeover statute or similar Legal Requirement applies or
purports to apply to the Merger, this Agreement, the Potomac Stockholder
Support Agreements or any of the other Contemplated Transactions.

2.19 Vote Required. The affirmative vote of the holders of a majority of the
shares of Potomac Common Stock and Potomac's Series A Preferred Stock, par
value $0.001 per share, each outstanding on the record date for the Potomac
Stockholder Written Consent and entitled to vote thereon, voting as a single
class (the "Required Potomac Stockholder Vote"), is the only

 vote of the holders of any class or series of Potomac Capital Stock necessary
to adopt or approve this Agreement and approve the Merger and the matters set
forth in Section 5.2(a).

2.20 Non-Contravention; Consents. Subject to compliance with the HSR Act and
any foreign antitrust Legal Requirement, obtaining the Required Potomac
Stockholder Vote for the applicable Contemplated Transactions and the filing
of the Certificate of Merger required by the DGCL, neither (x) the execution,
delivery or performance of this Agreement by Potomac, nor (y) the consummation
of the Merger or any of the other Contemplated Transactions, will directly or
indirectly (with or without notice or lapse of time):

(a) contravene, conflict with or result in a violation of (i) any of the
provisions of the certificate of incorporation, bylaws or other charter or
organizational documents of Potomac, or (ii) any resolution adopted by the
stockholders, the board of directors or any committee of the board of
directors of Potomac;

(b) contravene, conflict with or result in a material violation of, or give
any Governmental Body or other Person the right to challenge the Merger or any
of the other Contemplated Transactions or to exercise any remedy or obtain any
relief under, any Legal Requirement or any order, writ, injunction, judgment
or decree to which Potomac or its Subsidiaries, or any of the assets owned or
used by Potomac or its Subsidiaries, is subject;

(c) contravene, conflict with or result in a material violation of any of the
terms or requirements of, or give any Governmental Body the right to revoke,
withdraw, suspend, cancel, terminate or modify, any Governmental Authorization
that is held by Potomac or its Subsidiaries or that otherwise relates to the
business of Potomac or its Subsidiaries or to any of the assets owned or used
by Potomac or its Subsidiaries;

(d) contravene, conflict with or result in a violation or breach of, or result
in a default under, any provision of any Potomac Contract, or give any Person
the right to: (i) declare a default or exercise any remedy under any Potomac
Contract; (ii) a rebate, chargeback, penalty or change in delivery schedule
under any such Potomac Contract; (iii) accelerate the maturity or performance
of any Potomac Contract; or (iv) cancel, terminate or modify any term of any
Potomac Contract, except, in the case of any Potomac Material Contract, any
non-material breach, default, penalty or modification and, in the case of all
other Potomac Contracts, any breach, default, penalty or modification that
would not result in a Potomac Material Adverse Effect;

(e) result in the imposition or creation of any Encumbrance upon or with
respect to any asset owned or used by Potomac or its Subsidiaries (except for
minor liens that will not, in any case or in the aggregate, materially detract
from the value of the assets subject thereto or materially impair the
operations of Potomac); or

(f) result in, or increase the likelihood of, the transfer of any material
asset of Potomac or its Subsidiaries to any Person.

Except (i) for any Consent set forth on Part 2.20 of the Potomac Disclosure
Schedule under any Potomac Contract, (ii) the approval of this Agreement and
the Contemplated Transactions by

 Potomac's stockholders, (iii) the filing of the Certificate of Merger with the
Secretary of State of the State of Delaware pursuant to the DGCL, (iv) any
required filings under the HSR Act and any foreign antitrust Legal Requirement
and (v) such consents, waivers, approvals, orders, authorizations,
registrations, declarations and filings as may be required under applicable
federal and state securities laws, neither Potomac nor any of its Subsidiaries
was, is, or will be required to make any filing with or give any notice to, or
to obtain any Consent from, any Person in connection with (x) the execution,
delivery or performance of this Agreement, or (y) the consummation of the
Merger or any of the other Contemplated Transactions.

2.21 Bank Accounts; Receivables.

(a) Part 2.21(a) of the Potomac Disclosure Schedule provides accurate
information with respect to each account maintained by or for the benefit of
Potomac or any Potomac Subsidiary at any bank or other financial institution,
including the name of the bank or financial institution, the account number,
the balance as of June 27, 2014 and the names of all individuals authorized to
draw on or make withdrawals from such accounts.

(b) All existing accounts receivable of Potomac or any Potomac Subsidiary
(including those accounts receivable reflected on the Potomac Unaudited
Interim Balance Sheet that have not yet been collected and those accounts
receivable that have arisen since the date of the Potomac Unaudited Interim
Balance Sheet and have not yet been collected) (i) represent valid obligations
of customers of Potomac or any Potomac Subsidiary arising from bona fide
transactions entered into in the Ordinary Course of Business, and (ii) are
current and are expected to be collected in full when due, without any
counterclaim or set off, net of applicable reserves for bad debts on the
Potomac Unaudited Interim Balance Sheet.

2.22 No Financial Advisor. Except as set forth on Part 2.22 of the Potomac
Disclosure Schedule, no broker, finder or investment banker is entitled to any
brokerage fee, finder's fee, opinion fee, success fee, transaction fee or
other fee or commission in connection with the Merger or any of the other
Contemplated Transactions based upon arrangements made by or on behalf of
Potomac or any of its Subsidiaries.

2.23 Subscription Agreement. The Subscription Agreement has not been amended
or modified in any manner prior to the date of this Agreement. Neither Potomac
nor, to the Knowledge of Potomac, any of its affiliates (as that term is used
in Rule 145 under the Securities Act) has entered into any agreement, side
letter or other arrangement relating to the Potomac Pre-Closing Financing
other than as set forth in the Subscription Agreement. The respective
obligations and agreements contained in the Subscription Agreement have not
been withdrawn or rescinded in any respect. The Subscription Agreement is in
full force and effect and represents a valid, binding and enforceable
obligation of Potomac and, to the Knowledge of Potomac, of each party thereto,
subject to the qualification that such enforceability may be limited by
bankruptcy, insolvency, reorganization or other laws of general application
relating to or affecting rights of creditors. No event has occurred which,
with or without notice, lapse of time or both, would constitute a breach or
default on the part of Potomac, or to the Knowledge of Potomac, any other
party thereto, under the Subscription Agreement. To the Knowledge of Potomac,
no party thereto will be unable to satisfy on a timely basis any term of the
Subscription Agreement. There are no

 conditions precedent related to the consummation of the Potomac Pre-Closing
Financing contemplated by the Subscription Agreement, other than the
satisfaction or waiver of the conditions expressly set forth in Article 5 of
the Subscription Agreement. To the Knowledge of Potomac, the Potomac Pre-
Closing Financing will be made available to Potomac prior to the consummation
of the Merger.

2.24 Disclosure. The information supplied by Potomac and each Potomac
Subsidiary for inclusion in the Proxy Statement/Prospectus/Information
Statement (including any Potomac Financials) will not, as of the date of the
Proxy Statement/Prospectus/Information Statement or as of the date such
information is prepared or presented, (i) contain any statement that is
inaccurate or misleading with respect to any material facts, or (ii) omit to
state any material fact necessary in order to make such information, in the
light of the circumstances under which such information will be provided, not
false or misleading.

Section 3. REPRESENTATIONS AND WARRANTIES OF TIGRIS AND MERGER SUB

Tigris and Merger Sub represent and warrant to Potomac as follows, except as
set forth in the written disclosure schedule delivered by Tigris to Potomac
(the "Tigris Disclosure Schedule"). The Tigris Disclosure Schedule shall be
arranged in sections and subsections corresponding to the numbered and
lettered sections and subsections contained in this Section 3. The disclosures
in any section or subsection of the Tigris Disclosure Schedule shall qualify
other sections and subsections in this Section 3 to the extent it is
reasonably clear from a reading of the disclosure that such disclosure is
applicable to such other sections and subsections. The inclusion of any
information in the Tigris Disclosure Schedule (or any update thereto) shall
not be deemed to be an admission or acknowledgment, in and of itself, that
such information is required by the terms hereof to be disclosed, is material,
has resulted in or would result in a Tigris Material Adverse Effect, or is
outside the Ordinary Course of Business.

3.1 Subsidiaries; Due Organization; Etc.

(a) Tigris has no Subsidiaries, except for TPI and Merger Sub; and neither
Tigris nor any Tigris Subsidiary owns any capital stock of, or any equity
interest of any nature in, any other Entity, other than TPI and Merger Sub.
Neither Tigris nor any Tigris Subsidiary has agreed nor is obligated to make,
nor is bound by any Contract under which it may become obligated to make, any
future investment in or capital contribution to any other Entity. Neither
Tigris nor any Tigris Subsidiary has, at any time, been a general partner of,
or has otherwise been liable for any of the debts or other obligations of, any
general partnership, limited partnership or other Entity.

(b) Each of Tigris and its Subsidiaries is a corporation duly organized,
validly existing and in good standing under the laws of the jurisdiction of
its incorporation and has all necessary power and authority: (i) to conduct
its business in the manner in which its business is currently being conducted;
(ii) to own and use its assets in the manner in which its assets are currently
owned and used; and (iii) to perform its obligations under all Contracts by
which it is bound.

 (c) Each of Tigris and its Subsidiaries is qualified to do business as a
foreign corporation, and is in good standing, under the laws of all
jurisdictions where the nature of its business requires such qualification
other than in jurisdictions where the failure to be so qualified individually
or in the aggregate would not be reasonably expected to have a Tigris Material
Adverse Effect.

3.2 Certificate of Incorporation; Bylaws; Charters and Codes of Conduct.
Tigris has delivered to Potomac accurate and complete copies of the
certificate of incorporation, bylaws and other charter and organizational
documents, including all amendments thereto, for Tigris and each Tigris
Subsidiary. Part 3.2 of the Tigris Disclosure Schedule lists, and Tigris has
delivered to Potomac, accurate and complete copies of: (a) the charters of all
committees of Tigris' board of directors; and (b) any code of conduct or
similar policy adopted by Tigris or by the board of directors, or any
committee of the board of directors, of Tigris. Neither Tigris nor any of its
Subsidiaries has taken any action in breach or violation of any of the
provisions of its certificate of incorporation, bylaws and other charter and
organizational documents nor is in breach or violation of any of the material
provisions of their respective certificates of incorporation, bylaws and other
charter and organizational documents, except as would not reasonably be
expected to have, individually or in the aggregate, a Tigris Material Adverse
Effect.

3.3 Capitalization, Etc.

(a) The authorized capital stock of Tigris consists of (i) 100,000,000 shares
of Tigris Common Stock, par value $0.001 per share, of which 19,123,212 shares
have been issued and are outstanding as of June 26, 2014 (the "Capitalization
Date"), (ii) 4,000,000 shares of Preferred Stock, par value $0.001 per share,
of which no shares have been issued and are outstanding as of the
Capitalization Date and (iii) 1,000,000 shares of Series A Junior
Participating Preferred Stock, par value $0.001 per share, of which no shares
have been issued and are outstanding as of the Capitalization Date. Tigris
does not hold any shares of its capital stock in its treasury. All of the
outstanding shares of Tigris Common Stock have been duly authorized and
validly issued, and are fully paid and nonassessable. None of the outstanding
shares of Tigris Common Stock is entitled or subject to any preemptive right,
right of participation, right of maintenance or any similar right. None of the
outstanding shares of Tigris Common Stock is subject to any right of first
refusal in favor of Tigris, other than early exercise rights and rights of
repurchases in favor of Tigris with respect to such early exercise rights.
Except as contemplated herein and except as identified on Part 3.3(a)(i) of
the Tigris Disclosure Schedule there is no Tigris Contract relating to the
voting or registration of, or restricting any Person from purchasing, selling,
pledging or otherwise disposing of (or granting any option or similar right
with respect to), any shares of Tigris Common Stock. Tigris is not under any
obligation, nor is bound by any Contract pursuant to which it may become
obligated, to repurchase, redeem or otherwise acquire any outstanding shares
of Tigris Common Stock or other securities. Part 3.3(a)(ii) of the Tigris
Disclosure Schedule accurately and completely describes all repurchase rights
held by Tigris with respect to shares of Tigris Common Stock (including shares
issued pursuant to the exercise of stock options) and specifies which of those
repurchase rights are currently exercisable.

 (b) Except for the Tigris Amended and Restated 2002 Stock Option Plan, the
Tigris Amended and Restated 2006 Equity Incentive Plan and the Tigris 2009
Employee Stock Purchase Plan (collectively, the "Tigris Stock Plans"), or
except as set forth on Part 3.3(b) of the Tigris Disclosure Schedule, Tigris
does not have any stock option plan or any other plan, program, agreement or
arrangement providing for any equity or equity-based compensation for any
Person. Part 3.3(b) of the Tigris Disclosure Schedule sets forth the aggregate
number of Tigris Options outstanding and a weighted average exercise price of
such options. Tigris has made available to Potomac accurate and complete
copies of all stock option plans pursuant to which Tigris has ever granted
stock options, the forms of all stock option agreements evidencing such
options and evidence of board and stockholder approval of any of the Tigris
Stock Plans and amendments thereto.

(c) Except as identified on Part 3.3(c) of the Tigris Disclosure Schedule,
there is no: (i) outstanding subscription, option, call, warrant or right
(whether or not currently exercisable) to acquire any shares of the capital
stock or other securities of Tigris or any of its Subsidiaries; (ii)
outstanding security, instrument or obligation that is or may become
convertible into or exchangeable for any shares of the capital stock or other
securities of Tigris or any of its Subsidiaries; (iii) stockholder rights plan
(or similar plan commonly referred to as a "poison pill") or Contract under
which Tigris or any of its Subsidiaries is or may become obligated to sell or
otherwise issue any shares of its capital stock or any other securities; or
(iv) condition or circumstance that may give rise to or provide a basis for
the assertion of a claim by any Person to the effect that such Person is
entitled to acquire or receive any shares of capital stock or other securities
of Tigris or any of its Subsidiaries. There are no outstanding or authorized
stock appreciation, phantom stock, profit participating or other similar
rights with respect to Tigris.

(d) All outstanding shares of Tigris Common Stock and options, warrants and
other securities of Tigris have been issued and granted in compliance with (i)
all applicable securities laws and other applicable Legal Requirements, and
(ii) all requirements set forth in applicable Contracts. Except as identified
on Part 3.3(c) of the Tigris Disclosure Schedule, there are no Warrants to
purchase capital stock of Tigris outstanding on the date of this Agreement.

3.4 SEC Filings; Financial Statements.

(a) Tigris has delivered to Potomac accurate and complete copies of all
registration statements, proxy statements, Certifications (as defined below)
and other statements, reports, schedules, forms and other documents filed by
Tigris with the SEC since January 1, 2013 (the "Tigris SEC Documents"), other
than such documents that can be obtained on the SEC's website at www.sec.gov.
Except as set forth on Part 3.4(a) of the Tigris Disclosure Schedule, all
material statements, reports, schedules, forms and other documents required to
have been filed by Tigris or its officers with the SEC have been so filed on a
timely basis. As of the time it was filed with the SEC (or, if amended or
superseded by a filing prior to the date of this Agreement, then on the date
of such filing), each of the Tigris SEC Documents complied in all material
respects with the applicable requirements of the Securities Act or the
Exchange Act (as the case may be) and, to Tigris' Knowledge, as of the time
they were filed, none of the Tigris SEC Documents contained any untrue
statement of a material fact or omitted to state a material fact

 required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not
misleading. The certifications and statements required by (A) Rule 13a-14
under the Exchange Act and (B) 18 U.S.C. 1350 (Section 906 of the Sarbanes-
Oxley Act) relating to the Tigris SEC Documents (collectively, the
"Certifications") are accurate and complete and comply as to form and content
with all applicable Legal Requirements. As used in this Section 3, the term
"file" and variations thereof shall be broadly construed to include any manner
in which a document or information is furnished, supplied or otherwise made
available to the SEC.

(b) The consolidated financial statements (including any related notes)
contained or incorporated by reference in the Tigris SEC Documents: (i)
complied as to form in all material respects with the published rules and
regulations of the SEC applicable thereto; (ii) were prepared in accordance
with GAAP (except as may be indicated in the notes to such financial
statements or, in the case of unaudited financial statements, as permitted by
Form 10-Q of the SEC, and except that the unaudited financial statements may
not contain footnotes and are subject to normal and recurring year-end
adjustments that are not reasonably expected to be material in amount) applied
on a consistent basis unless otherwise noted therein throughout the periods
indicated; and (iii) fairly present the consolidated financial position of
Tigris as of the respective dates thereof and the consolidated results of
operations and cash flows of Tigris for the periods covered thereby. Other
than as expressly disclosed in the Tigris SEC Documents filed prior to the
date hereof, there has been no material change in Tigris' accounting methods
or principles that would be required to be disclosed in Tigris' financial
statements in accordance with GAAP. The books of account and other financial
records of Tigris and each of its Subsidiaries are true and complete in all
material respects.

(c) Tigris does not hold any auction rate securities, or other marketable
securities or cash equivalents which are not, to the Knowledge of Tigris,
fully liquid and freely tradable.

(d) Tigris' auditor has at all times since the date of enactment of the
Sarbanes-Oxley Act been: (i) a registered public accounting firm (as defined
in Section 2(a)(12) of the Sarbanes-Oxley Act); (ii) to the knowledge of
Tigris, "independent" with respect to Tigris within the meaning of Regulation
S-X under the Exchange Act; and (iii) to the knowledge of Tigris, in
compliance with subsections (g) through (l) of Section 10A of the Exchange Act
and the rules and regulations promulgated by the SEC and the Public Company
Accounting Oversight Board thereunder.

(e) From January 1, 2010, through the date hereof, Tigris has not received any
comment letter from the SEC or the staff thereof or any correspondence from
NASDAQ or the staff thereof relating to the delisting or maintenance of
listing of the Tigris Common Stock on the NASDAQ Global Market. Tigris has not
disclosed any unresolved comments in its SEC Documents.

(f) Since January 1, 2010, there have been no formal internal investigations
regarding financial reporting or accounting policies and practices discussed
with, reviewed by or initiated at the direction of the chief executive officer
or chief financial officer of Tigris, Tigris'

 Board of Directors or any committee thereof, other than ordinary course audits
or reviews of accounting policies and practices or internal controls required
by the Sarbanes-Oxley Act.

(g) Tigris is in compliance in all material respects with the applicable
provisions of the Sarbanes-Oxley Act and the applicable listing and governance
rules and regulations of the NASDAQ Global Market.

(h) Tigris and its Subsidiaries maintain a system of internal control over
financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the
Exchange Act) that is sufficient to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with GAAP, including policies and
procedures sufficient to provide reasonable assurance (i) that Tigris and its
Subsidiaries maintain records that in reasonable detail accurately and fairly
reflect Tigris' and its Subsidiaries' transactions and dispositions of assets,
(ii) that transactions are recorded as necessary to permit preparation of
financial statements in accordance with GAAP, (iii) that receipts and
expenditures are made only in accordance with authorizations of management and
Tigris' Board of Directors, and (iv) regarding prevention or timely detection
of the unauthorized acquisition, use or disposition of Tigris' and its
Subsidiaries' assets that could have a material effect on Tigris' consolidated
financial statements. Tigris has evaluated the effectiveness of Tigris' and
its Subsidiaries' internal control over financial reporting and, to the extent
required by applicable law, presented in any applicable Tigris SEC Document
that is a report on Form 10-K or Form 10-Q (or any amendment thereto) its
conclusions about the effectiveness of the internal control over financial
reporting as of the end of the period covered by such report or amendment
based on such evaluation. Tigris has disclosed to Tigris' auditors and the
Audit Committee of Tigris' Board of Directors (and made available to Potomac a
summary of the significant aspects of such disclosure) (A) all significant
deficiencies and material weaknesses in the design or operation of internal
control over financial reporting that are reasonably likely to adversely
affect Tigris' ability to record, process, summarize and report financial
information and (B) any fraud, whether or not material, that involves
management or other employees who have a significant role in Tigris' or its
Subsidiaries' internal control over financial reporting. Except as disclosed
in the Tigris SEC Documents filed prior to the date hereof, Tigris has not
identified any material weaknesses in the design or operation of the Tigris or
its Subsidiaries' internal control over financial reporting. Since December
31, 2013, there have been no material changes in Tigris and its Subsidiaries'
internal control over financial reporting.

(i) Tigris' and its Subsidiaries' "disclosure controls and procedures" (as
defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) are reasonably
designed to ensure that all information (both financial and non-financial)
required to be disclosed by Tigris in the reports that it files or submits
under the Exchange Act is recorded, processed, summarized and reported within
the time periods specified in the rules and forms of the SEC, and that all
such information is accumulated and communicated to Tigris' management as
appropriate to allow timely decisions regarding required disclosure and to
make the Certifications.



3.5 Absence of Changes. Except as set forth on Part 3.5 of the Tigris
Disclosure

 Schedule, between March 31, 2014 and the date of this Agreement:

(a) there has not been any Tigris Material Adverse Effect or an event or
development that would, individually or in the aggregate, reasonably be
expected to have a Tigris Material Adverse Effect;

(b) there has not been any material loss, damage or destruction to, or any
material interruption in the use of, any of the assets or business of Tigris
or any of its Subsidiaries (whether or not covered by insurance);

(c) Tigris has not: (i) declared, accrued, set aside or paid any dividend or
made any other distribution in respect of any shares of capital stock; or (ii)
repurchased, redeemed or otherwise reacquired any shares of capital stock or
other securities;

(d) Tigris has not sold, issued or granted, or authorized the issuance of: (i)
any capital stock or other security (except for Tigris Common Stock issued
upon the valid exercise of outstanding Tigris Options); (ii) any option,
warrant or right to acquire any capital stock or any other security (except
for Tigris Options identified in Part 3.3(b) of the Tigris Disclosure
Schedule); or (iii) any instrument convertible into or exchangeable for any
capital stock or other security;

(e) Tigris has not amended or waived any of its rights under, or exercised its
discretion to permit the acceleration of vesting under any provision of: (i)
any of the Tigris Stock Plans; (ii) any Tigris Option or any Contract
evidencing or relating to any Tigris Option; (iii) any restricted stock
purchase agreement; or (iv) any other Contract evidencing or relating to any
equity award (whether payable in cash or stock);

(f) there has been no amendment to the certificate of incorporation, bylaws or
other charter or organizational documents of Tigris or any of its
Subsidiaries, and neither Tigris nor any of its Subsidiaries has effected or
been a party to any merger, consolidation, share exchange, business
combination, recapitalization, reclassification of shares, stock split,
reverse stock split or similar transaction;

(g) neither Tigris nor any of its Subsidiaries has formed any Subsidiary other
than Merger Sub or acquired any equity interest or other interest in any other
Entity;

(h) neither Tigris nor any of its Subsidiaries has: (i) lent money to any
Person; (ii) incurred or guaranteed any indebtedness for borrowed money; (iii)
issued or sold any debt securities or options, warrants, calls or other rights
to acquire any debt securities; (iv) guaranteed any debt securities of others;
or (v) made any capital expenditure or commitment in excess of $100,000;

(i) neither Tigris nor any of its Subsidiaries has, other than in the Ordinary
Course of Business: (i) adopted, established or entered into any Tigris
Employee Plan; (ii) caused or permitted any Tigris Employee Plan to be amended
other than as required by law; or (iii) paid any bonus or made any profit-
sharing or similar payment to, or increased the amount of

 the wages, salary, commissions, fringe benefits or other compensation or
remuneration payable to, any of its directors or employees;

(j) neither Tigris nor any of its Subsidiaries has made, changed or revoked
any material Tax election, filed any material amendment to any Tax Return,
adopted or changed any accounting method in respect of Taxes, changed any
annual Tax accounting period, entered into any Tax allocation agreement, Tax
sharing agreement or Tax indemnity agreement, other than commercial contracts
entered into in the Ordinary Course of Business with vendors, customers or
landlords, entered into any closing agreement with respect to any Tax, settled
or compromised any claim, notice, audit report or assessment in respect of
material Taxes, applied for or entered into any ruling from any Tax authority
with respect to Taxes, surrendered any right to claim a material Tax refund,
or consented to any extension or waiver of the statute of limitations period
applicable to any material Tax claim or assessment;

(k) neither Tigris nor any of its Subsidiaries has commenced or settled any
Legal Proceeding;

(l) neither Tigris nor any of its Subsidiaries has entered into any material
transaction outside the Ordinary Course of Business;

(m) neither Tigris nor any of its Subsidiaries has acquired any material asset
nor sold, leased or otherwise irrevocably disposed of any of its material
assets or properties, nor has any Encumbrance been granted with respect to
such assets or properties, except in the Ordinary Course of Business
consistent with past practices;

(n) there has been no entry into, amendment or termination of any Tigris
Material Contract;

(o) there has been no (i) material change in pricing or royalties or other
payments set or charged by Tigris or any of its Subsidiaries to its customers
or licensees, (ii) agreement by any of Tigris or any of its Subsidiaries to
change pricing or royalties or other payments set or charged by persons who
have licensed Intellectual Property to any of Tigris or its Subsidiaries, or
(iii) as of the date of this Agreement, material change in pricing or
royalties or other payments set or charged by persons who have licensed
Intellectual Property to Tigris or any of its Subsidiaries; and

(p) neither Tigris nor any of its Subsidiaries has negotiated, agreed or
committed to take any of the actions referred to in clauses"(c)" through "(o)"
above (other than negotiations between the Parties to enter into this
Agreement).

3.6 Intellectual Property.

(a) Tigris, directly or through a Tigris Subsidiary, owns, or has the right to
use, all Intellectual Property owned, licensed, or controlled by Tigris or its
Subsidiaries listed on Part 3.6(a) of the Tigris Disclosure Schedule ("Tigris
IP Rights"), except for any failure to own

 or have the right to use, or have the right to bring actions that would not
reasonably be expected to have a Tigris Material Adverse Effect.

(b) Part 3.6(b) of the Tigris Disclosure Schedule is an accurate, true and
complete listing of all Tigris Registered IP.

(c) Tigris has delivered, or made available to Potomac, a complete and
accurate copy of all Tigris IP Rights Agreements. Neither Tigris nor any of
its Subsidiaries is a party to any Contract (A) pursuant to which the
execution, delivery and performance of this Agreement and the consummation of
the Contemplated Transactions will constitute a breach, or (B) as a result of
such execution, delivery and performance of this Agreement and the
consummation of the Contemplated Transactions will cause the forfeiture or
termination of or Encumbrance upon, or the grant of any license or other right
to, or give rise to a right of forfeiture or termination of or Encumbrance
upon, any Tigris IP Rights or impair the right of Tigris, any of its
Subsidiaries, or the Surviving Corporation to use, sell or license any Tigris
IP Rights or portion thereof, except for the occurrence of any such breach,
forfeiture, termination, Encumbrance, grant or impairment that would not
individually or in the aggregate, reasonably be expected to result in a Tigris
Material Adverse Effect. With respect to each of the Tigris IP Rights
Agreements: (i) each such agreement is valid and binding on Tigris or its
Subsidiaries, as applicable, and in full force and effect; (ii) neither Tigris
nor any of its Subsidiaries has received any notice of termination or
cancellation under such agreement, or received any notice of breach or default
under such agreement, which breach has not been cured or waived; and (iii)
neither Tigris nor any of its Subsidiaries, and to the Knowledge of Tigris, no
other party to such agreement, is in breach or default thereof in any material
respect.

(d) Except as set forth on Part 3.6(d) of the Tigris Disclosure Schedule,
neither the manufacture, marketing, license, sale or intended use of any
product or technology currently licensed or sold or under development by
Tigris or any of its Subsidiaries violates any license or agreement between
Tigris or any of its Subsidiaries and any third party or, to the Knowledge of
Tigris, infringes or misappropriates any valid Intellectual Property right of
any other party, which violation, infringement or misappropriation would
reasonably be expected to have a Tigris Material Adverse Effect. Tigris has
disclosed in correspondence to Potomac the third-party patents and patent
applications found during all freedom to operate searches that were conducted
by Tigris related to any product or technology currently licensed or sold or
under development by Tigris or its Subsidiaries. To the Knowledge of Tigris,
no third party is infringing upon, or violating any license or agreement with
Tigris or any of its Subsidiaries or relating to any Tigris IP Rights.

(e) There is no current or pending challenge, claim or Legal Proceeding
(including, but not limited to, opposition, interference or other proceeding
in any patent or other government office) contesting the validity, ownership
or right to use, sell, license or dispose of any Tigris IP Rights, nor has
Tigris or any of its Subsidiaries received any written notice asserting that
any Tigris IP Rights or the proposed use, sale, license or disposition thereof
conflicts with or infringes or misappropriates or will conflict with or
infringe or misappropriate the rights of any other party.

 (f) No trademark (whether registered or unregistered) or trade name owned,
used, or applied for by Tigris or any of its Subsidiaries conflicts or
interferes with any trademark (whether registered or unregistered) or trade
name owned, used, or applied for by any other Person. None of the goodwill
associated with or inherent in any trademark (whether registered or
unregistered) in which Tigris or a Tigris Subsidiary has or purports to have
an ownership interest has been impaired.

(g) Except as may be set forth in the Contracts listed on Part 3.6(g) of the
Tigris Disclosure Schedule (i) neither Tigris nor any of its Subsidiaries is
bound by any Contract to indemnify, defend, hold harmless, or reimburse any
other Person with respect to any Intellectual Property infringement,
misappropriation, or similar claim, and (ii) neither Tigris nor any of its
Subsidiaries has ever assumed, or agreed to discharge or otherwise take
responsibility for, any existing or potential liability of another Person for
infringement, misappropriation, or violation of any Intellectual Property
right.

3.7 Agreements, Contracts and Commitments. Part 3.7 of the Tigris Disclosure
Schedule identifies:

(a) each Tigris Contract relating to any bonus, deferred compensation,
severance, incentive compensation, pension, profit-sharing or retirement
plans, or any other employee benefit plans or arrangements;

(b) each Tigris Contract relating to the employment of, or the performance of
employment-related services by, any Person, including any employee, consultant
or independent contractor, or entity providing employment related, consulting
or independent contractor services, not terminable by Tigris or its
Subsidiaries on ninety (90) days notice without liability, except to the
extent general principles of wrongful termination law may limit Tigris' or its
Subsidiaries' ability to terminate employees at will;

(c) each Tigris Contract relating to any agreement or plan, including, without
limitation, any stock option plan, stock appreciation right plan or stock
purchase plan, any of the benefits of which will be increased, or the vesting
of benefits of which will be accelerated, by the occurrence of any of the
Contemplated Transactions (either alone or in conjunction with any other
event, such as termination of employment) or the value of any of the benefits
of which will be calculated on the basis of any of the Contemplated
Transactions;

(d) each Tigris Contract relating to any agreement of indemnification or
guaranty not entered into in the Ordinary Course of Business other than
indemnification agreements between Tigris and any of its officers or
directors;

(e) each Tigris Contract relating to any agreement, contract or commitment
containing any covenant limiting the freedom of Tigris, a Tigris Subsidiary or
the Surviving Corporation to engage in any line of business or compete with
any Person;

 (f) each Tigris Contract relating to any agreement, contract or commitment
relating to capital expenditures and involving obligations after the date of
this Agreement in excess of $100,000 and not cancelable without penalty;

(g) each Tigris Contract relating to any agreement, contract or commitment
currently in force relating to the disposition or acquisition of material
assets or any ownership interest in any Entity;

(h) each Tigris Contract relating to any mortgages, indentures, loans, notes
or credit agreements, security agreements or other agreements or instruments
relating to the borrowing of money or extension of credit in excess of
$100,000 or creating any Encumbrances with respect to any assets of Tigris or
a Tigris Subsidiary or any loans or debt obligations with officers or
directors of Tigris or a Tigris Subsidiary;

(i) each Tigris Contract relating to (i) any distribution agreement
(identifying any that contain exclusivity provisions); (ii) any agreement
involving provision of services or products with respect to any pre-clinical
or clinical development activities of Tigris or a Tigris Subsidiary (iii) any
dealer, distributor, joint marketing, alliance, joint venture, cooperation,
development or other agreement currently in force under which Tigris or a
Tigris Subsidiary has continuing obligations to develop or market any product,
technology or service, or any agreement pursuant to which Tigris or a Tigris
Subsidiary has continuing obligations to develop any Intellectual Property
that will not be owned, in whole or in part, by Tigris or a Tigris Subsidiary;
or (iv) any Contract currently in force to license any third party to
manufacture or produce any product, service or technology of Tigris or a
Tigris Subsidiary or any Contract currently in force to sell, distribute or
commercialize any products or service of Tigris or a Tigris Subsidiary except
agreements with distributors or sales representatives in the Ordinary Course
of Business;

(j) each Tigris Contract with any Person, including without limitation any
financial advisor, broker, finder, investment banker or other Person,
providing advisory services to Tigris or a Tigris Subsidiary in connection
with the Contemplated Transactions; or

(k) any other agreement, contract or commitment (i) which involves payment or
receipt by Tigris or a Tigris Subsidiary under any such agreement, contract or
commitment of $100,000 or more in the aggregate or obligations after the date
of this Agreement in excess of $100,000 in the aggregate, or (ii) that is
material to the business or operations of Tigris and its Subsidiaries.

Tigris has delivered or made available to Potomac accurate and complete
(except for applicable redactions thereto) copies of all Tigris Material
Contracts, including all amendments thereto. There are no Tigris Material
Contracts that are not in written form. Except as set forth on Part 3.7 of the
Tigris Disclosure Schedule, neither Tigris nor any Tigris Subsidiary, nor to
the Knowledge of Tigris, as of the date of this Agreement has any other party
to a Tigris Material Contract (as defined below), breached, violated or
defaulted under, or received notice that it has breached, violated or
defaulted under, any of the terms or conditions of any of the agreements,
contracts or commitments to which Tigris is a party or by which it is bound of
the type described

 in clauses (a) through (j) above (any such agreement, contract or commitment,
a "Tigris Material Contract") in such manner as would permit any other party
to cancel or terminate any such Tigris Material Contract, or would permit any
other party to seek damages which would reasonably be expected to have a
Tigris Material Adverse Effect. The consummation of the Contemplated
Transactions shall not (either alone or upon the occurrence of additional acts
or events) result in any material payment or payments becoming due from
Tigris, a Tigris Subsidiary or the Surviving Corporation to any Person under
any Tigris Contract.

3.8 Liabilities. As of the date hereof, neither Tigris nor any Tigris
Subsidiary has any Liability, individually or in the aggregate, except for:
(i) Liabilities identified as such in the "liabilities" column of the Tigris
Unaudited Interim Balance Sheet; (ii) normal and recurring current Liabilities
that have been incurred by Tigris or its Subsidiaries since the date of the
Tigris Unaudited Interim Balance Sheet in the Ordinary Course of Business;
(iii) Liabilities for performance of obligations of Tigris or any Tigris
Subsidiary under Tigris Contracts, (iii) Liabilities described in Part 3.8 of
the Tigris Disclosure Schedule and (iv) Liabilities incurred in connection
with the Contemplated Transactions.

3.9 Compliance; Permits; Restrictions.

(a) Each of Tigris and its Subsidiaries is, and since January 1, 2010 has
complied in all material respects with, is not in material violation of, and
has not received any written notices of alleged or actual material violation
with respect to, any foreign, federal, state or local statute, law or
regulation, including, but not limited to all applicable Legal Requirements.
No investigation, claim, suit, proceeding, audit or other action by any
Governmental Body or authority is pending or, to the Knowledge of Tigris,
threatened against Tigris or a Tigris Subsidiary, nor has any Governmental
Body or authority indicated to Potomac an intention to conduct the same. There
is no agreement, judgment, injunction, order or decree binding upon Tigris or
a Tigris Subsidiary which (i) has or could reasonably be expected to have the
effect of prohibiting or materially impairing any business practice of Tigris
or a Tigris Subsidiary, any acquisition of material property by Tigris or a
Tigris Subsidiary or the conduct of business by Tigris and any Subsidiary as
currently conducted, (ii) may have an adverse effect on Tigris' ability to
comply with or perform any covenant or obligation under this Agreement, or
(iii) may have the effect of preventing, delaying, making illegal or otherwise
interfering with the Merger or any of the Contemplated Transactions.

(b) Each of Tigris and its Subsidiaries holds all Governmental Authorizations
which are material to the operation of their businesses (collectively, the
"Tigris Permits") as currently conducted. Part 3.9(b) of the Tigris Disclosure
Schedule identifies each Tigris Permit. Each of Tigris and its Subsidiaries is
in material compliance with the terms of the Tigris Permits. No action,
proceeding, revocation proceeding, amendment procedure, writ, injunction or
claim is pending or, to the Knowledge of Tigris, threatened, which seeks to
revoke, limit, suspend, or materially modify any Tigris Permit. The rights and
benefits of each material Tigris Permit will be available to the Surviving
Corporation immediately after the Effective Time on terms substantially
identical to those enjoyed by Tigris and its Subsidiaries as of the date of
this Agreement and immediately prior to the Effective Time.

 (c) There are no proceedings pending or, to the Knowledge of Tigris,
threatened with respect to an alleged material violation by Tigris or a Tigris
Subsidiary of the FDCA, FDA regulations adopted thereunder, or any other
similar Legal Requirements promulgated by a Drug Regulatory Agency.

(d) Each of Tigris and its Subsidiaries holds all required Governmental
Authorizations issuable by any Drug Regulatory Agency necessary for the
conduct of the business of Tigris and its Subsidiaries as currently conducted,
and, as applicable, development, clinical testing, manufacturing, marketing,
distribution and importation or exportation, as currently conducted, of any of
its products or product candidates (the "Tigris Product Candidates") (the
"Tigris Regulatory Permits") and no such Tigris Regulatory Permit has been (i)
revoked, withdrawn, suspended, cancelled or terminated or (ii) modified in any
materially adverse manner. Neither Tigris nor its Subsidiaries has received
any written notice or other written communication from any Drug Regulatory
Agency regarding any revocation, withdrawal, suspension, cancellation,
termination or material modification of any Tigris Regulatory Permit. Except
for the information and files identified in Part 3.9(d) of the Tigris
Disclosure Schedule, Tigris has made available to Potomac all information in
its or its Subsidiaries' possession or control relating to the Tigris Product
Candidates and the development, clinical testing, manufacturing, importation
and exportation of the Tigris Product Candidates, including without
limitation, complete copies of the following (to the extent there are any):
(x) adverse event reports; clinical study reports and material study data; and
inspection reports, notices of adverse findings, warning letters, filings and
letters and other written correspondence to and from any Drug Regulatory
Agency; and meeting minutes with any Drug Regulatory Agency; and (y) similar
reports, material study data, notices, letters, filings, correspondence and
meeting minutes with any other Governmental Authority.

(e) All clinical, pre-clinical and other studies and tests conducted by or on
behalf of, or sponsored by, Tigris or a Tigris Subsidiary or in which Tigris
or a Tigris Subsidiary or their respective products or product candidates,
have participated were conducted in all material respects in accordance with
standard medical and scientific research procedures and in compliance with the
applicable regulations of the Drug Regulatory Agencies and other applicable
Legal Requirements, including, without limitation, 21 C.F.R. Parts 50, 54, 56,
58 and 312.

(f) Neither Tigris nor any of its Subsidiaries is the subject of any pending,
or to the Knowledge of Tigris, threatened investigation in respect of its
business or products by the FDA pursuant to its "Fraud, Untrue Statements of
Material Facts, Bribery, and Illegal Gratuities" Final Policy set forth in 56
Fed. Reg. 46191 (September 10, 1991) and any amendments thereto. To the
Knowledge of Tigris, neither Tigris nor any of its Subsidiaries has committed
any acts, made any statement, or failed to make any statement, in each case in
respect of its business or products that would violate FDA's "Fraud, Untrue
Statements of Material Facts, Bribery, and Illegal Gratuities" Final Policy,
and any amendments thereto. None of Tigris, any of its Subsidiaries, or any of
their respective officers, employees or agents has been convicted of any crime
or engaged in any conduct that could result in a material debarment or
exclusion (i) under 21 U.S.C. Section 335a or (ii) any similar applicable
Legal Requirement. To the Knowledge of Tigris, no material debarment or
exclusionary claims, actions, proceedings or investigations in

 respect of their business or products are pending or threatened against
Tigris, any Tigris Subsidiary or any of their respective officers, employees
or agents.

3.10 Tax Matters.

(a) Each of Tigris and its Subsidiaries has timely filed all federal income
Tax Returns and other material Tax Returns that they were required to file
under applicable Legal Requirements. All such Tax Returns were correct and
complete in all material respects and have been prepared in material
compliance with all applicable Legal Requirements. Neither Tigris nor any of
its Subsidiaries is currently the beneficiary of any extension of time within
which to file any Tax Return. No claim has ever been made by an authority in a
jurisdiction where Tigris or any Tigris Subsidiary does not file Tax Returns
that it is subject to taxation by that jurisdiction.

(b) All material Taxes due and owing by Tigris or any of its Subsidiaries on
or before the date hereof (whether or not shown on any Tax Return) have been
paid. The unpaid Taxes of Tigris have been reserved for on the Tigris
Unaudited Interim Balance Sheet in accordance with GAAP. Since the date of the
Tigris Unaudited Interim Balance Sheet, neither Tigris nor any of its
Subsidiaries has incurred any Liability for Taxes outside the Ordinary Course
of Business or otherwise inconsistent with past custom and practice.

(c) Each of Tigris and its Subsidiaries has withheld and paid all Taxes
required to have been withheld and paid in connection with any amounts paid or
owing to any employee, independent contractor, creditor, stockholder, or other
third party.

(d) There are no Encumbrances for Taxes (other than Taxes not yet due and
payable or Taxes that are being contested in good faith and for which adequate
reserves have been made on Tigris' Unaudited Interim Balance Sheet) upon any
of the assets of Tigris or any of its Subsidiaries.

(e) No deficiencies for Taxes with respect to Tigris or any of its
Subsidiaries have been claimed, proposed or assessed by any Governmental Body
in writing. There are no pending (or, based on written notice, threatened)
audits, assessments or other actions for or relating to any liability in
respect of Taxes of Tigris or any of its Subsidiaries. No issues relating to
Taxes of Tigris or any of its Subsidiaries were raised by the relevant Tax
authority in any completed audit or examination that would reasonably be
expected to result in a material amount of Taxes in a later taxable period.
Tigris has delivered or made available to Potomac complete and accurate copies
of all federal income Tax and all other material Tax Returns of Tigris (and
its Subsidiaries and predecessors) for all taxable years remaining open under
the applicable statute of limitations, and complete and accurate copies of all
examination reports and statements of deficiencies assessed against or agreed
to by Tigris (and its Subsidiaries and predecessors), with respect to federal
income Tax and all other material Taxes. Tigris (or any of its Subsidiaries or
predecessors) has not waived any statute of limitations in respect of Taxes or
agreed to any extension of time with respect to a Tax assessment or
deficiency, nor has any request been made in writing for any such extension or
waiver.

 (f) All material elections with respect to Taxes affecting Tigris or any
Tigris Subsidiary as of the date hereof, to the extent such elections are not
shown on or in the Tax Returns that have been delivered or made available to
Potomac, are set forth on Schedule 3.10(f). Neither Tigris nor any of its
Subsidiaries (i) has consented at any time under former Section 341(f)(1) of
the Code to have the provisions of former Section 341(f)(2) of the Code apply
to any disposition of the assets of Tigris or any Tigris Subsidiary; (ii) has
agreed, or is required, to make any adjustment under Section 481(a) of the
Code by reason of a change in accounting method or otherwise; (iii) has made
an election, or is required, to treat any of its assets as owned by another
Person for Tax purposes or as a tax-exempt bond financed property or tax-
exempt use property within the meaning of Section 168 of the Code; (iv) has
acquired or owns any assets that directly or indirectly secure any debt the
interest on which is tax exempt under Section 103(a) of the Code; (v) has made
or will make a consent dividend election under Section 565 of the Code; (vi)
has not elected at any time to be treated as an S corporation within the
meaning of Sections 1361 or 1362 of the Code; or (vii) has made any of the
foregoing elections or is required to apply any of the foregoing rules under
any comparable provision of state, local or foreign law.

(g) Neither Tigris nor any of its Subsidiaries has been a United States real
property holding corporation within the meaning of Section 897(c)(2) of the
Code during the applicable period specified in Section 897(c)(1)(A)(ii) of the
Code.

(h) Neither Tigris nor any of its Subsidiaries is a party to any Tax
allocation, Tax sharing or similar agreement (including indemnity
arrangements), other than commercial contracts entered into in the Ordinary
Course of Business with vendors, customers and landlords.

(i) Neither Tigris nor any of its Subsidiaries has ever been a member of an
affiliated group filing a consolidated, combined or unitary Tax Return (other
than a group the common parent of which is Tigris) for federal, state, local
or foreign Tax purposes. Neither Tigris nor any of its Subsidiaries has any
Liability for the Taxes of any Person (other than Tigris and its Subsidiaries)
under Treasury Regulations Section 1.1502-6 (or any similar provision of
state, local, or foreign law), as a transferee or successor, by Contract, or
otherwise.

(j) Neither Tigris nor any of its Subsidiaries has distributed stock of
another Person, or has had its stock distributed by another Person, in a
transaction that was purported or intended to be governed in whole or in part
by Section 355 of the Code or Section 361 of the Code.

(k) Neither Tigris nor any of its Subsidiaries is a partner for Tax purposes
with respect to any joint venture, partnership, or, to the Knowledge of
Tigris, other arrangement or contract which is treated as a partnership for
Tax purposes.

(l) Neither Tigris nor any of its Subsidiaries will be required to include any
item of income in, or exclude any item of deduction from, taxable income for
any period (or any portion thereof) ending after the Closing Date as a result
of any (i) installment sale or other open transaction disposition made on or
prior to the Closing Date, or (ii) agreement with any Tax authority (including
any closing agreement described in Section 7121 of the Code or any similar
provision of state, local or foreign law) made or entered into on or prior to
the Closing Date.

 (m) Neither Tigris nor any of its Subsidiaries has entered into any
transaction identified as a "listed transaction" for purposes of Treasury
Regulations Sections 1.6011-4(b)(2) or 301.6111-2(b)(2).

(n) Neither Tigris nor any of its Subsidiaries has taken any action, nor has
any knowledge of any fact or circumstance, that could reasonably be expected
to prevent the transactions contemplated hereby, including the Merger and the
Second Merger, considered together as a single integrated transaction for
United States federal income Tax purposes, from qualifying as a reorganization
within the meaning of Section 368(a) of the Code.

3.11 Employee and Labor Matters; Benefit Plans.

(a) The employment of Tigris' and its Subsidiaries' employees is terminable by
Tigris at will (or otherwise in accordance with general principles of wrongful
termination law). Tigris has made available to Potomac accurate and complete
copies of all employee manuals and handbooks, disclosure materials, policy
statements and other materials relating to the employment of Tigris Associates
to the extent currently effective and material.

(b) Neither Tigris nor any Tigris Subsidiary is a party to, bound by, or has a
duty to bargain under, any collective bargaining agreement or other Contract
with a labor organization representing any of its employees, and there are no
labor organizations representing, purporting to represent or, to the Knowledge
of Tigris, seeking to represent any employees of Tigris or any Tigris
Subsidiary.

(c) Part 3.11(c) of the Tigris Disclosure Schedule lists all written and
describes all non-written employee benefit plans (as defined in Section 3(3)
of ERISA) and all bonus, equity-based, incentive, deferred compensation,
retirement or supplemental retirement, profit sharing, severance, golden
parachute, vacation, cafeteria, dependent care, medical care, employee
assistance program, education or tuition assistance programs and other similar
fringe or employee benefit plans, programs or arrangements, including any
employment or executive compensation or severance agreements, written or
otherwise, which are currently in effect relating to any present or former
employee or director of Tigris (or any trade or business (whether or not
incorporated) which is a Tigris Affiliate) or which is maintained by,
administered or contributed to by, or required to be contributed to by,
Tigris, or any Tigris Affiliate, or under which Tigris or any Tigris Affiliate
has incurred or may incur any liability (each, an "Tigris Employee Plan").
Part 3.11(c) of the Tigris Disclosure Schedule sets forth all amounts owed to
any employee or consultant of Tigris or any of its Subsidiaries, under any
severance arrangement with Tigris or any Tigris Subsidiary, as a result of the
consummation of the Merger or the Contemplated Transactions.

(d) With respect to each Tigris Employee Plan, Tigris has made available to
Potomac a true and complete copy of, to the extent applicable, (i) such Tigris
Employee Plan, (ii) the three (3) most recent annual reports (Form 5500) as
filed with the Internal Revenue Service, (iii) each currently effective trust
agreement related to such Tigris Employee Plan, (iv) the most recent summary
plan description for each Tigris Employee Plan for which such description is
required, along with all summaries of material modifications, amendments,
resolutions and all other material plan documentation related thereto in the
possession of Tigris or any Tigris Subsidiary,

 and (v) the most recent Internal Revenue Service determination or opinion
letter or analogous ruling under foreign law issued with respect to any Tigris
Employee Plan.

(e) Each Tigris Employee Plan that is intended to be qualified under Section
401(a) of the Code has received a favorable determination with respect to such
qualified status from the Internal Revenue Service. To the Knowledge of
Tigris, nothing has occurred that would reasonably be expected to adversely
affect the qualified status of any such Tigris Employee Plan or the exempt
status of any related trust.

(f) Each Tigris Employee Plan has been maintained in compliance, in all
material respects, with its terms and, both as to form and operation, with all
applicable Legal Requirements, including without limitation, the Code and
ERISA.

(g) No Tigris Employee Plan is subject to Title IV or Section 302 of ERISA or
Section 412 of the Code, and neither Tigris nor any Tigris Affiliate has ever
maintained, contributed to or partially or completely withdrawn from, or
incurred any obligation or liability with respect to, any such plan. No Tigris
Employee Plan is a Multiemployer Plan, and neither Tigris nor any Tigris
Affiliate has ever contributed to or had an obligation to contribute, or
incurred any liability in respect of a contribution, to any Multiemployer
Plan. No Tigris Employee Plan is a Multiple Employer Plan.

(h) No Tigris Employee Plan (other than to the extent set forth in an
employment, retention, change in control, deferred compensation or severance
agreement or arrangement between Tigris or any of its Subsidiaries and any
present or former employee or director) provides for medical or death benefits
beyond termination of service or retirement, other than (i) pursuant to COBRA
or an analogous state law requirement or (ii) death or retirement benefits
under an Tigris Employee Plan qualified under Section 401(a) of the Code.

(i) With respect to Tigris Options granted pursuant to the Tigris Stock Plans,
(i) each Tigris Option intended to qualify as an "incentive stock option"
under Section 422 of the Code so qualifies, (ii) each grant of a Tigris Option
was duly authorized no later than the date on which the Grant Date by all
necessary corporate action, including, as applicable, approval by the board of
directors of Tigris (or a duly constituted and authorized committee thereof)
and any required stockholder approval by the necessary number of votes or
written consents, and the award agreement governing such grant (if any) was
duly executed and delivered by each party thereto, (iii) each Tigris Option
grant was made in accordance with the terms of the Tigris Stock Plans, the
Exchange Act and all other applicable laws and regulatory rules or
requirements, including the rules of the Nasdaq Global Market and any other
exchange on which Tigris securities are traded, (iv) the per share exercise
price of each Tigris Option was equal to the fair market value of a share of
Tigris Common Stock on the applicable Grant Date and (v) each such Tigris
Option grant was properly accounted for in accordance with GAAP in the
financial statements (including the related notes) of Tigris and disclosed in
Tigris filings with the Securities and Exchange Commission in accordance with
the Exchange Act and all other applicable laws. Tigris has not knowingly
granted, and there is no and has been no policy or practice of Tigris of
granting, Tigris Options prior to, or otherwise coordinate the grant of Tigris
Options with, the release or other public announcement of material information
regarding Tigris or its results of operations or prospects.

 (j) To the Knowledge of Tigris, no Tigris Options, stock appreciation rights
or other equity-based awards issued or granted by Tigris are subject to the
requirements of Code Section 409A. To the Knowledge of Tigris, each
"nonqualified deferred compensation plan" (as such term is defined under
Section 409A(d)(1) of the Code and the guidance thereunder) under which Tigris
or any of its Subsidiaries makes, is obligated to make or promises to make,
payments (each, a "409A Plan") complies in all material respects, in both form
and operation, with the requirements of Code Section 409A and the guidance
thereunder. No payment to be made under any 409A Plan is, or to the Knowledge
of Tigris will be, subject to the penalties of Code Section 409A(a)(1).

(k) Tigris and each of its Subsidiaries is in compliance with all of its
bonus, commission and other compensation plans and has paid any and all
amounts required to be paid under such plans, including any and all bonuses
and commissions (or pro rata portion thereof) that may have accrued or been
earned through the calendar quarter preceding the Effective Time, and is not
liable for any payments, taxes or penalties for failure to comply with any of
the terms or conditions of such plans or the laws governing such plans.

(l) Tigris and each of its Subsidiaries has complied with all state and
federal laws applicable to employees, including but not limited to COBRA,
FMLA, CFRA, HIPAA, the Women's Health and Cancer Rights Act of 1998, the
Newborn's and Mothers' Health Protection Act of 1996, and any similar
provisions of state law applicable to its employees. Neither Tigris nor any of
its Subsidiaries has any unsatisfied obligations to any of its employees or
qualified beneficiaries pursuant to COBRA, HIPAA or any state law governing
health care coverage or extension.

(m) Tigris and each of its Subsidiaries is in compliance with all applicable
foreign, federal, state and local laws, rules and regulations respecting
employment, employment practices, terms and conditions of employment, worker
classification, tax withholding, prohibited discrimination, equal employment,
fair employment practices, meal and rest periods, immigration status, employee
safety and health, wages (including overtime wages), compensation, and hours
of work, and in each case, with respect to employees: (i) has withheld and
reported all amounts required by law or by agreement to be withheld and
reported with respect to wages, salaries and other payments to employees, (ii)
is not liable for any arrears of wages, severance pay or any Taxes or any
penalty for failure to comply with any of the foregoing, and (iii) is not
liable for any payment to any trust or other fund governed by or maintained by
or on behalf of any governmental authority, with respect to unemployment
compensation benefits, social security or other benefits or obligations for
employees (other than routine payments to be made in the normal course of
business and consistent with past practice). There are no actions, suits,
claims or administrative matters pending, threatened or reasonably anticipated
against Tigris or any of its Subsidiaries relating to any employee, employment
agreement or Tigris Employee Plan. There are no pending or threatened or
reasonably anticipated claims or actions against Tigris, any of its
Subsidiaries, any Tigris trustee or any trustee of any Subsidiary under any
worker's compensation policy or long-term disability policy. Neither Tigris
nor any of its Subsidiaries is party to a conciliation agreement, consent
decree or other agreement or order with any federal, state, or local agency or
governmental authority with respect to employment practices. Part 3.11(m) of
the Disclosure Schedule lists all liabilities of Tigris or any of its
Subsidiaries to any of their respective employees that result from the
termination by Tigris

 or any of its Subsidiaries of such employee's employment or provision of
services, a change of control of Tigris, or a combination thereof. Neither
Tigris nor any of its Subsidiaries has any material liability with respect to
any misclassification of: (a) any Person as an independent contractor rather
than as an employee, (b) any employee leased from another employer, or (c) any
employee currently or formerly classified as exempt from overtime wages.
Neither Tigris nor any of its Subsidiaries has taken any action which would
constitute a "plant closing" or "mass layoff" within the meaning of the WARN
Act or similar state or local law, issued any notification of a plant closing
or mass layoff required by the WARN Act or similar state or local law, or
incurred any liability or obligation under WARN or any similar state or local
law that remains unsatisfied. No terminations of employees of Tigris or any of
its Subsidiaries prior to the Closing would trigger any notice or other
obligations under the WARN Act or similar state or local law.

(n) There has never been, nor has there been any threat of, any strike,
slowdown, work stoppage, lockout, job action, union, organizing activity,
question concerning representation or any similar activity or dispute,
affecting Tigris or any of its Subsidiaries. No event has occurred, and no
condition or circumstance exists, that might directly or indirectly be likely
to give rise to or provide a basis for the commencement of any such strike,
slowdown, work stoppage, lockout, job action, unior organizing activity,
question concerning representation or any similar activity or dispute.

(o) Neither Tigris nor any of its Subsidiaries is, nor has been, engaged in
any unfair labor practice within the meaning of the National Labor Relations
Act. There is no Legal Proceeding, claim, labor dispute or grievance pending
or, to the Knowledge of Tigris, threatened or reasonably anticipated relating
to any employment contract, privacy right, labor dispute, wages and hours,
leave of absence, plant closing notification, workers' compensation policy,
long-term disability policy, harassment, retaliation, immigration, employment
statute or regulation, safety or discrimination matter involving any Tigris
Associate, including charges of unfair labor practices or discrimination
complaints.

(p) There is no contract, agreement, plan or arrangement to which Tigris or
any Tigris Affiliate is a party or by which it is bound to compensate any of
its employees for excise taxes paid pursuant to Section 4999 of the Code.

(q) Neither Tigris nor any of its Subsidiaries is a party to any Contract that
has resulted or would reasonably be expected to result, separately or in the
aggregate, in the payment of (i) any "excess parachute payment" within the
meaning of section 280G of the Code and (ii) any amount the deduction for
which would be disallowed under Section 162(m) of the Code.



3.12 Environmental Matters. Each of Tigris and its Subsidiaries is in
compliance with all applicable Environmental Laws, which compliance includes
the possession by Tigris or a Tigris Subsidiary of all permits and other
Governmental Authorizations required under applicable Environmental Laws and
compliance with the terms and conditions thereof. Neither Tigris nor any of
its Subsidiaries has received since January 1, 2010 any written notice or
other communication (in writing or otherwise), whether from a Governmental
Body, citizens group, employee or otherwise, that alleges that Tigris or a
Tigris Subsidiary is not in compliance with

 any Environmental Law, and, to the Knowledge of Tigris, there are no
circumstances that may prevent or interfere with Tigris' or a Tigris
Subsidiary's compliance with any Environmental Law in the future. To the
Knowledge of Tigris: (i) no current or prior owner of any property leased or
controlled by Tigris or a Tigris Subsidiary has received since January 1, 2010
any written notice or other communication relating to property owned or leased
at any time by Tigris or a Tigris Subsidiary, whether from a Governmental
Body, citizens group, employee or otherwise, that alleges that such current or
prior owner or Tigris or a Tigris Subsidiary is not in compliance with or
violated any Environmental Law relating to such property and (ii) neither
Tigris nor any Tigris Subsidiary has any material liability under any
Environmental Law.

3.13 Insurance.

(a) Tigris made available to Potomac accurate and complete copies of all
material insurance policies and all material self insurance programs and
arrangements relating to the business, assets, liabilities and operations of
Tigris and its Subsidiaries. Each of such insurance policies is in full force
and effect and Tigris and its Subsidiaries are in compliance with the terms
thereof. Other than customary end of policy notifications from insurance
carriers, since January 1, 2010, neither Tigris nor any of its Subsidiaries
has received any notice or other communication regarding any actual or
possible: (i) cancellation or invalidation of any insurance policy; (ii)
refusal or denial of any coverage, reservation of rights or rejection of any
material claim under any insurance policy; or (iii) material adjustment in the
amount of the premiums payable with respect to any insurance policy. There is
no pending workers' compensation or other claim under or based upon any
insurance policy of Tigris or a Tigris Subsidiary. All information provided to
insurance carriers (in applications and otherwise) on behalf of Tigris is
accurate and complete. Each of Tigris and its Subsidiaries has provided timely
written notice to the appropriate insurance carrier(s) of each Legal
Proceeding pending or threatened in writing against Tigris or a Tigris
Subsidiary, and no such carrier has issued a denial of coverage or a
reservation of rights with respect to any such Legal Proceeding, or informed
Tigris or a Tigris Subsidiary of its intent to do so.

(b) Tigris has made available to Potomac accurate and complete copies of the
existing policies (primary and excess) of directors' and officers' liability
insurance maintained by Tigris and its Subsidiaries as of the date of this
Agreement (the "Existing Tigris DandO Policies"). Part 3.13(b) of the Tigris
Disclosure Schedule accurately sets forth the most recent annual premiums paid
by Tigris with respect to the Existing Tigris DandO Policies.

3.14 Transactions with Affiliates. Except as set forth in the Tigris SEC
Documents filed prior to the date of this Agreement, since the date of Tigris'
last proxy statement filed in 2014 with the SEC, no event has occurred that
would be required to be reported by Tigris or a Tigris Subsidiary pursuant to
Item 404 of Regulation S-K promulgated by the SEC. Part 3.14 of the Tigris
Disclosure Schedule identifies each Person who is (or who may be deemed to be)
an "affiliate" (as that term is used in Rule 145 under the Securities Act) of
Tigris as of the date of this Agreement.

3.15 Legal Proceedings; Orders.

 (a) Except as set forth in Part 3.15 of the Tigris Disclosure Schedule, there
is no pending Legal Proceeding, and, to the Knowledge of Tigris, no Person has
threatened in writing to commence any Legal Proceeding: (i) that involves
Tigris, a Tigris Subsidiary or any Tigris Associate (in his or her capacity as
such) or any of the material assets owned or used by Tigris or a Tigris
Subsidiary; or (ii) that challenges, or that may have the effect of
preventing, delaying, making illegal or otherwise interfering with, the Merger
or any of the other Contemplated Transactions. To the Knowledge of Tigris, no
event has occurred, and no claim, dispute or other condition or circumstance
exists, that will, or that would reasonably be expected to, give rise to or
serve as a basis for the commencement of any such Legal Proceeding. With
regard to any Legal Proceeding set forth on Part 3.15 of the Tigris Disclosure
Schedule, Tigris has provided Potomac or its counsel all pleadings and
material written correspondence related to such Legal Proceeding, all
insurance policies and material written correspondence with brokers and
insurers related to such Legal Proceedings and other information material to
an assessment of such Legal Proceeding. Tigris has an insurance policy or
policies that is expected to cover such Legal Proceeding and has complied with
the requirements of such insurance policy or policies to obtain coverage with
respect to such Legal Proceeding under such insurance policy or policies.

(b) There is no order, writ, injunction, judgment or decree to which Tigris, a
Tigris Subsidiary, or any of the assets owned or used by Tigris or any Tigris
Subsidiary, is subject. To the Knowledge of Tigris, no officer or other Key
Employee of Tigris or a Tigris Subsidiary is subject to any order, writ,
injunction, judgment or decree that prohibits such officer or other employee
from engaging in or continuing any conduct, activity or practice relating to
the business of Tigris or a Tigris Subsidiary or to any material assets owned
or used by Tigris or a Tigris Subsidiary.

3.16 Authority; Binding Nature of Agreement. Each of Tigris and Merger Sub has
all necessary corporate power and authority to enter into and to perform its
obligations under this Agreement. Each of the Boards of Directors of Tigris
and Merger Sub (at meetings duly called and held) has: (a) determined that the
Merger is advisable and fair to and in the best interests of such Party and
its stockholders; (b) duly authorized and approved by all necessary corporate
action, the execution, delivery and performance of this Agreement and the
transactions contemplated hereby, including the Merger; and (c) recommended
the adoption and approval of this Agreement by the holders of Tigris Common
Stock and directed that this Agreement and the issuance of shares of Tigris
Common Stock in the Merger be submitted for consideration by Tigris'
stockholders at the Tigris Stockholders' Meeting. This Agreement has been duly
executed and delivered by Tigris and Merger Sub, and assuming the due
authorization, execution and delivery by Potomac constitutes the legal, valid
and binding obligation of Tigris or Merger Sub (as applicable), enforceable
against each of Tigris and Merger Sub in accordance with its terms, subject
to: (i) laws of general application relating to bankruptcy, insolvency and the
relief of debtors; and (ii) rules of law governing specific performance,
injunctive relief and other equitable remedies. Prior to the execution of the
Tigris Stockholder Support Agreements, the Board of Directors of Tigris
approved the Tigris Stockholder Support Agreements and the transactions
contemplated thereby.

 3.17 Inapplicability of Anti-takeover Statutes. The Boards of Directors of
Tigris and Merger Sub have taken and will take all actions necessary to ensure
that the restrictions applicable to business combinations contained in Section
203 of the DGCL are, and will be, inapplicable to the execution, delivery and
performance of this Agreement and the Tigris Stockholder Support Agreements
and to the consummation of the Merger and the other Contemplated Transactions.
No other state takeover statute or similar Legal Requirement applies or
purports to apply to the Merger, this Agreement, the Tigris Stockholder
Support Agreements or any of the other Contemplated Transactions.

3.18 Vote Required. The affirmative vote of the holders of a majority of the
shares of Tigris Common Stock having voting power representing a majority of
the outstanding Common Stock is the only vote of the holders of any class or
series of Tigris' capital stock necessary to approve the Merger and the
issuance of Tigris Common Stock in the Merger (the "Required Tigris
Stockholder Vote").

3.19 Non-Contravention; Consents. Subject to compliance with the HSR Act and
any foreign antitrust Legal Requirement, obtaining the Required Tigris
Stockholder Vote for the applicable Contemplated Transactions and the filing
of the Certificate of Merger required by the DGCL, neither (x) the execution,
delivery or performance of this Agreement by Tigris or Merger Sub, nor (y) the
consummation of the Merger or any of the other Contemplated Transactions, will
directly or indirectly (with or without notice or lapse of time):

(a) contravene, conflict with or result in a violation of (i) any of the
provisions of the certificate of incorporation, bylaws or other charter or
organizational documents of Tigris or Merger Sub, or (ii) any resolution
adopted by the stockholders, the board of directors or any committee of the
board of directors of Tigris or Merger Sub;

(b) contravene, conflict with or result in a violation of, or give any
Governmental Body or other Person the right to challenge the Merger or any of
the other Contemplated Transactions or to exercise any remedy or obtain any
relief under, any Legal Requirement or any order, writ, injunction, judgment
or decree to which Tigris or a Tigris Subsidiary or any of the assets owned or
used by Tigris or a Tigris Subsidiary, is subject;

(c) contravene, conflict with or result in a violation of any of the terms or
requirements of, or give any Governmental Body the right to revoke, withdraw,
suspend, cancel, terminate or modify, any Governmental Authorization that is
held by Tigris or a Tigris Subsidiary or that otherwise relates to the
business of Tigris or a Tigris Subsidiary or to any of the assets owned or
used by Tigris or a Tigris Subsidiary;

(d) contravene, conflict with or result in a violation or breach of, or result
in a default under, any provision of any Tigris Contract, or give any Person
the right to: (i) declare a default or exercise any remedy under any Tigris
Contract; (ii) a rebate, chargeback, penalty or change in delivery schedule
under any such Tigris Contract; (iii) accelerate the maturity or performance
of any Tigris Contract; or (iv) cancel, terminate or modify any term of any
Tigris Contract; except, in the case of any Tigris Material Contract, any non-
material breach, default,

 penalty or modification and, in the case of all other Tigris Contracts, any
breach, default, penalty or modification that would not result in a Tigris
Material Adverse Effect;

(e) result in the imposition or creation of any Encumbrance upon or with
respect to any asset owned or used by Tigris or a Tigris Subsidiary (except
for minor liens that will not, in any case or in the aggregate, materially
detract from the value of the assets subject thereto or materially impair the
operations of Tigris or a Tigris Subsidiary); or

(f) result in, or increase the likelihood of, the transfer of any material
asset of Tigris or a Tigris Subsidiary to any Person.

Except (i) for any Consent set forth on Part 3.19 of the Tigris Disclosure
Schedule under any Tigris Contract, (ii) the approval of the Merger and the
issuance of shares of Tigris Common Stock in the Merger, (iii) the filing of
the Certificate of Merger with the Secretary of State of the State of Delaware
pursuant to the DGCL, (iv) any required filings under the HSR Act, any foreign
antitrust Legal Requirement and (v) such consents, waivers, approvals, orders,
authorizations, registrations, declarations and filings as may be required
under applicable federal and state securities laws, neither Tigris nor any of
its Subsidiaries was, is, or will be required to make any filing with or give
any notice to, or to obtain any Consent from, any Person in connection with
(x) the execution, delivery or performance of this Agreement, or (y) the
consummation of the Merger or any of the other Contemplated Transactions.

3.20 Bank Accounts; Receivables; Deposits.

(a) Part 3.20(a) of the Tigris Disclosure Schedule provides accurate
information with respect to each account maintained by or for the benefit of
Tigris or a Tigris Subsidiary at any bank or other financial institution,
including the name of the bank or financial institution, the account number,
the balance as of June 22, 2014 and the names of all individuals authorized to
draw on or make withdrawals from such accounts.

(b) All existing accounts receivable of Tigris or a Tigris Subsidiary
(including those accounts receivable reflected on the Tigris Unaudited Interim
Balance Sheet that have not yet been collected and those accounts receivable
that have arisen since the date of the Tigris Unaudited Interim Balance Sheet
and have not yet been collected), (i) represent valid obligations of customers
of Tigris or a Tigris Subsidiary arising from bona fide transactions entered
into in the Ordinary Course of Business, and (ii) are current and collectible
in full when due, without any counterclaim or set off, net of applicable
reserves for bad debts on the Tigris Unaudited Interim Balance Sheet

(c) All deposits of Tigris or a Tigris Subsidiary (including without
limitation those set forth on the Tigris Unaudited Interim Balance Sheet)
which are individually more than $25,000 or more than $50,000 in the aggregate
are fully refundable to Tigris or a Tigris Subsidiary.

3.21 No Financial Advisor. Except as set forth on Part 3.21 of the Tigris
Disclosure Schedule, no broker, finder or investment banker is entitled to any
brokerage fee, finder's fee,

 opinion fee, success fee, transaction fee or other fee or commission in
connection with the Merger or any of the other Contemplated Transactions based
upon arrangements made by or on behalf of Tigris or a Tigris Subsidiary.

3.22 Valid Issuance. The Tigris Common Stock to be issued in the Merger will,
when issued in accordance with the provisions of this Agreement be validly
issued, fully paid and nonassessable.

3.23 Code of Ethics. Tigris has adopted a code of ethics, as defined by Item
406(b) of Regulation S-K of the SEC, for senior financial officers, applicable
to its principal executive officer, principal financial officer, controller or
principal accounting officer, or persons performing similar functions. Tigris
has promptly disclosed any change in or waiver of Tigris' code of ethics with
respect to any such persons, as required by Section 406(b) of the Sarbanes-
Oxley Act. To the Knowledge of Tigris, there have been no violations of
provisions of Tigris' code of ethics by any such persons.

3.24 Title to Assets. Tigris and its Subsidiaries own, and have good and valid
title to, or, in the case of leased properties and assets, valid leasehold
interests in, all tangible properties or assets and equipment used or held for
use in their business or operations or purported to be owned by them.

3.25 Real Property; Leasehold. Neither Tigris nor any of its Subsidiaries owns
any real property or any interest in real property, except for the leaseholds
created under the real property leases identified in Part 3.24 of the Tigris
Disclosure Schedule, which are in full force and effect and with no existing
default thereunder.



Section 4. CERTAIN COVENANTS OF THE PARTIES

4.1 Access and Investigation. Subject to the terms of the Confidentiality
Agreement which the Parties agree will continue in full force following the
date of this Agreement, during the period commencing on the date of this
Agreement and ending at the Effective Time (the "Pre-Closing Period"), upon
reasonable notice each Party shall, and shall use commercially reasonable
efforts to cause such Party's Representatives to: (a) provide the other Party
and such other Party's Representatives with reasonable access during normal
business hours to such Party's Representatives, personnel and assets and to
all existing books, records, Tax Returns, work papers and other documents and
information relating to such Party and its Subsidiaries; (b) provide the other
Party and such other Party's Representatives with such copies of the existing
books, records, Tax Returns, work papers, product data, and other documents
and information relating to such Party and its Subsidiaries, and with such
additional financial, operating and other data and information regarding such
Party and its Subsidiaries as the other Party may reasonably request; and (c)
permit the other Party's officers and other employees to meet, upon reasonable
notice and during normal business hours, with the chief financial officer and
other officers and managers of such Party responsible for such Party's
financial statements and the internal controls of such Party to discuss such
matters as the other Party may deem necessary or appropriate in

 order to enable the other Party to satisfy its obligations under the Sarbanes-
Oxley Act and the rules and regulations relating thereto. Without limiting the
generality of any of the foregoing, during the Pre-Closing Period, each Party
shall promptly make available to the other Party copies of:

(i) the unaudited monthly consolidated balance sheets of such Party as of the
end of each calendar month and the related unaudited monthly consolidated
statements of operations, statements of stockholders' equity and statements of
cash flows for such calendar month, which shall be delivered within twenty
days after the end of such calendar month, or such longer periods as the
Parties may agree to in writing;

(ii) all material operating and financial reports prepared by such Party for
its senior management, including sales forecasts, marketing plans, development
plans, discount reports, write-off reports, hiring reports and capital
expenditure reports prepared for its management;

(iii) any written materials or communications sent by or on behalf of a Party
to its stockholders;

(iv) any material notice, document or other communication sent by or on behalf
of a Party to any party to any Tigris Material Contract or Potomac Material
Contract, as applicable, or sent to a Party by any party to any Tigris
Material Contract or Potomac Material Contract, as applicable (other than any
communication that relates solely to routine commercial transactions between
such Party and the other party to any such Tigris Material Contract or Potomac
Material Contract, as applicable, and that is of the type sent in the Ordinary
Course of Business and consistent with past practices);

(v) any notice, report or other document filed with or otherwise furnished,
submitted or sent to any Governmental Body on behalf of a Party in connection
with the Merger or any of the Contemplated Transactions;

(vi) any non-privileged notice, document or other communication sent by or on
behalf of, or sent to, a Party relating to any pending or threatened Legal
Proceeding involving or affecting such Party; and

(vii) any material notice, report or other document received by a Party from
any Governmental Body.

Notwithstanding the foregoing, any Party may restrict the foregoing access to
the extent that any Legal Requirement applicable to such party requires such
Party to restrict or prohibit access to any such properties or information.

4.2 Operation of Tigris' Business.

(a) Except as set forth on Part 4.2(a) of the Tigris Disclosure Schedule,
during the Pre-Closing Period: (i) Tigris shall and cause its Subsidiaries to
conduct its business and

 operations: (A) in the Ordinary Course of Business and, as reasonably deemed
appropriate and with the prior written consent of Potomac, with a view towards
winding down its operations; and (B) in compliance with all applicable Legal
Requirements and the requirements of all Contracts that constitute Tigris
Material Contracts; (ii) Tigris shall and cause its Subsidiaries to continue
to make regularly scheduled payments on their existing debt when due and
payable (and not make any prepayments), if any; (iii) Tigris shall and cause
its Subsidiaries to continue to pay outstanding accounts payable and other
current Liabilities (including payroll) when due and payable and (iv) Tigris
shall promptly notify Potomac of: (A) any notice or other communication from
any Person alleging that the Consent of such Person is or may be required in
connection with any of the Contemplated Transactions; (B) any Legal Proceeding
against, relating to, involving or otherwise affecting Tigris that is
commenced, or, to the Knowledge of Tigris, threatened against, Tigris after
the date of the Merger Agreement and (C) any notice or other communication
from any Person alleging that any payment or other obligation is or will be
owed to such Person at any time before or after the date of this Agreement,
except for invoices or other communications related to agreements or dealings
in the Ordinary Course of Business, payments or obligations related to the
Contemplated Transactions or payments or obligations identified in this
Agreement, including the Tigris Disclosure Schedule.

(b) During the Pre-Closing Period, Tigris shall promptly notify Potomac in
writing, by delivering an updated Tigris Disclosure Schedule, of: (i) the
discovery by Tigris of any event, condition, fact or circumstance that
occurred or existed on or prior to the date of this Agreement and that caused
or constitutes a material inaccuracy in any representation or warranty made by
Tigris in this Agreement; (ii) any event, condition, fact or circumstance that
occurs, arises or exists after the date of this Agreement and that would cause
or constitute a material inaccuracy in any representation or warranty made by
Tigris in this Agreement if: (A) such representation or warranty had been made
as of the time of the occurrence, existence or discovery of such event,
condition, fact or circumstance; or (B) such event, condition, fact or
circumstance had occurred, arisen or existed on or prior to the date of this
Agreement; (iii) any material breach of any covenant or obligation of Tigris;
and (iv) any event, condition, fact or circumstance that could reasonably be
expected to make the timely satisfaction of any of the conditions set forth in
Sections 6, 7 or 8 impossible or materially less likely. Without limiting the
generality of the foregoing, Tigris shall promptly advise Potomac in writing
of any Legal Proceeding or material, written claim threatened, commenced or
asserted against or with respect to, or otherwise affecting, Tigris or, to the
Knowledge of Tigris, any director, officer or Key Employee of Tigris. No
notification given to Potomac pursuant to this Section 4.2(b) shall change,
limit or otherwise affect any of the representations, warranties, covenants or
obligations of Tigris or any of its Subsidiaries contained in this Agreement
or the Tigris Disclosure Schedule for purposes of Section 8.1.

4.3 Operation of Potomac's Business.

(a) Except as set forth on Part 4.3(a) of the Potomac Disclosure Schedule,
during the Pre-Closing Period: (i) each of Potomac and its Subsidiaries shall
conduct its business and operations: (A) in the Ordinary Course of Business
and in accordance with past practices; and (B) in compliance with all
applicable Legal Requirements and the requirements of all

 Contracts that constitute Potomac Material Contracts; and (ii) each of Potomac
and its Subsidiaries shall preserve intact its current business organization,
use reasonable efforts to keep available the services of its current Key
Employees, officers and other employees and maintain its relations and
goodwill with all suppliers, customers, landlords, creditors, licensors,
licensees, employees and other Persons having business relationships with
Potomac or its Subsidiaries; (iii) continue to make regularly scheduled
payments on its existing debt when due and payable (and not make any
prepayments), if any; (iv) continue to pay outstanding accounts payable and
other current Liabilities (including payroll) when due and payable, and (v)
promptly notify Tigris of: (A) any notice or other communication from any
Person alleging that the Consent of such Person is or may be required in
connection with any of the Contemplated Transactions; and (B) any Legal
Proceeding against, relating to, involving or otherwise affecting Potomac or
any of its Subsidiaries that is commenced, or, to the Knowledge of Potomac,
threatened against, Potomac or any of its Subsidiaries.

(b) During the Pre-Closing Period, Potomac shall promptly notify Tigris in
writing, by delivery of an updated Potomac Disclosure Schedule, of: (i) the
discovery by Potomac of any event, condition, fact or circumstance that
occurred or existed on or prior to the date of this Agreement and that caused
or constitutes a material inaccuracy in any representation or warranty made by
Potomac in this Agreement; (ii) any event, condition, fact or circumstance
that occurs, arises or exists after the date of this Agreement and that would
cause or constitute a material inaccuracy in any representation or warranty
made by Potomac in this Agreement if: (A) such representation or warranty had
been made as of the time of the occurrence, existence or discovery of such
event, condition, fact or circumstance; or (B) such event, condition, fact or
circumstance had occurred, arisen or existed on or prior to the date of this
Agreement; (iii) any material breach of any covenant or obligation of Potomac;
and (iv) any event, condition, fact or circumstance that could reasonably be
expected to make the timely satisfaction of any of the conditions set forth in
Sections 6, 7 or 8 impossible or materially less likely. Without limiting the
generality of the foregoing, Potomac shall promptly advise Tigris in writing
of any Legal Proceeding or material, written claim threatened in writing,
commenced or asserted against or with respect to, or otherwise affecting,
Potomac or any of its Subsidiaries or, to the Knowledge of Potomac, any
director, officer or Key Employee of Potomac or any of its Subsidiaries. No
notification given to Tigris pursuant to this Section 4.3(b) shall change,
limit or otherwise affect any of the representations, warranties, covenants or
obligations of Potomac contained in this Agreement or the Potomac Disclosure
Schedule for purposes of Section 7.1.

4.4 Negative Obligations.

(a) Except (i) as expressly contemplated or permitted by this Agreement, (ii)
as set forth in Part 4.4(a) of the Tigris Disclosure Schedule, or (iii) with
the prior written consent of Potomac, at all times during the period
commencing with the execution and delivery of this Agreement and continuing
until the earlier to occur of the termination of this Agreement pursuant to
Section 9 and the Effective Time, Tigris shall not, nor shall it cause or
permit any of its Subsidiaries to, to do any of the following:

 (i) declare, accrue, set aside or pay any dividend or made any other
distribution in respect of any shares of its capital stock (except, for the
avoidance of doubt, as permitted under Section 5.16); or repurchase, redeem or
otherwise reacquire any shares of its capital stock or other securities
(except for shares of Tigris Common Stock from terminated employees of
Tigris);

(ii) except for contractual commitments in place at the time of this Agreement
as listed in Part 4.4(a)(ii) of the Tigris Disclosure Schedule, sell, issue or
grant, or authorize the issuance of: (i) any capital stock or other security
(except for Tigris Common Stock issued upon the valid exercise of outstanding
Tigris Options); (ii) any option, warrant or right to acquire any capital
stock or any other security; or (iii) any instrument convertible into or
exchangeable for any capital stock or other security;

(iii) amend the certificate of incorporation, bylaws or other charter or
organizational documents of Tigris, or effect or be a party to any merger,
consolidation, share exchange, business combination, recapitalization,
reclassification of shares, stock split, reverse stock split or similar
transaction except as related to the Contemplated Transactions;

(iv) form any Subsidiary or acquire any equity interest or other interest in
any other Entity;

(v) lend money to any Person; other than in the Ordinary Course of Business,
incur or guarantee any indebtedness for borrowed money; issue or sell any debt
securities or options, warrants, calls or other rights to acquire any debt
securities; guarantee any debt securities of others; or make any capital
expenditure or commitment;

(vi) (i) adopt, establish or enter into any Tigris Employee Plan; (ii) cause
or permit any Tigris Employee Plan to be amended other than as required by law
or in order to make amendments for the purposes of Section 409A of the Code,
subject to prior review and approval (with such approval not to be
unreasonably withheld) by Potomac; (iii) other than in the Ordinary Course of
Business, pay any bonus or make any profit-sharing or similar payment to, or
increase the amount of the wages, salary, commissions, fringe benefits or
other compensation or remuneration payable to, any of its directors or
employees; or (iv) increase the severance or change of control benefits
offered to any current or new service providers, provided, that, Tigris may
pay those severance and retention payments owed under existing Tigris Employee
Plans scheduled on Part 3.11(m) of the Tigris Disclosure Schedule to its
current employees in connection with their termination of employment;

(vii) enter into any material transaction outside the Ordinary Course of
Business;

(viii) acquire any material asset, except in the Ordinary Course of Business
consistent with past practices;

(ix) make, change or revoke any material Tax election; file any material
amendment to any Tax Return; adopt or change any accounting method in respect
of Taxes;

 change any annual Tax accounting period; enter into any Tax allocation
agreement, Tax sharing agreement or Tax indemnity agreement, other than
commercial contracts entered into in the Ordinary Course of Business with
vendors, customers or landlords; enter into any closing agreement with respect
to any Tax; settle or compromise any claim, notice, audit report or assessment
in respect of material Taxes; apply for or enter into any ruling from any Tax
authority with respect to Taxes; surrender any right to claim a material Tax
refund; or consent to any extension or waiver of the statute of limitations
period applicable to any material Tax claim or assessment;

(x) enter into any Tigris Material Contract;

(xi) (i) materially change pricing or royalties or other payments set or
charged by Tigris to its customers or licensees, (ii) agree to materially
increase pricing or royalties or other payments set or charged by persons who
have licensed Intellectual Property to Tigris, or (iii) as of the date of this
Agreement, materially increase pricing or royalties or other payments set or
charged by persons who have licensed Intellectual Property to Tigris; or

(xii) agree, resolve or commit to do any of the foregoing.

(b) Except (i) as expressly contemplated or permitted by this Agreement, (ii)
as set forth on Part 4.4(b) of the Potomac Disclosure Schedule, or (iii) with
the prior written consent of Tigris, at all times during the period commencing
with the execution and delivery of this Agreement and continuing until the
earlier to occur of the termination of this Agreement pursuant to Section 9
and the Effective Time, Potomac shall not, nor shall it cause or permit any of
its Subsidiaries to, do any of the following:

(i) declare, accrue, set aside or pay any dividend or make any other
distribution in respect of any shares of capital stock; or repurchase, redeem
or otherwise reacquire any shares of capital stock or other securities (except
for shares of Potomac Common Stock from terminated employees of Potomac);

(ii) amend the certificate of incorporation, bylaws or other charter or
organizational documents of Potomac, or effect or be a party to any merger,
consolidation, share exchange, business combination, recapitalization,
reclassification of shares, stock split, reverse stock split or similar
transaction;

(iii) sell, issue or grant, or authorize the issuance of, or make any
commitments to do any of the foregoing, other than as contemplated by the
Contemplated Transactions: (i) any capital stock or other security (except for
shares of outstanding Potomac Common Stock issued upon the valid exercise of
Potomac Options); (ii) any option, warrant or right to acquire any capital
stock or any other security; or (iii) any instrument convertible into or
exchangeable for any capital stock or other security;

(iv) form any Subsidiary or acquire any equity interest or other interest in
any other Entity;

 (v) other than in the Ordinary Course of Business, lend money to any Person;
incur or guarantee any indebtedness for borrowed money; issue or sell any debt
securities or options, warrants, calls or other rights to acquire any debt
securities; guarantee any debt securities of others; or make any capital
expenditure or commitment in excess of $150,000;

(vi) other than in the Ordinary Course of Business, and in observance of
common practice for a similarly-situated company: (i) adopt, establish or
enter into any Potomac Employee Plan; (ii) cause or permit any Potomac
Employee Plan to be amended other than as required by law; or (iii) pay any
bonus or made any profit-sharing or similar payment to, or increase the amount
of the wages, salary, commissions, fringe benefits or other compensation or
remuneration payable to, any of its directors, officers or employees;

(vii) enter into any material transaction outside the Ordinary Course of
Business;

(viii) acquire any material asset nor sell, lease other otherwise irrevocably
dispose of any of its assets or properties, or grant any Encumbrance with
respect to such assets or properties, except in the Ordinary Course of
Business consistent with past practices;

(ix) make, change or revoke any material Tax election; file any material
amendment to any Tax Return; adopt or change any accounting method in respect
of Taxes; change any annual Tax accounting period; enter into any Tax
allocation agreement, Tax sharing agreement or Tax indemnity agreement, other
than commercial contracts entered into in the Ordinary Course of Business with
vendors, customers or landlords; enter into any closing agreement with respect
to any Tax; settle or compromise any claim, notice, audit report or assessment
in respect of material Taxes; apply for or enter into any ruling from any Tax
authority with respect to Taxes; surrender any right to claim a material Tax
refund; or consent to any extension or waiver of the statute of limitations
period applicable to any material Tax claim or assessment;

(x) enter into, amend or terminate any Potomac Material Contract;

(xi) (i) materially change pricing or royalties or other payments set or
charged by Potomac or any Potomac Subsidiary to its customers or licensees,
(ii) agree to change pricing or royalties or other payments set or charged by
persons who have licensed Intellectual Property to Potomac or any Potomac
Subsidiary, or (iii) as of the date of this Agreement, materially change
pricing or royalties or other payments set or charged by persons who have
licensed Intellectual Property to Potomac or any Potomac Subsidiary; or

(xii) agree, resolve or commit to do any of the foregoing.

4.5 No Solicitation.

(a) Each Party agrees that neither it nor any of its Subsidiaries shall, nor
shall it nor any of its Subsidiaries authorize or permit any of the officers,
directors, employees,

 investment bankers, attorneys, accountants, Representatives, consultants or
other agents retained by it or any of its Subsidiaries to directly or
indirectly: (i) solicit, initiate, encourage, induce or knowingly facilitate
the communication, making, submission or announcement of any Acquisition
Proposal or Acquisition Inquiry or take any action that could reasonably be
expected to lead to an Acquisition Proposal or Acquisition Inquiry; (ii)
furnish any information regarding such Party to any Person in connection with
or in response to an Acquisition Proposal or Acquisition Inquiry; (iii) engage
in discussions or negotiations with any Person with respect to any Acquisition
Proposal or Acquisition Inquiry; (iv) approve, endorse or recommend any
Acquisition Proposal (subject to Section 5.2); (v) execute or enter into any
letter of intent or similar document or any Contract contemplating or
otherwise relating to any Acquisition Transaction; or (vi) grant any waiver or
release under any confidentiality, standstill or similar agreement (other than
to the other Party); provided, however, that, notwithstanding anything
contained in this Section 4.5(a), prior to the adoption and approval of this
Agreement by the Required Potomac Stockholder Vote or the Required Tigris
Stockholder Vote, as applicable, each Party may furnish nonpublic information
regarding such Party to, and enter into discussions or negotiations with, any
Person in response to a bona fide written Acquisition Proposal, which such
Party's Board of Directors determines in good faith, after consultation with a
nationally recognized independent financial advisor, if any, and its outside
legal counsel, constitutes, or is reasonably likely to result in, a Superior
Offer (and is not withdrawn) if: (A) neither such Party nor any Representative
of such Party shall have breached this Section 4.5; (B) the Board of Directors
of such Party concludes in good faith based on the advice of outside legal
counsel, that the failure to take such action is reasonably likely to result
in a breach of the fiduciary duties of the Board of Directors of such Party
under applicable Legal Requirements; (C) at least five (5) Business Days prior
to furnishing any such nonpublic information to, or entering into discussions
with, such Person, such Party gives the other Party written notice of the
identity of such Person and of such Party's intention to furnish nonpublic
information to, or enter into discussions with, such Person; (D) such Party
receives from such Person an executed confidentiality agreement containing
provisions (including nondisclosure provisions, use restrictions, non-
solicitation provisions, no hire provisions and "standstill" provisions) at
least as favorable to such Party as those contained in the Confidentiality
Agreement; and (E) at least five (5) Business Days prior to furnishing any
such nonpublic information to such Person, such Party furnishes such nonpublic
information to the other Party (to the extent such nonpublic information has
not been previously furnished by such Party to the other Party). Without
limiting the generality of the foregoing, each Party acknowledges and agrees
that, in the event any Representative of such Party (whether or not such
Representative is purporting to act on behalf of such Party) takes any action
that, if taken by such Party, would constitute a breach of this Section 4.5 by
such Party, the taking of such action by such Representative shall be deemed
to constitute a breach of this Section 4.5 by such Party for purposes of this
Agreement.

(b) If any Party or any Representative of such Party receives an Acquisition
Proposal or Acquisition Inquiry at any time during the Pre-Closing Period,
then such Party shall promptly (and in no event later than 24 hours after such
Party becomes aware of such Acquisition Proposal or Acquisition Inquiry)
advise the other Party orally and in writing of such Acquisition Proposal or
Acquisition Inquiry (including the identity of the Person making or submitting
such Acquisition Proposal or Acquisition Inquiry, and the terms thereof). Such
Party

 shall keep the other Party informed in all material respects with respect to
the status and terms of any such Acquisition Proposal or Acquisition Inquiry
and any modification or proposed modification thereto. In addition to the
foregoing, each Party shall provide the other Party with at least five (5)
Business Days' written notice of a meeting of its board of directors (or any
committee thereof) at which its board of directors (or any committee thereof)
is reasonably expected to consider an Acquisition Proposal or Acquisition
Inquiry it has received.

(c) Each Party shall immediately cease and cause to be terminated any existing
discussions, negotiations and communications with any Person that relate to
any Acquisition Proposal or Acquisition Inquiry as of the date of this
Agreement and cause the destruction or return of any nonpublic information
provided to such Person.



4.6 Undisclosed liabilities. In the event that during the Pre-Closing Period,
Potomac identifies a bona fide Liability of Tigris which was not disclosed to
Potomac in this Agreement or in Section 3.8 of the Tigris Disclosure Schedule
and which such Liability is of a nature that would result in a specific
reduction in the amount of Net Cash, Potomac shall provide notice of such bona
fide Liability to Tigris within three (3) Business Days, and Potomac and
Tigris shall promptly meet (no later than three (3) Business Days following
Potomac's notice of such bona fide Liability to Tigris pursuant to this
Section 4.6) and work in good faith to determine a mutually agreed to
estimated amount for such bona fide Liability, which shall represent a good
faith estimate of a reasonable amount of such Liability by Potomac, with the
advice of Potomac's outside legal counsel and/or financial advisers (as
applicable), subject to Tigris's consent, which shall not be unreasonably
withheld, including estimated litigation costs (if any) in connection with
resolving such matter (the "Pre-Closing Liability Amount"). The Pre-Closing
Liability Amount shall be deducted in the determination of Net Cash (without
duplication) pursuant to Section 1.6, if not finally settled prior to the
Closing.



Section 5. ADDITIONAL AGREEMENTS OF THE PARTIES

5.1 Registration Statement; Proxy Statement/Prospectus/Information Statement.

(a) As promptly as practicable after the date of this Agreement, and in any
event no later than 45 days following the date of this Agreement, the Parties
shall prepare and cause to be filed with the SEC the Proxy
Statement/Prospectus/Information Statement and Tigris shall prepare and cause
to be filed with the SEC the Form S-4 Registration Statement, in which the
Proxy Statement/Prospectus/Information Statement will be included as a
prospectus. Tigris covenants and agrees that the Proxy
Statement/Prospectus/Information Statement, including, without limitation, any
pro forma financial statements included therein, (and the letter to
stockholders, notice of meeting and form of proxy included therewith) will
not, at the time that the Proxy Statement/Prospectus/Information Statement or
any amendment or supplement thereto is filed with the SEC or is first mailed
to the stockholders of Tigris, at the time of the Tigris Stockholders' Meeting
and at the Effective Time, contain any untrue statement of a material fact or
omit to state any material fact required to be stated therein or necessary in
order to make the statements made therein, in light of the circumstances under
which they were made, not

 misleading. Notwithstanding the foregoing, Tigris makes no covenant,
representation or warranty with respect to statements made in the Proxy
Statement/Prospectus/Information Statement (and the letter to stockholders,
notice of meeting and form of proxy included therewith), if any, based on
information furnished in writing by Potomac specifically for inclusion
therein. Each of the Parties shall use commercially reasonable efforts to
cause the Form S-4 Registration Statement and the Proxy
Statement/Prospectus/Information Statement to comply with the applicable rules
and regulations promulgated by the SEC, to respond promptly to any comments of
the SEC or its staff and to have the Form S-4 Registration Statement declared
effective under the Securities Act as promptly as practicable after it is
filed with the SEC. Each of the Parties shall use commercially reasonable
efforts to cause the Proxy Statement/Prospectus/Information Statement to be
mailed to Tigris' stockholders as promptly as practicable after the Form S-4
Registration Statement is declared effective under the Securities Act. Each
Party shall promptly furnish to the other Party all information concerning
such Party and such Party's subsidiaries and such Party's stockholders that
may be required or reasonably requested in connection with any action
contemplated by this Section 5.1. If any event relating to Potomac occurs, or
if Potomac becomes aware of any information, that should be disclosed in an
amendment or supplement to the Form S-4 Registration Statement or the Proxy
Statement/Prospectus/ Information Statement, then Potomac shall promptly
inform Tigris thereof and shall cooperate fully with Tigris in filing such
amendment or supplement with the SEC and, if appropriate, in mailing such
amendment or supplement to the stockholders of Potomac.

(b) Prior to the Effective Time, Tigris shall use commercially reasonable
efforts to obtain all regulatory approvals needed to ensure that the Tigris
Common Stock to be issued in the Merger (to the extent required) be registered
or qualified or exempt from registration or qualification under the securities
law of every jurisdiction of the United States in which any registered holder
of Potomac Capital Stock has an address of record on the record date for
determining the stockholders entitled to notice of and to vote pursuant to the
Potomac Stockholder Written Consent; provided, however, that Tigris shall not
be required: (i) to qualify to do business as a foreign corporation in any
jurisdiction in which it is not now qualified; or (ii) to file a general
consent to service of process in any jurisdiction.

(c) Potomac shall reasonably cooperate with Tigris and provide Tigris, and
require its Representatives, advisors, accountants and attorneys to provide,
Tigris and its Representatives, advisors, accountants and attorneys, with all
true, correct and complete information regarding Potomac that is required by
law to be included in the Form S-4 Registration Statement or reasonably
requested from Potomac to be included in the Form S-4 Registration Statement.

5.2 Potomac Stockholder Written Consent.

(a) Promptly after the S-4 Registration Statement shall have been declared
effective under the Securities Act, and in any event no later than four (4)
Business Days thereafter, Potomac shall obtain the approval by written consent
from certain of those Potomac stockholders sufficient for the Required Potomac
Stockholder Vote in lieu of a meeting pursuant to Section 228 of the DGCL,
which such Potomac stockholders are parties to the Potomac

 Stockholder Support Agreements, for purposes of (i) adopting this Agreement
and approving the Merger, and all other transactions contemplated hereby,
including the Preferred Stock Conversion, (ii) acknowledging that the approval
given thereby is irrevocable and that such stockholder is aware of its rights
to demand appraisal for its shares pursuant to Section 262 of the DGCL, a copy
of which was attached thereto, and that such stockholder has received and read
a copy of Section 262 of the DGCL, and (iii) acknowledging that by its
approval of the Merger it is not entitled to appraisal rights with respect to
its shares in connection with the Merger and thereby waives any rights to
receive payment of the fair value of its capital stock under the DGCL. Under
no circumstances shall Potomac assert that any other approval or consent is
necessary by its stockholders to approve the Merger or this Agreement.

(b) Potomac agrees that, subject to Section 5.2(c): (i) Potomac's Board of
Directors shall recommend that Potomac's stockholders vote to adopt and
approve this Agreement and the Merger and shall use commercially reasonable
efforts to solicit such approval within the time set forth in Section 5.2(a)
(the recommendation of Potomac's Board of Directors that Potomac's
stockholders vote to adopt and approve this Agreement being referred to as the
"Potomac Board Recommendation"); and (ii) the Potomac Board Recommendation
shall not be withdrawn or modified in a manner adverse to Tigris, and no
resolution by the Board of Directors of Potomac or any committee thereof to
withdraw or modify the Potomac Board Recommendation in a manner adverse to
Tigris shall be adopted or proposed.

(c) Notwithstanding anything to the contrary contained in Section 5.2(b), at
any time prior to the approval of this Agreement by the Required Potomac
Stockholder Vote, Potomac's Board of Directors may withhold, amend, withdraw
or modify the Potomac Board Recommendation in a manner adverse to Tigris if,
but only if Potomac's Board of Directors determined in good faith, based on
such matters as it deems relevant following consultation with its outside
legal counsel, that the failure to withdraw, withhold, amend, or modify such
recommendation would result in a breach of its fiduciary duties under
applicable Legal Requirements; provided that Tigris receives written notice
from Potomac confirming that Potomac's Board of Directors has determined to
change its recommendation at least five (5) Business Days in advance of the
Potomac Board Recommendation being so withdrawn, withheld, amended or modified
in a manner adverse to Tigris.

(d) Potomac's obligation to solicit the consent of its stockholders to sign
the Potomac Stockholder Written Consent in accordance with Section 5.2(a)
shall not be limited or otherwise affected by the commencement, disclosure,
announcement or submission of any Superior Offer or other Acquisition
Proposal, or by any withdrawal or modification of the Potomac Board
Recommendation.

5.3 Tigris Stockholders' Meeting.

(a) Tigris shall take all action necessary under applicable Legal Requirements
to call, give notice of and hold a meeting of the holders of Tigris Common
Stock to vote on the Merger and the issuance of Tigris Common Stock in the
Merger (such meeting, the "Tigris Stockholders' Meeting"). The Tigris
Stockholders' Meeting shall be held as promptly as practicable after the Form
S-4 Registration Statement is declared effective under the Securities

 Act. Tigris shall take reasonable measures to ensure that all proxies
solicited in connection with the Tigris Stockholders' Meeting are solicited in
compliance with all applicable Legal Requirements.

(b) Tigris agrees that, subject to Section 5.3(c): (i) Tigris' Board of
Directors shall recommend that the holders of Tigris Common Stock vote to
approve the Merger and the issuance of Tigris Common Stock in the Merger and
shall use commercially reasonable efforts to solicit such approval within the
timeframe set forth in Section 5.3(a) above, (ii) the Proxy
Statement/Prospectus/Information Statement shall include a statement to the
effect that the Board of Directors of Tigris recommends that Tigris'
stockholders vote to approve the Merger and the issuance of Tigris Common
Stock in the Merger (the recommendation of Tigris' Board of Directors that
Tigris' stockholders vote to approve the Merger and the issuance of Tigris
Common Stock in the Merger being referred to as the "Tigris Board
Recommendation"); and (iii) the Tigris Board Recommendation shall not be
withdrawn or modified in a manner adverse to Potomac, and no resolution by the
Board of Directors of Tigris or any committee thereof to withdraw or modify
the Tigris Board Recommendation in a manner adverse to Potomac shall be
adopted or proposed.

(c) Notwithstanding anything to the contrary contained in Section 5.3(b), at
any time prior to the approval of the issuance of Tigris Common Stock in the
Merger by the stockholders of Tigris by the Required Tigris Stockholder Vote,
Tigris' Board of Directors may withhold, amend, withdraw or modify the Tigris
Board Recommendation in a manner adverse to Potomac if, but only if Tigris'
Board of Directors determines in good faith, based on such matters as it deems
relevant following consultation with its outside legal counsel, that the
failure to withhold, amend, withdraw or modify such recommendation would
result in a breach of its fiduciary duties under applicable Legal
Requirements; provided that Potomac receives written notice from Tigris
confirming that Tigris' Board of Directors has determined to change its
recommendation at least five (5) Business Days in advance of the Tigris Board
Recommendation being withdrawn, withheld, amended or modified in a manner
adverse to Potomac.

(d) Tigris' obligation to call, give notice of and hold the Tigris
Stockholders' Meeting in accordance with Section 5.3(a) shall not be limited
or otherwise affected by the commencement, disclosure, announcement or
submission of any Superior Offer or Acquisition Proposal, or by any withdrawal
or modification of the Tigris Board Recommendation.

(e) Nothing contained in this Agreement shall prohibit Tigris or its Board of
Directors from complying with Rules 14d-9 and 14e-2(a) promulgated under the
Exchange Act; provided however, that any disclosure made by Tigris or its
Board of Directors pursuant to Rules 14d-9 and 14e-2(a) shall be limited to a
statement that Tigris is unable to take a position with respect to the
bidder's tender offer unless Tigris' Board of Directors determines in good
faith, after consultation with its outside legal counsel, that such statement
would result in a breach of its fiduciary duties under applicable Legal
Requirements. Tigris shall not withdraw or modify in a manner adverse to
Potomac the Tigris Board Recommendation unless specifically permitted pursuant
to the terms of Section 5.3(b).

 5.4 Regulatory Approvals. Each Party shall use commercially reasonable efforts
to file or otherwise submit, as soon as practicable after the date of this
Agreement, all applications, notices, reports and other documents reasonably
required to be filed by such Party with or otherwise submitted by such Party
to any Governmental Body with respect to the Merger and the other Contemplated
Transactions, and to submit promptly any additional information requested by
any such Governmental Body. Without limiting the generality of the foregoing,
the Parties shall, promptly after the date of this Agreement, prepare and
file, if any, (a) the notification and report forms required to be filed under
the HSR Act and (b) any notification or other document required to be filed in
connection with the Merger under any applicable foreign Legal Requirement
relating to antitrust or competition matters. Potomac and Tigris shall respond
as promptly as is practicable to respond in compliance with: (i) any inquiries
or requests received from the Federal Trade Commission or the Department of
Justice for additional information or documentation; and (ii) any inquiries or
requests received from any state attorney general, foreign antitrust or
competition authority or other Governmental Body in connection with antitrust
or competition matters.

5.5 Potomac Options and Warrants.

(a) Subject to Section 5.5(c), at the Effective Time, each Potomac Option that
is outstanding and unexercised immediately prior to the Effective Time under
the 2014 Plan, whether or not vested, shall be converted into and become an
option to purchase Tigris Common Stock, and Tigris shall assume the 2014 Plan.
All other Potomac Options shall be cancelled immediately prior to the
Effective Time. All rights with respect to Potomac Common Stock under Potomac
Options assumed by Tigris shall thereupon be converted into rights with
respect to Tigris Common Stock. Accordingly, from and after the Effective
Time: (i) each Potomac Option assumed by Tigris may be exercised solely for
shares of Tigris Common Stock; (ii) the number of shares of Tigris Common
Stock subject to each Potomac Option assumed by Tigris shall be determined by
multiplying (A) the number of shares of Potomac Common Stock that were subject
to such Potomac Option, as in effect immediately prior to the Effective Time
by (B) the Exchange Ratio and rounding the resulting number down to the
nearest whole number of shares of Tigris Common Stock; (iii) the per share
exercise price for the Tigris Common Stock issuable upon exercise of each
Potomac Option assumed by Tigris shall be determined by dividing (A) the per
share exercise price of Potomac Common Stock subject to such Potomac Option,
as in effect immediately prior to the Effective Time, by (B) the Exchange
Ratio and rounding the resulting exercise price up to the nearest whole cent;
and (iv) any restriction on the exercise of any Potomac Option assumed by
Tigris shall continue in full force and effect and the term, exercisability,
vesting schedule and other provisions of such Potomac Option shall otherwise
remain unchanged; provided, however, that: (A) to the extent provided under
the terms of a Potomac Option, such Potomac Option assumed by Tigris in
accordance with this Section 5.5(a) shall, in accordance with its terms, be
subject to further adjustment as appropriate to reflect any stock split,
division or subdivision of shares, stock dividend, reverse stock split,
consolidation of shares, reclassification, recapitalization or other similar
transaction with respect to Tigris Common Stock subsequent to the Effective
Time; and (B) Tigris' Board of Directors or a committee thereof shall succeed
to the authority and responsibility of Potomac's Board of Directors or any
committee thereof with respect to each Potomac Option assumed by Tigris.

 Notwithstanding anything to the contrary in this Section 5.5(a), the
conversion of each Potomac Option (regardless of whether such option qualifies
as an "incentive stock option" within the meaning of Section 422 of the Code)
into an option to purchase shares of Tigris Common Stock shall be made in a
manner consistent with Treasury Regulation Section 1.424-1, such that the
conversion of a Potomac Option shall not constitute a "modification" of such
Potomac Option for purposes of Section 409A or Section 424 of the Code.

(b) Tigris shall file with the SEC, no later than 60 days after the Effective
Time, a registration statement on Form S-8, if available for use by Tigris,
relating to the shares of Tigris Common Stock issuable with respect to Potomac
Options assumed by Tigris in accordance with Section 5.5(a).

(c) Subject to Section 5.5(d), at the Effective Time, each Potomac Warrant
that is outstanding and unexercised immediately prior to the Effective Time,
shall become converted into and become a warrant to purchase Tigris Common
Stock and Tigris shall assume each such Potomac Warrant in accordance with its
terms. All rights with respect to Potomac Common Stock or Potomac Preferred
Stock under Potomac Warrants assumed by Tigris shall thereupon be converted
into rights with respect to Tigris Common Stock. Accordingly, from and after
the Effective Time: (i) each Potomac Warrant assumed by Tigris may be
exercised solely for shares of Tigris Common Stock; (ii) the number of shares
of Tigris Common Stock subject to each Potomac Warrant assumed by Tigris shall
be determined by multiplying (A) the number of shares of Potomac Common Stock,
or the number of shares of Potomac Common Stock issuable upon conversion of
the shares of Potomac Preferred Stock issuable upon exercise of the Potomac
Warrant, as applicable, that were subject to such Potomac Warrant immediately
prior to the Effective Time by (B) the Exchange Ratio and rounding the
resulting number down to the nearest whole number of shares of Tigris Common
Stock; (iii) the per share exercise price for the Tigris Common Stock issuable
upon exercise of each Potomac Warrant assumed by Tigris shall be determined by
dividing the per share exercise price of Potomac Common Stock or Potomac
Preferred Stock, subject to such Potomac Warrant, as in effect immediately
prior to the Effective Time, by the Exchange Ratio and rounding the resulting
exercise price up to the nearest whole cent; and (iv) any restriction on any
Potomac Warrant assumed by Tigris shall continue in full force and effect and
the term and other provisions of such Potomac Warrant shall otherwise remain
unchanged.

(d) Prior to the Effective Time, Potomac shall take all actions that may be
necessary (under the Potomac Stock Option Plans, the Potomac Warrants and
otherwise) to effectuate the provisions of this Section 5.5 and to ensure
that, from and after the Effective Time, holders of Potomac Options and
Potomac Warrants have no rights with respect thereto other than those
specifically provided in this Section 5.5.

5.6 Employee Benefits. Tigris and Potomac shall cause Tigris to comply with
terms of any employment, severance, retention, change of control, or similar
agreement specified on Part 3.11(c) of the Tigris Disclosure Schedule as being
applicable to this Section 5.6, subject to the provisions of such agreements,
including the maintenance of COBRA insurance for Tigris' former officers and
employees.

 5.7 Indemnification of Officers and Directors.

(a) From the Effective Time through the sixth anniversary of the date on which
the Effective Time occurs, each of Tigris and the Surviving Corporation shall,
jointly and severally, indemnify and hold harmless each person who is now, or
has been at any time prior to the date hereof, or who becomes prior to the
Effective Time, a director or officer of Tigris or Potomac (the "DandO
Indemnified Parties"), against all claims, losses, liabilities, damages,
judgments, fines and reasonable fees, costs and expenses, including attorneys'
fees and disbursements (collectively, "Costs"), incurred in connection with
any claim, action, suit, proceeding or investigation, whether civil, criminal,
administrative or investigative, arising out of or pertaining to the fact that
the DandO Indemnified Party is or was a director or officer of Tigris or
Potomac, whether asserted or claimed prior to, at or after the Effective Time,
to the fullest extent permitted under the DGCL for directors or officers of
Delaware corporations. Each DandO Indemnified Party will be entitled to
advancement of expenses incurred in the defense of any such claim, action,
suit, proceeding or investigation from each of Tigris and the Surviving
Corporation, jointly and severally, upon receipt by Tigris or the Surviving
Corporation from the DandO Indemnified Party of a request therefor; provided
that any person to whom expenses are advanced provides an undertaking, to the
extent then required by the DGCL or the laws of the State of California, as
applicable, to repay such advances if it is ultimately determined that such
person is not entitled to indemnification.

(b) The certificate of incorporation and bylaws of each of Tigris and the
Surviving Corporation shall contain, and Tigris shall cause the certificate of
incorporation and bylaws of the Surviving Corporation to so contain,
provisions no less favorable with respect to indemnification, advancement of
expenses and exculpation of present and former directors and officers of each
of Tigris and Potomac than are presently set forth in the certificate of
incorporation and bylaws of Tigris and Potomac, as applicable, which
provisions shall not be amended, modified or repealed for a period of six
years' time from the Effective Time in a manner that would adversely affect
the rights thereunder of individuals who, at or prior to the Effective Time,
were officers or directors of Tigris or Potomac.

(c) Potomac shall negotiate and Tigris shall purchase an insurance policy,
with an effective date as of the Closing, which maintains in effect for six
years from the Closing the current directors' and officers' liability
insurance policies maintained by Potomac (provided that Tigris may substitute
therefor policies of at least the same coverage containing terms and
conditions that are not materially less favorable); provided, however, that in
no event shall Tigris be required to expend pursuant to this Section 5.7(c)
more than an amount equal to 300% of current annual premiums paid by Potomac
for such insurance.

(d) Tigris shall maintain directors' and officers' liability insurance
policies, with an effective date as of the Closing, on commercially available
terms and conditions and with coverage limits customary for U.S. public
companies similarly situated to Tigris.

(e) Tigris shall pay all expenses, including reasonable attorneys' fees, that
may be incurred by the persons referred to in this Section 5.7 in connection
with their enforcement of their rights provided in this Section 5.7.

 (f) The provisions of this Section 5.7 are intended to be in addition to the
rights otherwise available to the current and former officers and directors of
Tigris and Potomac by law, charter, statute, bylaw or agreement, and shall
operate for the benefit of, and shall be enforceable by, each of the DandO
Indemnified Parties, their heirs and their representatives.

(g) In the event Tigris or the Surviving Corporation or any of their
respective successors or assigns (i) consolidates with or merges into any
other person and shall not be the continuing or surviving corporation or
entity of such consolidation or merger, or (ii) transfers all or substantially
all of its properties and assets to any person, then, and in each such case,
proper provision shall be made so that the successors and assigns of Tigris or
the Surviving Corporation, as the case may be, shall succeed to the
obligations set forth in this Section 5.7. Tigris shall cause the Surviving
Corporation to perform all of the obligations of the Surviving Corporation
under this Section 5.7.

5.8 Additional Agreements.

(a) Subject to Section 5.8(b), the Parties shall use commercially reasonable
efforts to cause to be taken all actions necessary to consummate the Merger
and make effective the other Contemplated Transactions. Without limiting the
generality of the foregoing, but subject to Section 5.8(b), each Party to this
Agreement: (i) shall make all filings and other submissions (if any) and give
all notices (if any) required to be made and given by such Party in connection
with the Merger and the other Contemplated Transactions; (ii) shall use
commercially reasonable efforts to obtain each Consent (if any) reasonably
required to be obtained (pursuant to any applicable Legal Requirement or
Contract, or otherwise) by such Party in connection with the Merger or any of
the other Contemplated Transactions or for such Contract to remain in full
force and effect; (iii) shall use commercially reasonable efforts to lift any
injunction prohibiting, or any other legal bar to, the Merger or any of the
other Contemplated Transactions; and (iv) shall use commercially reasonable
efforts to satisfy the conditions precedent to the consummation of this
Agreement.

(b) Notwithstanding anything to the contrary contained in this Agreement and
except as set forth on Part 4.2(a) of the Tigris Disclosure Schedule, no Party
shall have any obligation under this Agreement: (i) to dispose of or transfer
or cause any of its Subsidiaries to dispose of or transfer any assets; (ii) to
discontinue or cause any of its Subsidiaries to discontinue offering any
product or service; (iii) to license or otherwise make available, or cause any
of its Subsidiaries to license or otherwise make available to any Person any
Intellectual Property; (iv) to hold separate or cause any of its Subsidiaries
to hold separate any assets or operations (either before or after the Closing
Date); (v) to make or cause any of its Subsidiaries to make any commitment (to
any Governmental Body or otherwise) regarding its future operations; or (vi)
to contest any Legal Proceeding or any order, writ, injunction or decree
relating to the Merger or any of the other Contemplated Transactions if such
Party determines in good faith that contesting such Legal Proceeding or order,
writ, injunction or decree might not be advisable.

5.9 Disclosure. Without limiting any of either Party's obligations under the
Confidentiality Agreement, each Party shall not, and shall not permit any of
its Subsidiaries or any Representative of such Party to, issue any press
release or make any disclosure (to any

 customers or employees of such Party, to the public or otherwise) regarding
the Merger or any of the other Contemplated Transactions unless: (a) the other
Party shall have approved such press release or disclosure in writing; or (b)
such Party shall have determined in good faith, upon the advice of outside
legal counsel, that such disclosure is required by applicable Legal
Requirements and, to the extent practicable, before such press release or
disclosure is issued or made, such Party advises the other Party of, and
consults with the other Party regarding, the text of such press release or
disclosure; provided, however, that each of Potomac and Tigris may make any
public statement in response to specific questions by the press, analysts,
investors or those attending industry conferences or financial analyst
conference calls, so long as any such statements are consistent with previous
press releases, public disclosures or public statements made by Potomac or
Tigris in compliance with this Section 5.9.

5.10 Listing. Tigris shall use its commercially reasonable efforts to maintain
its existing listing on the NASDAQ Global Market, to obtain approval of the
listing of the combined company on the NASDAQ Global Market and to cause the
shares of Tigris Common Stock being issued in the Merger to be approved for
listing (subject to notice of issuance) on the NASDAQ Global Market at or
prior to the Effective Time.

5.11 Tax Matters.

(a) Tigris, Merger Sub and Potomac shall use their respective commercially
reasonable efforts to cause the Merger and the Second Merger, considered
together as a single integrated transaction for United States federal income
Tax purposes, to qualify, and agree not to, and not to permit or cause any
affiliate or any Subsidiary to, take any actions or cause any action to be
taken which would reasonably be expected to prevent the Merger and the Second
Merger, considered together as a single integrated transaction for United
States federal income Tax purposes, from qualifying, as a "reorganization"
under Section 368(a) of the Code.

(b) This Agreement is intended to constitute, and the parties hereto hereby
adopt this Agreement as, a "plan of reorganization" within the meaning
Treasury Regulation Sections 1.368-2(g) and 1.368-3(a). The Parties shall
treat and shall not take any tax reporting position inconsistent with the
treatment of the Merger and the Second Merger, considered together as a single
integrated transaction for United States federal income Tax purposes, as a
reorganization within the meaning of Section 368(a) of the Code for U.S.
federal, state and other relevant Tax purposes, unless otherwise required
pursuant to a "determination" within the meaning of Section 1313(a) of the
Code.

(c) The parties hereto shall cooperate and use their commercially reasonable
efforts in order for Potomac to obtain the opinion of Pepper Hamilton LLP (
"Pepper Hamilton"), in form and substance reasonably acceptable to Potomac,
dated as of the Closing (the "Pepper Opinion"), and Tigris to obtain the
opinion of Latham and Watkins LLP ("Latham"), in form and substance reasonably
acceptable to Tigris, dated as of the Closing Date (the "Latham Opinion"),
each to the effect that, on the basis of the facts, representations and
assumptions set forth or referred to in such opinions, for U.S. federal income
tax purposes, the Merger and the Second Merger, considered together as a
single integrated transaction for United States federal income Tax purposes,
will qualify as a reorganization within the meaning of Section 368(a) of

 the Code. As a condition precedent to the rendering of such opinions, Tigris,
Merger Sub, Merger LLC and Potomac shall, as of the Closing Date, execute and
deliver to Pepper Hamilton and Latham tax representation letters, in form and
substance reasonably acceptable to Latham, Pepper Hamilton, Tigris and Potomac
(the "Tax Representation Letters"), dated and executed as of the dates of such
opinions, on which such Tax Representation Letters Latham and Pepper Hamilton
shall be entitled to rely. Tigris, Merger Sub, Merger LLC and Potomac shall,
as of the date for filing the Form S-4 Registration Statement, execute and
deliver to Pepper Hamilton and Latham Tax Representation Letters, dated and
executed as of the filing date, on which such Tax Representation Letters
Latham and Pepper Hamilton shall be entitled to rely, including in rendering
their respective opinions to be filed (if required) in connection with the
Form S-4 Registration Statement.



(d) All transfer, documentary, sales, use, stamp, registration and other such
Taxes and fees (including any penalties and interest) incurred in connection
with this Agreement (collectively, "Transfer Taxes") shall be paid by the
Shareholders when due, and the Shareholders will, at their own expense, file
all necessary Tax Returns and other documentation with respect to all such
Transfer Taxes, and, if required by applicable Law, Tigris will, and will
cause its Affiliates to, join in the execution of any such Tax Returns and
other documentation. The Shareholders shall provide Tigris with (A) evidence
reasonably satisfactory to Tigris that such Transfer Taxes have been paid by
the Shareholders and (B) a clearance certificate or similar documents which
may be required by any Tax authority to relieve Tigris of any obligation to
withhold any portion of the payments to the Shareholders pursuant to this
Agreement.

5.12 Legends. Tigris shall be entitled to place appropriate legends on the
certificates evidencing any shares of Tigris Common Stock to be received in
the Merger by equityholders of Potomac who may be considered "affiliates" of
Tigris for purposes of Rules 144 and 145 under the Securities Act reflecting
the restrictions set forth in Rules 144 and 145 and to issue appropriate stop
transfer instructions to the transfer agent for Tigris Common Stock.

5.13 Interpretation of Certain Agreements. Each of the Parties agrees that the
consummation of the Contemplated Transactions shall constitute a "change in
control" for purposes of each plan, agreement, contract or arrangement
identified on Part 5.13 of the Tigris Disclosure Schedule and Tigris shall
construe, interpret and administer each such plan, agreement, contract or
arrangement in a manner consistent with such interpretation. The failure to
identify a plan, agreement, contract or arrangement on Part 5.13 of the Tigris
Disclosure Schedule shall not be deemed to reflect a determination that the
consummation of the Contemplated Transactions is not a "change in control" for
purposes of such plan, agreement, contract or arrangement.

5.14 Cooperation. Each Party shall cooperate reasonably with the other Party
and shall provide the other Party with such assistance as may be reasonably
requested for the purpose of facilitating the performance by each Party of
their obligations under this Agreement and to enable the combined entity to
continue to meet its obligations following the Closing.

 5.15 Potomac Stockholder Approval. Potomac shall use its commercially
reasonable efforts to obtain the Required Potomac Stockholder Vote and have
the requisite number of stockholders sign the Potomac Stockholder Written
Consent as promptly as possible, and in any event within four (4) Business
Days following the date upon which the S-4 Registration Statement shall have
been declared effective under the Securities Act.

5.16 Pre-Closing Dividend. Promptly following the final determination of Net
Cash as of the Determination Date pursuant to Section 1.6, and in any event,
prior to the Closing, Tigris shall take all actions reasonably necessary to
dividend (the "Pre-Closing Dividend") to its stockholders (a) the excess, if
any, of such Net Cash amount over $14,491,250 (the "Minimum Cash Amount") and
(b) those assets and rights described on Schedule C hereto (the amounts and
rights set forth in clauses (a) and (b), the "Pre-Closing Dividend Assets").
Prior to the Closing, Tigris shall also take all other actions described on
Schedule C hereto.

5.17 Directors and Officers. Tigris and Potomac shall obtain and deliver to
the other Party at or prior to the Effective Time the resignation of each
officer and director of Tigris or Potomac who is not continuing as an officer
or director of Tigris, the Surviving Corporation or the Surviving Company, as
applicable, following the Effective Time. All of the directors of Tigris,
other than the Remaining Tigris Directors (as defined below), shall resign at
or prior to the Effective Time. Two designees selected by Tigris shall be
elected to or remain on, as applicable, the Board of Directors of Tigris at
the Effective Time, which two directors shall be reasonably acceptable to
Potomac (the "Remaining Tigris Directors"). The Remaining Tigris Directors
shall elect, to be effective as of the Effective Time, five designees selected
by Potomac (the "Additional Directors"), each to serve as members of the Board
of Directors of Tigris in staggered classes to be agreed upon by the Parties
prior to the Closing Date (provided, that, one Remaining Tigris Director shall
be appointed to the class whose term expires in 2015 and one Remaining Tigris
Director shall be appointed to the class whose term expires in 2016). The
Board of Directors of Tigris shall appoint each of the individuals set forth
on Part 5.17(a) of the Tigris Disclosure Schedule as officers of Tigris,
effective as of the Effective Time. The Board of Directors of Tigris shall
appoint each of the directors set forth on Part 5.17(b) of the Tigris
Disclosure Schedule to the committees of the Board of Directors set forth
opposite his or her name, effective as of the Effective Time.

5.18 Termination of Certain Agreements and Rights. Potomac shall use its
commercially reasonable efforts to terminate at or prior to the Effective
Time, those agreements set forth on Schedule F (collectively, the "Investor
Agreements").

5.19 Disclosure of Liabilities. For purposes of the computation of Net Cash
pursuant to Section 1.6, on or prior to the Determination Date, Tigris shall
provide Potomac with a list of all Liabilities of Tigris or any of its
Subsidiaries as of the Determination Date which are individually in excess of
$25,000 or in excess of $100,000 in the aggregate, that had not previously
been disclosed to Potomac in the Tigris Disclosure Schedules.

 5.20 Tigris Options.

(a) Prior to the Closing, the Tigris Board of Directors shall have adopted
appropriate resolutions and taken all other actions necessary and appropriate
to provide that each unexpired and unexercised Tigris Option, whether vested
or unvested, shall be cancelled and retired and cease to exist effective as of
the Effective Time, and, in exchange therefor, each former holder of any
Tigris Option having an exercise price per share less than the Tigris Closing
Price shall be entitled to receive in consideration of the cancellation of
such former holder's Tigris Option and in settlement therefor, a number of
shares of Tigris Common Stock calculated by dividing (i) the product of (A)
the total number of shares of Tigris Common Stock previously subject to such
Company Option, and (B) the excess of the Tigris Closing Price over the
exercise price per share of Tigris Common Stock previously subject to such
Tigris Option by (ii) the Tigris Closing Price. Notwithstanding anything
herein to the contrary, the tax withholding obligations for each holder
receiving shares of Tigris Common Stock in accordance with the preceding
sentence shall be satisfied by Tigris withholding from issuance that number of
shares of Tigris Common Stock calculated by multiplying the minimum statutory
withholding rate for such holder in connection with such issuance times the
number of shares of Tigris Common Stock to be issued in accordance with the
preceding sentence, and rounding up to the nearest whole share.

(b) Prior to the Closing Date, the Tigris Board of Directors shall have
adopted appropriate resolutions and taken all other actions necessary and
appropriate (under the Tigris Stock Plans and otherwise) to cause the issuance
to each individual set forth on Schedule G of that number of shares of Tigris
Common Stock calculated by dividing the amount set forth opposite such
individual's name on Schedule G by the Tigris Closing Price, with such
issuance to occur as of the Effective Time. Notwithstanding anything herein to
the contrary, the tax withholding obligations for each individual receiving
shares of Tigris Common Stock in accordance with the preceding sentence shall
be satisfied by Tigris withholding from issuance that number of shares of
Tigris Common Stock calculated by multiplying the minimum statutory
withholding rate for such individual in connection with such issuance times
the number of shares of Tigris Common Stock to be issued in accordance with
the preceding sentence, and rounding up to the nearest whole share.

Section 6. CONDITIONS PRECEDENT TO OBLIGATIONS OF EACH PARTY

The obligations of each Party to effect the Merger and otherwise consummate
the transactions to be consummated at the Closing are subject to the
satisfaction or, to the extent permitted by applicable law, the written waiver
by each of the Parties, at or prior to the Closing, of each of the following
conditions:

6.1 Effectiveness of Registration Statement. The Form S-4 Registration
Statement shall have become effective in accordance with the provisions of the
Securities Act, and shall not be subject to any stop order or proceeding (or
threatened proceeding by the SEC) seeking a stop order with respect to the
Form S-4 Registration Statement.

 6.2 No Restraints. No temporary restraining order, preliminary or permanent
injunction or other order preventing the consummation of the Merger shall have
been issued by any court of competent jurisdiction or other Governmental Body
of competent jurisdiction and remain in effect, and there shall not be any
Legal Requirement which has the effect of making the consummation of the
Merger illegal.

6.3 Stockholder Approval. This Agreement, the Merger and the other
transactions contemplated by this Agreement shall have been duly adopted and
approved by the Required Potomac Stockholder Vote, and the issuance of the
Tigris Common Stock in the Merger and the Merger shall have been duly approved
by the Required Tigris Stockholder Vote.

6.4 Listing. The existing shares of Tigris Common Stock shall have been
continually listed on the NASDAQ Global Market as of and from the date of this
Agreement through the Closing Date, the approval of the listing of the
additional shares of Tigris Common Stock on the NASDAQ Global Market shall
have been obtained and the shares of Tigris Common Stock to be issued in the
Merger shall be approved for listing (subject to official notice of issuance)
on the NASDAQ Global Market as of the Effective Time.

6.5 Regulatory Matters. Any waiting period applicable to the consummation of
the Merger under the HSR Act shall have expired or been terminated, and there
shall not be in effect any voluntary agreement between Tigris, Merger Sub and
Potomac and the Federal Trade Commission, the Department of Justice or any
foreign Governmental Body pursuant to which such Party has agreed not to
consummate the Merger for any period of time; provided, that Potomac, on the
one hand, nor Tigris or Merger Sub, on the other hand, shall enter into any
such voluntary agreement without the written consent of all Parties.

6.6 No Governmental Proceedings Relating to Contemplated Transactions or Right
to Operate Business. There shall not be any Legal Proceeding pending, or
overtly threatened in writing by an official of a Governmental Body in which
such Governmental Body indicates that it intends to conduct any Legal
Proceeding or take any other action: (a) challenging or seeking to restrain or
prohibit the consummation of the Merger; (b) relating to the Merger and
seeking to obtain from Tigris, Merger Sub or Potomac any damages or other
relief that may be material to Tigris or Potomac; (c) seeking to prohibit or
limit in any material and adverse respect a Party's ability to vote, transfer,
receive dividends with respect to or otherwise exercise ownership rights with
respect to the stock of Tigris; (d) that would materially and adversely affect
the right or ability of Tigris or Potomac to own the assets or operate the
business of Tigris or Potomac; or (e) seeking to compel Potomac, Tigris or any
Subsidiary of Tigris to dispose of or hold separate any material assets as a
result of the Merger.

Section 7. ADDITIONAL CONDITIONS PRECEDENT TO OBLIGATIONS OF TIGRIS AND MERGER
SUB

The obligations of Tigris and Merger Sub to effect the Merger and otherwise
consummate the transactions to be consummated at the Closing are subject to
the satisfaction or the written waiver by Tigris, at or prior to the Closing,
of each of the following conditions:

 7.1 Accuracy of Representations. The representations and warranties of Potomac
contained in this Agreement shall have been true and correct as of the date of
this Agreement and shall be true and correct on and as of the Closing Date
with the same force and effect as if made on the Closing Date except (A) in
each case, or in the aggregate, where the failure to be true and correct would
not reasonably be expected to have a Potomac Material Adverse Effect, or (B)
for those representations and warranties which address matters only as of a
particular date (which representations shall have been true and correct,
subject to the qualifications as set forth in the preceding clause (A), as of
such particular date) (it being understood that, for purposes of determining
the accuracy of such representations and warranties, any update of or
modification to the Potomac Disclosure Schedule made or purported to have been
made after the date of this Agreement shall be disregarded).

7.2 Performance of Covenants. Each of the covenants and obligations in this
Agreement that Potomac is required to comply with or to perform at or prior to
the Closing shall have been complied with and performed by Potomac in all
material respects.

7.3 Lock-up Agreements. Tigris shall have received a copy of a Lock-up
Agreement, substantially in the form attached hereto as Exhibit E (the "Lock-
up Agreement"), duly executed by holders representing at least 45% of the
aggregate shares of Tigris Common Stock outstanding immediately following the
Merger, each of which shall be in full force and effect.

7.4 Agreements and Other Documents. Tigris shall have received the following
agreements and other documents, each of which shall be in full force and
effect:

(a) the Latham Opinion dated as of the Closing Date and addressed to Tigris;
provided, that the condition set forth in this Section 7.4(a) shall not be
waivable by Tigris after receipt of the Required Potomac Stockholder Vote and
the Required Tigris Stockholder Vote unless further stockholder approvals are
obtained with appropriate disclosure;

(b) a certificate executed by the Chief Executive Officer and Chief Financial
Officer of Potomac confirming that the conditions set forth in Sections 7.1,
7.2, 7.5, 7.6, 7.8 and 7.10 have been duly satisfied;

(c) certificates of good standing (or equivalent documentation) of Potomac in
its jurisdiction of organization and the various foreign jurisdictions in
which it is qualified, certified charter documents, a certificate as to the
incumbency of officers and the adoption of resolutions of the board of
directors of Potomac authorizing the execution of this Agreement and the
consummation of the Contemplated Transactions to be performed by Potomac
hereunder; and

(d) written resignations in forms satisfactory to Tigris, dated as of the
Closing Date and effective as of the Closing, executed by the officers and
directors of Potomac who will not be officers or directors of the Surviving
Corporation pursuant to Section 5.17 hereof.

7.5 No Other Proceedings. There shall not be pending any Legal Proceeding in
which, in the reasonable judgment of Tigris, would result in an outcome that
is material and

 adverse to Tigris or Potomac: (a) challenging or seeking to restrain or
prohibit the consummation of the Merger or any of the other Contemplated
Transactions; (b) relating to the Merger or any of the other Contemplated
Transactions and seeking to obtain from Tigris or Potomac, any damages or
other relief that may be material to Tigris or Potomac; (c) seeking to
prohibit or limit in any material respect Tigris' stockholders' ability to
vote, transfer, receive dividends with respect to or otherwise exercise
ownership rights with respect to the stock of Tigris; (d) that would
materially and adversely affect the right or ability of Tigris or Potomac to
own the assets or operate the business of Potomac; or (e) seeking to compel
Potomac, Tigris or any Subsidiary of Tigris to dispose of or hold separate any
material assets as a result of the Merger or any of the Contemplated
Transactions in such a manner that would have a Tigris Material Adverse
Effect.

7.6 Potomac Pre-Closing Financing. The Potomac Pre-Closing Financing shall
have been consummated and Potomac shall have received the proceeds of the
Potomac Pre-Closing Financing on the terms and conditions set forth in the
Subscription Agreement.

7.7 FIRPTA Certificate. Tigris shall have received from Potomac a form of
notice to the Internal Revenue Service in accordance with the requirements of
Treasury Regulation Section 1.897-2(h) and in form and substance reasonably
acceptable to Tigris along with written authorization for Tigris to deliver
such notice form to the Internal Revenue Service on behalf of Potomac upon the
Closing.

7.8 No Potomac Material Adverse Effect. Since the date of this Agreement,
there shall not have occurred any Potomac Material Adverse Effect that is
continuing.

7.9 Termination of Investor Agreements. The Investor Agreements shall have
been terminated.

7.10 Preferred Stock Conversion. Potomac shall have effected a conversion of
Potomac Preferred Stock into Common Stock immediately prior to the Effective
Time (the "Preferred Stock Conversion").

Section 8. ADDITIONAL CONDITIONS PRECEDENT TO OBLIGATION OF POTOMAC

The obligations of Potomac to effect the Merger and otherwise consummate the
transactions to be consummated at the Closing are subject to the satisfaction
or the written wavier by Potomac, at or prior to the Closing, of each of the
following conditions:

8.1 Accuracy of Representations. The representations and warranties of Tigris
and Merger Sub contained in this Agreement shall have been true and correct as
of the date of this Agreement and shall be true and correct on and as of the
Closing Date with the same force and effect as if made on the Closing Date
except (A) in each case, or in the aggregate, where the failure to be true and
correct would not reasonably be expected to have a Tigris Material Adverse
Effect, or (B) for those representations and warranties which address matters
only as of a particular date (which representations shall have been true and
correct, subject to the

 qualifications as set forth in the preceding clause (A), as of such particular
date) (it being understood that, for purposes of determining the accuracy of
such representations and warranties, any update of or modification to the
Tigris Disclosure Schedule made or purported to have been made after the date
of this Agreement shall be disregarded).

8.2 Performance of Covenants. All of the covenants and obligations in this
Agreement that Tigris or Merger Sub is required to comply with or to perform
at or prior to the Closing shall have been complied with and performed in all
material respects.

8.3 Lock-up Agreements. Potomac shall have received a copy of a Lock-up
Agreement duly executed by each of the Persons listed on Schedule B hereto,
each of which shall be in full force and effect.

8.4 Documents. Potomac shall have received the following documents, each of
which shall be in full force and effect:

(a) the Pepper Opinion dated as of the Closing Date and addressed to Potomac;
provided, that the condition set forth in this Section 8.4(a) shall not be
waivable by Potomac after receipt of the Required Potomac Stockholder Vote and
the Required Tigris Stockholder Vote unless further stockholder approvals are
obtained with appropriate disclosure;

(b) a certificate executed by the Chief Executive Officer and Chief Financial
Officer of Tigris confirming that the conditions set forth in Sections 8.1,
8.2, 8.5, 8.6 and 8.8 have been duly satisfied;

(c) certificates of good standing of each of Tigris and Merger Sub in its
jurisdiction of organization and the various foreign jurisdictions in which it
is qualified, certified charter documents, certificates as to the incumbency
of officers and the adoption of resolutions of its board of directors
authorizing the execution of this Agreement and the consummation of the
Contemplated Transactions to be performed by Tigris and Merger Sub hereunder;
and

(d) written resignations in forms satisfactory to Potomac, dated as of the
Closing Date and effective as of the Closing executed by the officers and
directors of Tigris who are not to continue as officers or directors of Tigris
pursuant to Section 5.17 hereof.

8.5 No Other Proceedings. There shall not be pending or threatened in writing
any Legal Proceeding in which, in the reasonable judgment of Potomac, would
result in an outcome that is material and adverse to Tigris or Potomac: (a)
challenging or seeking to restrain or prohibit the consummation of the Merger
or any of the other Contemplated Transactions; (b) relating to the Merger or
any of the other Contemplated Transactions and seeking to obtain from Tigris
or Potomac, any damages or other relief that may be material to Tigris or
Potomac; (c) seeking to prohibit or limit in any material respect Tigris'
stockholders' ability to vote, transfer, receive dividends with respect to or
otherwise exercise ownership rights with respect to the stock of Tigris; (d)
that would materially and adversely affect the right or ability of Tigris or
Potomac to own the assets or operate the business of Potomac; or (e) seeking
to compel Potomac, Tigris or any Subsidiary of Tigris to dispose of or hold
separate any material assets as a result of the

 Merger or any of the Contemplated Transactions in such a manner that would
have a Potomac Material Adverse Effect.

8.6 Sarbanes-Oxley Certifications. Neither the principal executive officer nor
the principal financial officer of Tigris shall have failed to provide, with
respect to any Tigris SEC Document filed (or required to be filed) with the
SEC on or after the date of this Agreement, any necessary certification in the
form required under Rule 13a-14 under the Exchange Act and 18 U.S.C. 1350.

8.7 Board of Directors. Tigris shall have caused the Board of Directors of
Tigris to be constituted as set forth in Section 5.17 of this Agreement
effective as of the Effective Time.

8.8 No Tigris Material Adverse Effect. Since the date of this Agreement, there
shall not have occurred any Tigris Material Adverse Effect that is continuing.

8.9 Potomac Pre-Closing Financing. The Potomac Pre-Closing Financing shall
have been consummated and Potomac shall have received the proceeds of the
Potomac Pre-Closing Financing on the terms and conditions set forth in the
Subscription Agreement.

Section 9. TERMINATION

9.1 Termination. This Agreement may be terminated prior to the Effective Time
(whether before or after adoption of this Agreement by Potomac's stockholders
and whether before or after approval of the Merger and issuance of Tigris
Common Stock in the Merger by Tigris' stockholders, unless otherwise specified
below):

(a) by mutual written consent duly authorized by the Boards of Directors of
Tigris and Potomac;

(b) by either Tigris or Potomac if the Merger shall not have been consummated
by December 31, 2014; provided, however, that the right to terminate this
Agreement under this Section 9.1(b) shall not be available to Potomac, on the
one hand, or to Tigris and Merger Sub, on the other hand, if such Party's
action or failure to act has been a principal cause of the failure of the
Merger to occur on or before such date and such action or failure to act
constitutes a breach of this Agreement, provided, further, however, that, in
the event that the waiting period under the HSR Act has not expired, or a
request for additional information has been made by any Governmental
Authority, or in the event that the SEC has not declared effective under the
Securities Act the Form S-4 Registration Statement by such date, then either
Potomac or Tigris shall be entitled to extend the date for termination of this
Agreement pursuant to this Section 9.1(b) for an additional sixty (60) days;

(c) by either Tigris or Potomac if a court of competent jurisdiction or other
Governmental Body shall have issued a final and nonappealable order, decree or
ruling, or shall have taken any other action, having the effect of permanently
restraining, enjoining or otherwise prohibiting the Merger;

 (d) by Tigris if the Required Potomac Stockholder Vote shall not have been
obtained within five (5) Business Days of the Form S-4 Registration Statement
becoming effective in accordance with the provisions of the Securities Act;
provided, however, that once the Required Potomac Stockholder Vote has been
obtained, Tigris may not terminate this Agreement pursuant to this Section
9.1(d);

(e) by either Tigris or Potomac if (i) the Tigris Stockholders' Meeting
(including any adjournments and postponements thereof) shall have been held
and completed and Tigris' stockholders shall have taken a final vote on the
Merger and the issuance of shares of Tigris Common Stock in the Merger and
(ii) the Merger or the issuance of Tigris Common Stock in the Merger shall not
have been approved at the Tigris Stockholders' Meeting (and shall not have
been approved at any adjournment or postponement thereof) by the Required
Tigris Stockholder Vote; provided, however, that the right to terminate this
Agreement under this Section 9.1(e) shall not be available to Tigris where the
failure to obtain the Required Tigris Stockholder Vote shall have been caused
by the action or failure to act of Tigris and such action or failure to act
constitutes a material breach by Tigris of this Agreement);

(f) by Potomac (at any time prior to the approval of the Merger and the
issuance of Tigris Common Stock in the Merger by the Required Tigris
Stockholder Vote) if a Tigris Triggering Event shall have occurred;

(g) by Tigris (at any time prior to the approval of the Merger by the Required
Potomac Stockholder Vote) if a Potomac Triggering Event shall have occurred;

(h) by Potomac, upon a breach of any representation, warranty, covenant or
agreement on the part of Tigris or Merger Sub set forth in this Agreement, or
if any representation or warranty of Tigris or Merger Sub shall have become
inaccurate, in either case such that the conditions set forth in Section 8.1
or Section 8.2 would not be satisfied as of the time of such breach or as of
the time such representation or warranty shall have become inaccurate,
provided that if such inaccuracy in Tigris' or Merger Sub's representations
and warranties or breach by Tigris or Merger Sub is curable by Tigris or
Merger Sub, then this Agreement shall not terminate pursuant to this Section
9.1(h) as a result of such particular breach or inaccuracy until the earlier
of (i) the expiration of a 30 day period commencing upon delivery of written
notice from Tigris or Merger Sub to Potomac of such breach or inaccuracy and
(ii) Tigris or Merger Sub (as applicable) ceasing to exercise commercially
reasonable efforts to cure such breach (it being understood that this
Agreement shall not terminate pursuant to this Section 9.1(h) as a result of
such particular breach or inaccuracy if such breach by Tigris or Merger Sub is
cured prior to such termination becoming effective);

(i) by Tigris, upon a breach of any representation, warranty, covenant or
agreement on the part of Potomac set forth in this Agreement, or if any
representation or warranty of Potomac shall have become inaccurate, in either
case such that the conditions set forth in Section 7.1 or Section 7.2 would
not be satisfied as of the time of such breach or as of the time such
representation or warranty shall have become inaccurate, provided that if such
inaccuracy in Potomac's representations and warranties or breach by Potomac is
curable by Potomac then this Agreement shall not terminate pursuant to this
Section 9.1(i) as a result of

 such particular breach or inaccuracy until the earlier of (i) the expiration
of a 30 day period commencing upon delivery of written notice from Potomac to
Tigris of such breach or inaccuracy and (ii) Potomac ceasing to exercise
commercially reasonable efforts to cure such breach (it being understood that
this Agreement shall not terminate pursuant to this Section 9.1(i) as a result
of such particular breach or inaccuracy if such breach by Potomac is cured
prior to such termination becoming effective); or

(j) by Tigris, at any time, if (i) all conditions in Sections 6 and 8 have
been satisfied (other than those conditions set forth in Section 8.9 and those
conditions that by their nature are to be satisfied by actions taken at the
Closing), and remain so satisfied and (ii) Tigris irrevocably confirms by
written notice to Potomac that (A) each of the conditions in Section 7, other
than the condition set forth in Section 7.6, has been satisfied or that Tigris
is willing to waive any such conditions that have not been satisfied (other
than those conditions that by their nature are to be satisfied by actions
taken at the Closing) and (B) it is prepared to consummate the Closing upon
satisfaction of the condition set forth in Section 7.6; provided, that this
Agreement shall not terminate pursuant to this Section 9.1(j) unless the
condition set forth in Section 7.6 has not been satisfied within five (5)
calendar days after delivery of the written notice from Tigris to Potomac
pursuant to clause (ii) of this Section 9.1(j).

The Party desiring to terminate this Agreement pursuant to this Section 9.1
(other than pursuant to Section 9.1(a)) shall give a notice of such
termination to the other Party specifying the provisions hereof pursuant to
which such termination is made and the basis therefor described in reasonable
detail.



9.2 Effect of Termination. In the event of the termination of this Agreement
as provided in Section 9.1, this Agreement shall be of no further force or
effect; provided, however, that (i) this Section 9.2, Section 9.3, and Section
10 shall survive the termination of this Agreement and shall remain in full
force and effect, and (ii) the termination of this Agreement shall not relieve
any Party for its fraud or from any liability for any willful and material
breach of any representation, warranty, covenant, obligation or other
provision contained in this Agreement.

9.3 Expenses; Termination Fees.

(a) Except as set forth in this Section 9.3, all fees and expenses incurred in
connection with this Agreement and the Contemplated Transactions shall be paid
by the Party incurring such expenses, whether or not the Merger is
consummated; provided, however, that Tigris and Potomac shall share equally
all fees and expenses, other than attorneys' and accountants' fees and
expenses, incurred in relation to the filings by the parties under any filing
requirement under the HSR Act and any foreign antitrust Legal Requirement
applicable to this Agreement and the transactions contemplated hereby;
provided, further however, that Tigris and Potomac shall also share equally
all fees and expenses incurred (up to a maximum of $125,000 payable by
Potomac) in relation to the printing and filing with the SEC of the Form S-4
Registration Statement (including any financial statements and exhibits) and
any amendments or supplements thereto and paid to a financial printer or the
SEC.

 (b) (i) If (x) this Agreement is terminated by Tigris or Potomac pursuant to
Section 9.1(e) or (f), (y) at any time before the Tigris Stockholders' Meeting
an Acquisition Proposal with respect to Tigris shall have been publicly
announced, disclosed or otherwise communicated to Tigris' Board of Directors
and (z) in the event this Agreement is terminated pursuant Section 9.1(e),
within 12 months after the date of such termination, Tigris enters into a
definitive agreement with respect to a Subsequent Transaction or consummates a
Subsequent Transaction, Tigris shall pay to Potomac, within ten (10) Business
Days after termination, a nonrefundable fee in an amount equal to $6,300,000
(the "Potomac Termination Fee"), in addition to any amount payable to Potomac
pursuant to Sections 9.3(c) or 9.3(e);

(i) If (x) this Agreement is terminated by Tigris pursuant to Section 9.1(d)
or (g), (y) at any time before obtaining the Required Potomac Stockholder Vote
an Acquisition Proposal with respect to Potomac shall have been publicly
announced, disclosed or otherwise communicated to Potomac's Board of
Directors, and (z) in the event this Agreement is terminated pursuant Section
9.1(d), within 12 months after the date of such termination, Potomac enters
into a definitive agreement with respect to a Subsequent Transaction or
consummates a Subsequent Transaction, Potomac shall pay to Tigris, within ten
(10) Business Days after termination, a nonrefundable fee in an amount equal
to $6,300,000 (the "Tigris Termination Fee"), in addition to any amount
payable to Tigris pursuant to Sections 9.3(d) or 9.3(e); or

(ii) If this Agreement is terminated by Tigris pursuant to Section 9.1(j) and
prior to such termination, a requisite group of Purchasers (as defined in the
Subscription Agreement) have not irrevocably confirmed by written notice to
Tigris that such Purchasers are prepared to consummate an acquisition of
Potomac Common Stock on the terms and conditions set forth in the Subscription
Agreement with aggregate gross cash proceeds to Potomac of at least
$93,000,000, Potomac shall pay to Tigris, within ten (10) Business Days after
termination, the Tigris Termination Fee, in addition to any amount payable to
Tigris pursuant to Sections 9.3(d) or 9.3(e).

(c) (i) If this Agreement is terminated by Potomac pursuant to Sections
9.1(e), (f) or (h), or (ii) if this Agreement is terminated by Tigris pursuant
to Section 9.1(e), or (iii) in the event of a failure of Potomac to consummate
the transactions to be consummated at the Closing solely as a result of a
Tigris Material Adverse Effect as set forth in Section 8.8 (provided that at
such time all of the other conditions precedent to Tigris' obligation to close
set forth in Sections 6 and 7 of this Agreement have been satisfied by
Potomac, are capable of being satisfied by Potomac or have been waived by
Tigris), Tigris shall reimburse Potomac for all reasonable fees and expenses
incurred by Potomac in connection with this Agreement and the transactions
contemplated hereby, including (x) all fees and expenses incurred in
connection with the preparation, printing and filing, as applicable, of the
Form S-4 Registration Statement (including any preliminary materials related
thereto and all amendments and supplements thereto, as well as any financial
statements and schedules thereto) and (y) all fees and expenses incurred in
connection with the preparation and filing under any filing requirement of any
Governmental Authority applicable to this Agreement and the transactions
contemplated hereby (such expenses, including (x) and (y) above, collectively,
the "Third Party Expenses"), up to a maximum of $1,000,000, by wire transfer
of same-day funds within ten (10) Business Days

 following the date on which Potomac submits to Tigris true and correct copies
of reasonable documentation supporting such Third Party Expenses; provided,
however, that such Third Party Expenses shall not include any amounts for a
financial advisor to Potomac except for reasonably documented out-of-pocket
expenses otherwise reimbursable by Potomac to such financial advisor pursuant
to the terms of Potomac's engagement letter or similar arrangement with
financial advisor.

(d) (i) If this Agreement is terminated by Tigris pursuant to Sections 9.1(d),
(g), (i) or (j) or (ii) in the event of a failure of Tigris to consummate the
transactions to be consummated at the Closing solely as a result of a Potomac
Material Adverse Effect as set forth in Section 7.8 (provided that at such
time all of the other conditions precedent to Potomac's obligation to close
set forth in Sections 6 and 8 of this Agreement have been satisfied by Tigris,
are capable of being satisfied by Tigris or have been waived by Potomac),
Potomac shall reimburse Tigris for all Third Party Expenses incurred by Tigris
up to a maximum of $1,000,000, by wire transfer of same-day funds within ten
(10) Business Days following the date on which Tigris submits to Potomac true
and correct copies of reasonable documentation supporting such Third Party
Expenses; provided, however, that such Third Party Expenses shall not include
any amounts for a financial advisor to Tigris except for reasonably documented
out-of-pocket expenses otherwise reimbursable by Tigris to such financial
advisor pursuant to the terms of Tigris' engagement letter or similar
arrangement with financial advisor.

(e) If either Party fails to pay when due any amount payable by such Party
under Section 9.3(b), (c) or (d), then (i) such Party shall reimburse the
other Party for reasonable costs and expenses (including reasonable fees and
disbursements of counsel) incurred in connection with the collection of such
overdue amount and the enforcement by the other Party of its rights under this
Section 9.3, and (ii) such Party shall pay to the other Party interest on such
overdue amount (for the period commencing as of the date such overdue amount
was originally required to be paid and ending on the date such overdue amount
is actually paid to the other Party in full) at a rate per annum equal to the
"prime rate" (as announced by Bank of America or any successor thereto) in
effect on the date such overdue amount was originally required to be paid.

(f) The Parties agree that the payment of the fees and expenses set forth in
this Section 9.3, subject to Section 9.2, shall be the sole and exclusive
remedy of each Party following a termination of this Agreement under the
circumstances described in this Section 9.3, it being understood that in no
event shall either Tigris or Potomac be required to pay fees or damages
payable pursuant to this Section 9.3 on more than one occasion. Subject to
Section 9.2, the payment of the fees and expenses set forth in this Section
9.3 and Section 10.11, each of the Parties and their respective affiliates (as
that term is used in Rule 145 under the Securities Act) shall have no
liability, shall not be entitled to bring or maintain any other claim, action
or proceeding against the other, shall be precluded from any other remedy
against the other, at law or in equity or otherwise, and shall not seek to
obtain any recovery, judgment or damages of any kind against the other (or any
partner, member, stockholder, director, officer, employee, Subsidiary,
affiliate, agent or other representative of such Party) in connection with or
arising out of the termination of this Agreement, any breach by any Party
giving rise to such termination or

 the failure of the Merger and the other Contemplated Transactions to be
consummated. Each of the Parties acknowledges that (i) the agreements
contained in this Section 9.3 are an integral part of the Contemplated
Transactions, (ii) without these agreements, the Parties would not enter into
this Agreement and (iii) any amount payable pursuant to this Section 9.3 is
not a penalty, but rather is liquidated damages in a reasonable amount that
will compensate the Parties in the circumstances in which such amount is
payable.

(g) Notwithstanding anything to the contrary in this Section 9.3, any amount
payable by Tigris to Potomac pursuant to this Section 9.3 shall be reduced and
offset by any amounts owed by Potomac to Tigris pursuant to the Tigris Notes.

Section 10. MISCELLANEOUS PROVISIONS

10.1 Non-Survival of Representations and Warranties. The representations and
warranties of Potomac, Merger Sub and Tigris contained in this Agreement or
any certificate or instrument delivered pursuant to this Agreement shall
terminate at the Effective Time, and only the covenants that by their terms
survive the Effective Time and this Section 10 shall survive the Effective
Time.

10.2 Amendment. This Agreement may be amended with the approval of the
respective Boards of Directors of Potomac, Merger Sub and Tigris at any time
(whether before or after the adoption and approval of this Agreement by
Potomac's stockholders or before or after the approval of the Merger or
issuance of shares of Tigris Common Stock in the Merger); provided, however,
that after any such adoption and approval of this Agreement by a Party's
stockholders, no amendment shall be made which by law requires further
approval of the stockholders of such Party without the further approval of
such stockholders. This Agreement may not be amended except by an instrument
in writing signed on behalf of each of Potomac, Merger Sub and Tigris.

10.3 Waiver.

(a) No failure on the part of any Party to exercise any power, right,
privilege or remedy under this Agreement, and no delay on the part of any
Party in exercising any power, right, privilege or remedy under this
Agreement, shall operate as a waiver of such power, right, privilege or
remedy; and no single or partial exercise of any such power, right, privilege
or remedy shall preclude any other or further exercise thereof or of any other
power, right, privilege or remedy.

(b) No Party shall be deemed to have waived any claim arising out of this
Agreement, or any power, right, privilege or remedy under this Agreement,
unless the waiver of such claim, power, right, privilege or remedy is
expressly set forth in a written instrument duly executed and delivered on
behalf of such Party; and any such waiver shall not be applicable or have any
effect except in the specific instance in which it is given.

10.4 Entire Agreement; Counterparts; Exchanges by Facsimile. This Agreement
and the other agreements referred to in this Agreement constitute the entire
agreement and

 supersede all prior agreements and understandings, both written and oral,
among or between any of the Parties with respect to the subject matter hereof
and thereof; provided, however, that the Confidentiality Agreement shall not
be superseded and shall remain in full force and effect in accordance with its
terms. This Agreement may be executed in several counterparts, each of which
shall be deemed an original and all of which shall constitute one and the same
instrument. The exchange of a fully executed Agreement (in counterparts or
otherwise) by all Parties by facsimile or electronic transmission in .PDF
format shall be sufficient to bind the Parties to the terms and conditions of
this Agreement.

10.5 Applicable Law; Jurisdiction. This Agreement shall be governed by, and
construed in accordance with, the laws of the State of Delaware, regardless of
the laws that might otherwise govern under applicable principles of conflicts
of laws. In any action or suit between any of the Parties arising out of or
relating to this Agreement or any of the Contemplated Transactions: (a) each
of the Parties irrevocably and unconditionally consents and submits to the
exclusive jurisdiction and venue of the state and federal courts located in
the State of Delaware; (b) if any such action or suit is commenced in a state
court, then, subject to applicable Legal Requirements, no Party shall object
to the removal of such action or suit to any federal court located in the
District of Delaware; and (c) each of the Parties irrevocably waives the right
to trial by jury.

10.6 Attorneys' Fees. In any action at law or suit in equity to enforce this
Agreement or the rights of any of the parties under this Agreement, the
prevailing Party in such action or suit shall be entitled to receive a
reasonable sum for its attorneys' fees and all other reasonable costs and
expenses incurred in such action or suit.

10.7 Assignability. This Agreement shall be binding upon, and shall be
enforceable by and inure solely to the benefit of, the parties hereto and
their respective successors and assigns; provided, however, that neither this
Agreement nor any of a Party's rights or obligations hereunder may be assigned
or delegated by such Party without the prior written consent of the other
Party, and any attempted assignment or delegation of this Agreement or any of
such rights or obligations by such Party without the other Party's prior
written consent shall be void and of no effect. Nothing in this Agreement,
express or implied, is intended to or shall confer upon any Person (other
than: (a) the parties hereto; (b) the DandO Indemnified Parties to the extent of
their respective rights pursuant to Section 5.7; and (c) the rights of the
applicable stockholders of Tigris to receive the Pre-Closing Dividend Assets
and enforce their rights under Schedule C) any right, benefit or remedy of any
nature whatsoever under or by reason of this Agreement.

10.8 Notices. Any notice or other communication required or permitted to be
delivered to any Party under this Agreement shall be in writing and shall be
deemed properly delivered, given and received when delivered by hand, by
registered mail, by courier or express delivery service or by facsimile to the
address or facsimile telephone number set forth beneath the name of such Party
below (or to such other address or facsimile telephone number as such Party
shall have specified in a written notice given to the other parties hereto):

if to Tigris or Merger Sub:

 Transcept Pharmaceuticals, Inc.

1003 W. Cutting Blvd., Suite #110

Point Richmond, California 94804

Telephone: (510) 215-3500

Fax: (510) 215-3535

Attention: Chief Executive Officer

with a copy to:

Latham and Watkins LLP

140 Scott Drive

Menlo Park, California 94025

Telephone: (650) 328-4600

Fax: (650) 463-2600

Attention: Alan C. Mendelson



if to Potomac:

75 Kneeland Street

Boston, MA 02111

Telephone No.: (617) 275-0040

Facsimile No.: (617) 275-0039

Attention: Chief Executive Officer

with a copy to:

Pepper Hamilton LLP

19th Floor, High Street Tower

125 High Street

Boston, Massachusetts 02110-2736

Telephone: (617) 204-5107

Fax: (617) 204-5150

Attention: Steven R. London



10.9 Cooperation. Each Party agrees to cooperate fully with the other Party
and to execute and deliver such further documents, certificates, agreements
and instruments and to take such other actions as may be reasonably requested
by the other Party to evidence or reflect the Contemplated Transactions and to
carry out the intent and purposes of this Agreement.

10.10 Severability. Any term or provision of this Agreement that is invalid or
unenforceable in any situation in any jurisdiction shall not affect the
validity or enforceability of the remaining terms and provisions of this
Agreement or the validity or enforceability of the offending term or provision
in any other situation or in any other jurisdiction. If a final judgment of a
court of competent jurisdiction declares that any term or provision of this
Agreement is invalid or unenforceable, the Parties hereto agree that the court
making such determination shall

 have the power to limit such term or provision, to delete specific words or
phrases or to replace such term or provision with a term or provision that is
valid and enforceable and that comes closest to expressing the intention of
the invalid or unenforceable term or provision, and this Agreement shall be
valid and enforceable as so modified. In the event such court does not
exercise the power granted to it in the prior sentence, the Parties hereto
agree to replace such invalid or unenforceable term or provision with a valid
and enforceable term or provision that will achieve, to the extent possible,
the economic, business and other purposes of such invalid or unenforceable
term or provision.

10.11 Other Remedies; Specific Performance. Except as otherwise provided
herein, any and all remedies herein expressly conferred upon a Party will be
deemed cumulative with and not exclusive of any other remedy conferred hereby,
or by law or equity upon such Party, and the exercise by a Party of any one
remedy will not preclude the exercise of any other remedy. The Parties hereto
agree that irreparable damage would occur in the event that any of the
provisions of this Agreement were not performed in accordance with their
specific terms or were otherwise breached. It is accordingly agreed that the
Parties shall be entitled to an injunction or injunctions to prevent breaches
of this Agreement and to enforce specifically the terms and provisions hereof
in any court of the United States or any state having jurisdiction, this being
in addition to any other remedy to which they are entitled at law or in
equity, and each of the Parties hereto waives any bond, surety or other
security that might be required of any other Party with respect thereto.

10.12 No Third Party Beneficiaries. Except for the provisions set forth in
Section 5.7(f) of this Agreement, this Agreement is not intended to and shall
not confer upon any Person other than the parties hereto any rights or
remedies hereunder.

[Remainder of page intentionally left blank]



10.13 Construction.

(a) For purposes of this Agreement, whenever the context requires: the
singular number shall include the plural, and vice versa; the masculine gender
shall include the feminine and neuter genders; the feminine gender shall
include the masculine and neuter genders; and the neuter gender shall include
masculine and feminine genders.

(b) The Parties hereto agree that any rule of construction to the effect that
ambiguities are to be resolved against the drafting Party shall not be applied
in the construction or interpretation of this Agreement.

(c) As used in this Agreement, the words "include" and "including," and
variations thereof, shall not be deemed to be terms of limitation, but rather
shall be deemed to be followed by the words "without limitation."

 (d) Except as otherwise indicated, all references in this Agreement to
"Sections," "Exhibits" and "Schedules" are intended to refer to Sections of
this Agreement and Exhibits and Schedules to this Agreement, respectively.

(e) The bold-faced headings contained in this Agreement are for convenience of
reference only, shall not be deemed to be a part of this Agreement and shall
not be referred to in connection with the construction or interpretation of
this Agreement.

[Remainder of page intentionally left blank]





 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed as
of the date first above written.

TRANSCEPT PHARMACEUTICALS, INC.

By: /s/ Glenn A. Oclassen

Name: Glenn A. Oclassen

Title: Chairman and Chief Executive Officer



TIGRIS MERGER SUB, INC.

By: /s/ Glenn A. Oclassen

Name: Glenn A. Oclassen

Title: President and Chief Executive Officer



TIGRIS ACQUISITION SUB, LLC

By: /s/ Glenn A. Oclassen

Name: Glenn A. Oclassen

Title: President and Chief Executive Officer



PARATEK PHARMACEUTICALS, INC.

By: /s/ Michael F. Bigham

Name: Michael F. Bigham

Title: Chairman and Chief Executive Officer







EXHIBIT A

CERTAIN DEFINITIONS

For purposes of the Agreement (including this Exhibit A):

2014 Plan. "2014 Plan" shall have the meaning set forth in Section 2.3(b).

409A Plan. "409A Plan" shall have the meaning set forth in Section 3.11(j).

Accounting Firm. "Accounting Firm" shall have the meaning set forth in Section
1.6(e).

Acquisition Inquiry. "Acquisition Inquiry" shall mean, with respect to a
Party, an inquiry, indication of interest or request for information (other
than an inquiry, indication of interest or request for information made or
submitted by Potomac, on the one hand or Tigris, on the other hand, to the
other Party) that could reasonably be expected to lead to an Acquisition
Proposal with such Party.

Acquisition Proposal. "Acquisition Proposal" shall mean, with respect to a
Party, any offer or proposal, whether written or oral (other than an offer or
proposal made or submitted by or on behalf of Potomac or any of its
"affiliates" (as that term is used in Rule 145 under the Securities Act), on
the one hand, or by or on behalf of Tigris or any of its "affiliates" (as that
term is used in Rule 145 under the Securities Act), on the other hand, to the
other Party) contemplating or otherwise relating to any Acquisition
Transaction with such Party.

Acquisition Transaction. "Acquisition Transaction" shall mean any transaction
or series of transactions involving:

(a) any merger, consolidation, amalgamation, share exchange, business
combination, issuance of securities, acquisition of securities,
reorganization, recapitalization, tender offer, exchange offer or other
similar transaction: (i) in which a Party is a constituent corporation; (ii)
in which a Person or "group" (as defined in the Exchange Act and the rules
promulgated thereunder) of Persons directly or indirectly acquires beneficial
or record ownership of securities representing more than 15% of the
outstanding securities of any class of voting securities of a Party or any of
its Subsidiaries; or (iii) in which a Party or any of its Subsidiaries issues
securities representing more than 15% of the outstanding securities of any
class of voting securities of such Party or any of its Subsidiaries; provided
however, in the case of Tigris, the Potomac Pre-Closing Financing shall not be
an "Acquisition Transaction";

(b) any sale, lease, exchange, transfer, license, acquisition or disposition
of any business or businesses or assets that constitute or account for 15% or
more of the consolidated book value or the fair market value of the assets of
a Party and its Subsidiaries, taken as a whole; or

(c) any liquidation or dissolution of a Party.

 Additional Directors. "Additional Directors" shall have the meaning set forth
in Section 5.17.

Agreement. "Agreement" shall mean the Agreement and Plan of Merger and
Reorganization to which this Exhibit A is attached, as it may be amended from
time to time.

Anticipated Closing Date. "Anticipated Closing Date" shall have the meaning
set forth in Section 1.6(a).

Business Day. "Business Day" shall mean any day other than a day on which
banks in the State of New York are authorized or obligated to be closed.

Capitalization Date. "Capitalization Date" shall have the meaning set forth in
Section 3.3(a).

Certificate of Merger. "Certificate of Merger" shall have the meaning set
forth in Section 1.3.

Certifications. "Certifications" shall have the meaning set forth in Section
3.4(a).

Closing. "Closing" shall have the meaning set forth in Section 1.3.

Closing Date. "Closing Date" shall have the meaning set forth in Section 1.3.

COBRA. "COBRA" means the Consolidated Omnibus Budget Reconciliation Act of
1985, as amended, as set forth in Section 4980B of the Code and Part 6 of
Title I of ERISA.

Code. "Code" shall mean the Internal Revenue Code of 1986, as amended.

Confidentiality Agreement. "Confidentiality Agreement" shall mean the
Confidentiality Agreement dated March 24, 2014, between Potomac and Tigris.

Consent. "Consent" shall mean any approval, consent, ratification, permission,
waiver or authorization (including any Governmental Authorization).

Contemplated Transactions. "Contemplated Transactions" shall mean the Merger
and the other transactions and actions contemplated by the Agreement.

Contract. "Contract" shall, with respect to any Person, mean any written
agreement, contract, subcontract, lease (whether real or personal property),
mortgage, understanding, arrangement, instrument, note, option, warranty,
purchase order, license, sublicense, insurance policy, benefit plan or legally
binding commitment or undertaking of any nature to which such Person is a
party or by which such Person or any of its assets are bound or affected under
applicable law.

Costs. "Costs" shall have the meaning set forth in Section 5.7(a).

 DandO Indemnified Parties. "DandO Indemnified Parties" shall have the meaning set
forth in Section 5.7(a).

Determination Date. "Determination Date" shall have the meaning set forth in
Section 1.6(a).

DGCL. "DGCL" shall mean the General Corporation Law of the State of Delaware.

Dispute Notice. "Dispute Notice" shall have the meaning set forth in Section
1.6(b).

Dissenting Shares. "Dissenting Shares" shall have the meaning set forth in
Section 1.9(a).

DLLCA. "DLLCA" shall have the meaning set forth in the recitals.

Drug Regulatory Agency. "Drug Regulatory Agency" shall have the meaning set
forth in Section 2.11(c).

Effective Time. "Effective Time" shall have the meaning set forth in Section
1.3.

Encumbrance. "Encumbrance" shall mean any lien, pledge, hypothecation, charge,
mortgage, security interest, encumbrance, claim, infringement, interference,
option, right of first refusal, preemptive right, community property interest
or restriction of any nature (including any restriction on the voting of any
security, any restriction on the transfer of any security or other asset, any
restriction on the receipt of any income derived from any asset, any
restriction on the use of any asset and any restriction on the possession,
exercise or transfer of any other attribute of ownership of any asset).

Entity. "Entity" shall mean any corporation (including any non-profit
corporation), partnership (including any general partnership, limited
partnership or limited liability partnership), joint venture, estate, trust,
company (including any company limited by shares, limited liability company or
joint stock company), firm, society or other enterprise, association,
organization or entity, and each of its successors.

Environmental Law. "Environmental Law" means any federal, state, local or
foreign Legal Requirement relating to pollution or protection of human health
or the environment (including ambient air, surface water, ground water, land
surface or subsurface strata), including any law or regulation relating to
emissions, discharges, releases or threatened releases of Hazardous Materials,
or otherwise relating to the manufacture, processing, distribution, use,
treatment, storage, disposal, transport or handling of Hazardous Materials.

ERISA. "ERISA" shall mean the Employee Retirement Income Security Act of 1974,
as amended.

Exchange Act. "Exchange Act" shall mean the Securities Exchange Act of 1934,
as amended.

 Exchange Agent. "Exchange Agent" shall have the meaning set forth in Section
1.8(a).

Exchange Fund. "Exchange Fund" shall have the meaning set forth in Section
1.8(a).

Exchange Ratio. "Exchange Ratio" shall be equal to 0.81.

Existing Potomac DandO Policies. "Existing Potomac DandO Policies" shall have the
meaning set forth in Section 2.15(b).

Existing Tigris DandO Policies. "Existing Tigris DandO Policies" shall have the
meaning set forth in Section 3.13(b).

FDA. "FDA" shall have the meaning set forth in Section 2.11(c).

FDCA. "FDCA" shall have the meaning set forth in Section 2.11(c).

Firms. "Firms" shall have the meaning set forth in Section 5.21.

Form S-4 Registration Statement. "Form S-4 Registration Statement" shall mean
the registration statement on Form S-4 to be filed with the SEC by Tigris
registering the public offering and sale of Tigris Common Stock to some or all
holders of Potomac Common Stock in the Merger, whether or not including the
shares of Tigris Common Stock to be issued in exchange for shares of Potomac
Common Stock issued in connection with the consummation of the Potomac Pre-
Closing Financing, but including all shares of Tigris Common Stock to be
issued in exchange for all other shares of Potomac Common Stock in the Merger,
as said registration statement may be amended prior to the time it is declared
effective by the SEC.

GAAP. "GAAP" shall have the meaning set forth in Section 2.4(a).

Governmental Authority. "Governmental Authority" means any court or tribunal,
governmental, quasi-governmental or regulatory body, administrative agency or
bureau, commission or authority or other body exercising similar powers or
authority.

Governmental Authorization. "Governmental Authorization" shall mean any: (a)
permit, license, certificate, franchise, permission, variance, exceptions,
orders, clearance, registration, qualification or authorization issued,
granted, given or otherwise made available by or under the authority of any
Governmental Body or pursuant to any Legal Requirement; or (b) right under any
Contract with any Governmental Body.

Governmental Body. "Governmental Body" shall mean any: (a) nation, state,
commonwealth, province, territory, county, municipality, district or other
jurisdiction of any nature; (b) federal, state, local, municipal, foreign or
other government; (c) governmental or quasi-Governmental Authority of any
nature (including any governmental division, department, agency, commission,
instrumentality, official, ministry, fund, foundation, center, organization,
unit, body or Entity and any court or other tribunal, and for the avoidance of
doubt, any Taxing authority); or (d) self-regulatory organization (including
the NASDAQ Stock Market).

 Grant Date. "Grant Date" shall have the meaning set forth in Section 2.13(f).

Hazardous Materials. "Hazardous Materials" shall mean any pollutant, chemical,
substance and any toxic, infectious, carcinogenic, reactive, corrosive,
ignitable or flammable chemical, or chemical compound, or hazardous substance,
material or waste, whether solid, liquid or gas, that is subject to
regulation, control or remediation under any Environmental Law, including
without limitation, crude oil or any fraction thereof, and petroleum products
or by-products.

HSR Act. "HSR Act" shall mean the Hart-Scott-Rodino Antitrust Improvements Act
of 1976, as amended.

Intellectual Property. "Intellectual Property" shall mean (a) United States,
foreign and international patents, patent applications, including provisional
applications, statutory invention registrations, invention disclosures and
inventions, (b) trademarks, service marks, trade names, domain names, URLs,
trade dress, logos and other source identifiers, including registrations and
applications for registration thereof, (c) copyrights, including registrations
and applications for registration thereof, and (d) software, formulae,
customer lists, trade secrets, know-how, confidential information and other
proprietary rights and intellectual property, whether patentable or not.

Investor Agreements. "Investor Agreements" shall have the meaning set forth in
Section 5.18.

IRS. "IRS" shall mean the United States Internal Revenue Service.

Key Employee. "Key Employee" shall mean, with respect to the Potomac or
Tigris, an executive officer or any employee that reports directly to the
Board of Directors or Chief Executive Officer or Chief Operating Officer.

Knowledge. "Knowledge" means, with respect to an individual, that such
individual is actually aware of the relevant fact or such individual would
reasonably be expected to know such fact in the ordinary course of the
performance of the individual's employee or professional responsibility. Any
Person that is an Entity shall have Knowledge if any officer or director of
such Person as of the date such knowledge is imputed has Knowledge of such
fact or other matter.

Latham. "Latham" shall have the meaning set forth in Section 5.11(c).

Latham Opinion. "Latham Opinion" shall have the meaning set forth in Section
5.11(c).

Legal Proceeding. "Legal Proceeding" shall mean any action, suit, litigation,
arbitration, proceeding (including any civil, criminal, administrative,
investigative or appellate proceeding), hearing, inquiry, audit, examination
or investigation commenced, brought,

 conducted or heard by or before, or otherwise involving, any court or other
Governmental Body or any arbitrator or arbitration panel.

Legal Requirement. "Legal Requirement" shall mean any federal, state, foreign,
material local or municipal or other law, statute, constitution, principle of
common law, resolution, ordinance, code, edict, decree, rule, regulation,
ruling or requirement issued, enacted, adopted, promulgated, implemented or
otherwise put into effect by or under the authority of any Governmental Body
(or under the authority of the NASDAQ Stock Market or the Financial Industry
Regulatory Authority).

Liability. "Liability" shall have the meaning set forth in Section 2.10.

Lock-up Agreement. "Lock-up Agreement" shall have the meaning set forth in
Section 7.3.

Merger. "Merger" shall have the meaning set forth in the recitals.

Merger LLC. "Merger LLC" shall have the meaning set forth in the Preamble.

Merger Sub. "Merger Sub" shall have the meaning set forth in the Preamble.

Minimum Cash Amount. "Minimum Cash Amount" shall have the meaning set forth in
Section 5.16.

Multiemployer Plan. "Multiemployer Plan" shall mean (A) a "multiemployer
plan," as defined in Section 3(37) or 4001(a)(3) of ERISA, or (B) a plan which
if maintained or administered in or otherwise subject to the laws of the
United States would be described in paragraph (A).

Multiple Employer Plan. "Multiple Employer Plan" shall mean (A) a "multiple
employer plan" within the meaning of Section 413(c) of the Code or Section
3(40) of ERISA, or (B) a plan which if maintained or administered in or
otherwise subject to the laws of the United States would be described in
paragraph (A).

Net Cash. "Net Cash" shall mean (a) the sum of Tigris' and its Subsidiaries'
cash and cash equivalents, marketable securities, accounts and interest
receivable and deposits (to the extent refundable to Tigris), in each case as
of the close of business on the last Business Day prior to the date of
determination, determined in a manner consistent with the manner in which such
items were historically determined and in accordance with Tigris' Audited
Financial Statements and Unaudited Interim Balance Sheet minus (b) the sum of
Tigris' and its Subsidiaries' accounts payable and accrued expenses (other
than accrued expenses listed below), in each case as of such date and
determined in a manner consistent with the manner in which such items were
historically determined and in accordance with Tigris' Audited Financial
Statements and Unaudited Interim Balance Sheet minus (c) the cash cost of any
change of control payments or severance payments that are or become due to any
employee of Tigris or its Subsidiaries minus (d) the cash cost of any accrued
and unpaid retention payments due to any

 employee of Tigris or its Subsidiaries as of the Closing Date, minus (e) any
remaining fees and expenses (including, but not limited to, any attorney's,
accountant's, financial advisor's or finder's fees) as of such date for which
Tigris or any of its Subsidiaries is liable incurred by Tigris or any of its
Subsidiaries in connection with this Agreement and the Contemplated
Transactions or otherwise minus (f) the fees and expenses of the Accounting
Firm allocated to Tigris pursuant to Section 1.6(e), minus (g) any bona fide
current liabilities payable in cash, in each case to the extent not cancelled
at or prior to the Determination Date; provided that in no event shall any
liabilities or accruals relating to the Legal Proceeding described on Schedule
D hereto be taken into account as a reduction in Net Cash, minus (h) any
unpaid amounts payable by Tigris in satisfaction of its obligations under
Section 5.7(c) for the period after the Closing, plus (i) the amount of any
outstanding principal and accrued interest under the Tigris Note as of the
Anticipated Closing Date in excess of $3,508,750, plus (j) any amounts due to
be reimbursed to Tigris by Potomac pursuant to Section 9.3(a).

Net Cash Calculation. "Net Cash Calculation" shall have the meaning set forth
in Section 1.6(a).

Net Cash Schedule. "Net Cash Schedule" shall have the meaning set forth in
Section 1.6(a).

Ordinary Course of Business. "Ordinary Course of Business" shall mean, in the
case of each of Potomac and Tigris, such actions taken in the ordinary course
of its normal operations and consistent with its past practices, and
consistent with the operating plans delivered to the other Party.

Party. "Party" or "Parties" shall mean Potomac, Merger Sub, Merger LLC and
Tigris.

Pepper Hamilton. "Pepper Hamilton" shall have the meaning set forth in Section
5.11(c).

Pepper Opinion. "Pepper Opinion" shall have the meaning set forth in Section
5.11(c).

Permitted Dividend. "Permitted Dividend" shall have the meaning set forth in
Section 4.2(a).

Person. "Person" shall mean any individual, Entity or Governmental Body.

Potomac. "Potomac" shall have the meaning set forth in the Preamble.

Potomac Affiliate. "Potomac Affiliate" shall mean any Person that is (or at
any relevant time was) under common control with Potomac within the meaning of
Sections 414(b), (c), (m) and (o) of the Code, and the regulations issued
thereunder.

Potomac Associate. "Potomac Associate" shall mean any current or former
employee, independent contractor, officer or director of Potomac or any
Potomac Affiliate.

 Potomac Board of Directors. "Potomac Board of Directors" shall mean the board
of directors of Potomac.

Potomac Board Recommendation. "Potomac Board Recommendation" shall have the
meaning set forth in Section 5.2(b).

Potomac Capital Stock. "Potomac Capital Stock" shall mean the Potomac Common
Stock and the Potomac Preferred Stock.

Potomac Common Stock. "Potomac Common Stock" shall mean the Common Stock,
$0.001 par value per share, of Potomac.

Potomac Contract. "Potomac Contract" shall mean any Contract: (a) to which
Potomac or any of its Subsidiaries is a Party; (b) by which Potomac or any
Potomac Subsidiary or any Potomac IP Rights or any other asset of Potomac or
its Subsidiaries is or may become bound or under which Potomac or any Potomac
Subsidiary has, or may become subject to, any obligation; or (c) under which
Potomac or Potomac Subsidiary has or may acquire any right or interest.

Potomac Disclosure Schedule. "Potomac Disclosure Schedule" shall have the
meaning set forth in Section 2.

Potomac Employee Plan. "Potomac Employee Plan" shall have the meaning set
forth in Section 2.13(e).

Potomac Financials. "Potomac Financials" shall have the meaning set forth in
Section 2.4(a).

Potomac IP Rights. "Potomac IP Rights" shall mean all Intellectual Property
owned, licensed, or controlled by Potomac or its Subsidiaries that is
necessary or used in the business of Potomac and its Subsidiaries as presently
conducted.

Potomac IP Rights Agreement. "Potomac IP Rights Agreement" shall mean any
instrument or agreement governing, related or pertaining to any Potomac IP
Rights.

Potomac Material Adverse Effect. "Potomac Material Adverse Effect" shall mean
any effect, change, event, circumstance, or development (any such item, an
"Effect") that, considered together with all other Effects that had occurred
prior to the date of determination of the occurrence of the Potomac Material
Adverse Effect, is or could reasonably be expected to be materially adverse
to, or has or could reasonably be expected to have or result in a material
adverse effect on: (a) the business, condition (financial or otherwise),
capitalization, assets (including Intellectual Property), operations or
financial performance of Potomac and its Subsidiaries taken as a whole; or (b)
the ability of Potomac to consummate the Merger or any of the other
Contemplated Transactions or to perform any of its covenants or obligations
under the Agreement in all material respects; provided, however, that none of
the following shall be deemed to constitute a Potomac Material Adverse Effect:
(1) any rejection by a Governmental

 Body of a registration or filing by Potomac relating to Potomac IP Rights; (2)
resignation, termination or death of any individual director or officer of
Potomac, provided, however, that the resignation or termination of more than
fifty percent (50%) of Potomac's directors or more than fifty percent (50%) of
Potomac's officers (each except as required by the terms of this Merger
Agreement) during the period on and after the date hereof and prior to Closing
may give rise to a Potomac Material Adverse Effect; (3) announcement or
publication regarding the interest of an Entity in competition with Potomac's
business as currently conducted or as proposed to be conducted; (4) any change
in the cash position of Potomac which results from operations in the Ordinary
Course of Business; (5) any Effect resulting from the announcement or pendency
of the Merger or the Potomac Pre-Closing Financing; (6) any act or threat of
terrorism or war anywhere in the world, any armed hostilities or terrorist
activities anywhere in the world, any threat or escalation or armed
hostilities or terrorist activities anywhere in the world or any governmental
or other response or reaction to any of the foregoing; (7) any change in
accounting requirements or principles or any change in applicable laws, rules
or regulations or the interpretation thereof; or (8) any adverse change,
effect or occurrence attributable to the United States economy as a whole or
the industries in which Potomac operates.

Potomac Material Contract. "Potomac Material Contract" shall have the meaning
set forth in Section 2.9.

Potomac Options. "Potomac Options" shall mean options or other rights to
purchase shares of Potomac Common Stock issued by Potomac.

Potomac Permits. "Potomac Permits" shall have the meaning set forth in Section
2.11(b).

Potomac Pre-Closing Financing. "Potomac Pre-Closing Financing" means an
acquisition of Potomac Common Stock to be consummated prior to the Closing
with aggregate gross cash proceeds to Potomac of $93,000,000, not including
any conversion of promissory notes in connection therewith.

Potomac Preferred Stock. "Potomac Preferred Stock" shall have the meaning set
forth in Section 2.3(a).

Potomac Product Candidates. "Potomac Product Candidates" shall have the
meaning set forth in Section 2.11(d).

Potomac Registered IP. "Potomac Registered IP" shall mean all Potomac IP
Rights that are registered, filed or issued under the authority of, with or by
any Governmental Body, including all patents, registered copyrights and
registered trademarks and all applications for any of the foregoing.

Potomac Regulatory Permits. "Potomac Regulatory Permits" shall have the
meaning set forth in Section 2.11(d).

 Potomac Stock Certificate. "Potomac Stock Certificate" shall have the meaning
set forth in Section 1.7.

Potomac Stockholder Support Agreements. "Potomac Stockholder Support
Agreements" shall have the meaning set forth in the recitals.

Potomac Stockholder Written Consent. "Potomac Stockholder Written Consent"
shall have the meaning set forth in the recitals.

Potomac Termination Fee. "Potomac Termination Fee" shall have the meaning set
forth in Section 9.3(b)(i).

Potomac Triggering Event. A "Potomac Triggering Event" shall be deemed to have
occurred if: (i) the Board of Directors of Potomac shall have failed to
recommend that Potomac's stockholders vote to approve the Merger or shall for
any reason have withdrawn or shall have modified in a manner adverse to Tigris
the Potomac Board Recommendation; (ii) Potomac shall have failed to include in
the Proxy Statement/Prospectus/Information Statement the Potomac Board
Recommendation; (iii) the Board of Directors of Potomac shall have approved,
endorsed or recommended any Acquisition Proposal; (iv) Potomac shall have
entered into any letter of intent or similar document or any Contract relating
to any Acquisition Proposal (other than a confidentiality agreement permitted
pursuant to Section 4.5); or (v) Potomac or any director, officer or agent of
Potomac shall have willfully and intentionally breached the provisions set
forth in Section 4.5 of the Agreement.

Potomac Unaudited Interim Balance Sheet. "Potomac Unaudited Interim Balance
Sheet" shall mean the draft unaudited consolidated balance sheet of Potomac
and its consolidated Subsidiaries as of March 31, 2014, provided to Tigris
prior to the date of this Agreement.

Potomac Warrants. "Potomac Warrants" shall have the meaning set forth in
Section 2.3(b).

Pre-Closing Dividend. "Pre-Closing Dividend" shall have the meaning set forth
in Section 5.16.

Pre-Closing Dividend Assets. "Pre-Closing Dividend Assets" shall have the
meaning set forth in Section 5.16.

Pre-Closing Liability Amount. "Pre-Closing Liability Amount" shall have the
meaning set forth in Section 4.6.

Pre-Closing Period. "Pre-Closing Period" shall have the meaning set forth in
Section 4.1.

Preferred Stock Conversion. "Preferred Stock Conversion" shall have the
meaning set forth in Section 7.10.

 Proxy Statement/Prospectus/Information Statement. "Proxy
Statement/Prospectus/Information Statement" shall mean the proxy
statement/prospectus/information statement to be sent to Potomac's
stockholders in connection with the approval of this Agreement and the Merger
by signing the Potomac Stockholder Written Consents and to Tigris'
stockholders in connection with the Tigris Stockholders' Meeting.

Remaining Tigris Directors. "Remaining Tigris Directors" shall have the
meaning set forth in Section 5.16.

Representatives. "Representatives" shall mean directors, officers, other
employees, agents, attorneys, accountants, advisors and representatives.

Required Potomac Stockholder Vote. "Required Potomac Stockholder Vote" shall
have the meaning set forth in Section 2.19.

Required Tigris Stockholder Vote. "Required Tigris Stockholder Vote" shall
have the meaning set forth in Section 3.18.

Response Date. "Response Date" shall have the meaning set forth in Section
1.6(b).

Sarbanes-Oxley Act. "Sarbanes-Oxley Act" shall mean the Sarbanes-Oxley Act of
2002, as it may be amended from time to time.

SEC. "SEC" shall mean the United States Securities and Exchange Commission.

Second Merger. "Second Merger" shall have the meaning set forth in Section
1.1(b).

Second Step Certificate of Merger. "Second Step Certificate of Merger" shall
have the meaning set forth in Section 1.5(g).

Securities Act. "Securities Act" shall mean the Securities Act of 1933, as
amended.

Shareholder. "Shareholder" shall mean each stockholder of Potomac, and
"Shareholders" shall mean all stockholders of Potomac, in each case as
determined immediately prior to the Effective Time.

Subscription Agreement. "Subscription Agreement" means the Subscription
Agreement attached hereto as Schedule E, among Potomac and the Persons named
therein, pursuant to which such Persons have agreed to purchase the number of
shares of Potomac Capital Stock set forth therein in connection with the
Potomac Pre-Closing Financing.

Subsequent Transaction. "Subsequent Transaction" shall mean any Acquisition
Transaction that results or would result in any third party beneficially
owning securities of a Party representing more than fifty percent (50%) of the
voting power of the outstanding securities of a Party or owning or exclusively
licensing tangible or intangible assets representing more than fifty percent
(50%) of the fair market value of the income-generating assets of a Party and
its Subsidiaries, taken as a whole.

 Subsidiary. An entity shall be deemed to be a "Subsidiary" of another Person
if such Person directly or indirectly owns or purports to own, beneficially or
of record, (a) an amount of voting securities of other interests in such
entity that is sufficient to enable such Person to elect at least a majority
of the members of such entity's board of directors or other governing body, or
(b) at least 50% of the outstanding equity, voting, beneficial or financial
interests in such Entity.

Superior Offer. "Superior Offer" shall mean an unsolicited bona fide written
offer by a third party to enter into (i) a merger, consolidation,
amalgamation, share exchange, business combination, issuance of securities,
acquisition of securities, reorganization, recapitalization, tender offer,
exchange offer or other similar transaction as a result of which either (A)
the Party's stockholders prior to such transaction in the aggregate cease to
own at least 50% of the voting securities of the entity surviving or resulting
from such transaction (or the ultimate parent entity thereof) or (B) in which
a Person or "group" (as defined in the Exchange Act and the rules promulgated
thereunder) directly or indirectly acquires beneficial or record ownership of
securities representing 50% or more of the Party's capital stock or (ii) a
sale, lease, exchange transfer, license, acquisition or disposition of any
business or other disposition of at least 50% of the assets of the Party or
its Subsidiaries, taken as a whole, in a single transaction or a series of
related transactions that: (a) was not obtained or made as a direct or
indirect result of a breach of (or in violation of) this Agreement; and (b) is
on terms and conditions that the Board of Directors of Tigris or Potomac, as
applicable, determines, in its reasonable, good faith judgment, after
obtaining and taking into account such matters that its Board of Directors
deems relevant following consultation with its outside legal counsel and
financial advisor, if any: (x) is reasonably likely to be more favorable, from
a financial point of view, to Tigris' stockholders or Potomac's stockholders,
as applicable, than the terms of the Merger; and (y) is reasonably capable of
being consummated; provided, however, that any such offer shall not be deemed
to be a "Superior Offer" if any financing required to consummate the
transaction contemplated by such offer is not committed and is not reasonably
capable of being obtained by such third party, or if the consummation of such
transaction is contingent on any such financing being obtained.

Surviving Company. "Surviving Company" shall have the meaning set forth in
Section 1.1(b).

Surviving Corporation. "Surviving Corporation" shall have the meaning set
forth in Section 1.1(a).

Tax. "Tax" shall mean any federal, state, local, foreign or other tax,
including any income tax, franchise tax, capital gains tax, gross receipts
tax, value-added tax, surtax, estimated tax, unemployment tax, national health
insurance tax, excise tax, ad valorem tax, transfer tax, stamp tax, sales tax,
use tax, property tax, business tax, withholding tax, payroll tax, customs
duty, alternative or add-on minimum or other tax of any kind whatsoever, and
including any fine, penalty, addition to tax or interest, whether disputed or
not.

Tax Representation Letters. "Tax Representation Letters" shall have the
meaning set forth in Section 5.11(c).

 Tax Return. "Tax Return" shall mean any return (including any information
return), report, statement, declaration, estimate, schedule, notice,
notification, form, election, certificate or other document or information,
and any amendment or supplement to any of the foregoing, filed with or
submitted to, or required to be filed with or submitted to, any Governmental
Body in connection with the determination, assessment, collection or payment
of any Tax or in connection with the administration, implementation or
enforcement of or compliance with any Legal Requirement relating to any Tax.

Third Party Expenses. "Third Party Expenses" shall have the meaning set forth
in Section 9.3(c).

Tigris. "Tigris" shall have the meaning set forth in the Preamble.

Tigris Affiliate. "Tigris Affiliate" shall mean any Person that is (or at any
relevant time was) under common control with Tigris within the meaning of
Sections 414(b), (c), (m) and (o) of the Code, and the regulations issued
thereunder.

Tigris Associate. "Tigris Associate" shall mean any current or former
employee, independent contractor, officer or director of Tigris or any Tigris
Affiliate.

Tigris Board of Directors. "Tigris Board of Directors" shall mean the board of
directors of Tigris.

Tigris Board Recommendation. "Tigris Board Recommendation" shall have the
meaning set forth in Section 5.3(b).

Tigris Closing Price. "Tigris Closing Price" means the volume weighted average
closing trading price of a share of Tigris Common Stock on The NASDAQ Global
Market (or such other NASDAQ market on which the Tigris Common Stock then
trades) for the five trading days ending the trading day immediately prior to
the date upon which the Merger becomes effective.

Tigris Common Stock. "Tigris Common Stock" shall mean the Common Stock, $0.001
par value per share, of Tigris.

Tigris Contract. "Tigris Contract" shall mean any Contract: (a) to which
Tigris or any of its Subsidiaries is a party; (b) by which Tigris or any of
its Subsidiaries or any Tigris IP Rights or any other asset of Tigris or any
of its Subsidiaries is or may become bound or under which Tigris has, or may
become subject to, any obligation; or (c) under which Tigris or any of its
Subsidiaries has or may acquire any right or interest.

Tigris Disclosure Schedule. "Tigris Disclosure Schedule" shall have the
meaning set forth in Section 3.

Tigris Employee Plan. "Tigris Employee Plan" shall have the meaning set forth
in Section 3.11(f).

 Tigris IP Rights. "Tigris IP Rights" shall have the meaning set forth in
Section 3.6(b).

Tigris IP Rights Agreement. "Tigris IP Rights Agreement" shall mean any
instrument or agreement governing, related or pertaining to any Tigris IP
Rights.

Tigris Material Adverse Effect. "Tigris Material Adverse Effect" shall mean
any Effect that, considered together with all other Effects that had occurred
prior to the date of determination of the occurrence of the Tigris Material
Adverse Effect, is or could reasonably be expected to be or to become
materially adverse to, or has or could reasonably be expected to have or
result in a material adverse effect on: (a) the business, condition (financial
or otherwise), capitalization, assets (including Intellectual Property),
operations or financial performance of Tigris and its Subsidiaries, taken as a
whole; or (b) the ability of Tigris to consummate the Merger or any of the
other Contemplated Transactions or to perform any of its covenants or
obligations under the Agreement in all material respects; provided, however,
that none of the following shall be deemed to constitute an Tigris Material
Adverse Effect: (1) any demands, pending, threatened, or actual litigation, or
the settlement, or failure to settle, any demands, pending, threatened or
actual litigation, (2) the termination, sublease or assignment of Tigris'
facility lease, or failure to do the foregoing, (3) any Effect resulting from
the announcement or pendency of the Merger, (4) any change in the stock price
or trading volume of Tigris independent of any other event that would be
deemed to have a Tigris Material Adverse Effect, (5) any act or threat of
terrorism or war anywhere in the world, any armed hostilities or terrorist
activities anywhere in the world, any threat or escalation or armed
hostilities or terrorist activities anywhere in the world or any governmental
or other response or reaction to any of the foregoing, (6) any change in
accounting requirements or principles or any change in applicable laws, rules
or regulations or the interpretation thereof, or (7) any adverse change,
effect or occurrence attributable to the United States economy as a whole or
the industries in which Tigris competes.

Tigris Material Contract. "Tigris Material Contract" shall have the meaning
set forth in Section 3.7.

Tigris Note. "Tigris Note" shall have the meaning set forth in the recitals.

Tigris Options. "Tigris Options" shall mean options or other rights to
purchase shares of Tigris Common Stock issued by Tigris.

Tigris Permits. "Tigris Permits" shall have the meaning set forth in Section
3.9(b).

Tigris Product Candidates. "Tigris Product Candidates" shall have the meaning
set forth in Section 3.9(d).

Tigris Registered IP. "Tigris Registered IP" shall mean all Tigris IP Rights
that are registered, filed or issued under the authority of, with or by any
Governmental Body, including all patents, registered copyrights and registered
trademarks and all applications for any of the foregoing.

 Tigris Regulatory Permits. "Tigris Regulatory Permits" shall have the meaning
set forth in Section 3.9(d).

Tigris SEC Documents. "Tigris SEC Documents" shall have the meaning set forth
in Section 3.4(a).

Tigris Stock Plans. "Tigris Stock Plans" shall have the meaning set forth in
Section 3.3(b).

Tigris Stockholder Support Agreements. "Tigris Stockholder Support Agreements"
shall have the meaning set forth in the recitals.

Tigris Stockholders' Meeting. "Tigris Stockholders' Meeting" shall have the
meaning set forth in Section 5.3(a).

Tigris Termination Fee. "Tigris Termination Fee" shall have the meaning set
forth in Section 9.3(b)(ii).

Tigris Triggering Event. A "Tigris Triggering Event" shall be deemed to have
occurred if: (i) the Board of Directors of Tigris shall have failed to
recommend that Tigris' stockholders vote to approve the Merger and the
issuance of Tigris Common Stock in the Merger or shall for any reason have
withdrawn or shall have modified in a manner adverse to Potomac the Tigris
Board Recommendation; (ii) Tigris shall have failed to include in the Proxy
Statement/Prospectus/Information Statement the Tigris Board Recommendation;
(iii) Tigris shall have failed to hold the Tigris Stockholders' Meeting within
60 days after the Form S-4 Registration Statement is declared effective under
the Securities Act (other than to the extent that the Form S-4 Registration
Statement is subject to any stop order or proceeding (or threatened proceeding
by the SEC) seeking a stop order with respect to the Form S-4 Registration
Statement, in which case such 60 day period shall be tolled for the earlier of
60 days or so long as such stop order remains in effect or proceeding or
threatened proceeding remains pending); (iv) the Board of Directors of Tigris
shall have approved, endorsed or recommended any Acquisition Proposal; (v)
Tigris shall have entered into any letter of intent or similar document or any
Contract relating to any Acquisition Proposal (other than a confidentiality
agreement permitted pursuant to Section 4.5); or (vi) Tigris or any director,
officer or agent of Tigris shall have willfully and intentionally breached the
provisions set forth in Section 4.5 of the Agreement.

Tigris Unaudited Interim Balance Sheet. "Tigris Unaudited Interim Balance
Sheet" shall mean the unaudited consolidated balance sheet of Tigris as of
March 31, 2014, included in Tigris' Report on Form 10-Q for the fiscal quarter
ended March 31, 2014, as filed with the SEC.

TPI. "TPI" shall mean Transcept Pharma, Inc., Inc., a wholly-owned subsidiary
of Tigris.

Transfer Taxes. "Transfer Taxes" shall have the meaning set forth in Section
5.11(e).

Treasury Regulations. "Treasury Regulations" shall mean the United States
Treasury regulations promulgated under the Code.



A-15



\t    '

